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Tuberculosis (TB) is the most significant infectious disease afflicting human 
populations (1). The causative agent is Mycobacterium tuberculosis (Mtb), a 
bacterium capable of surviving in an intracellular niche after uptake by phagocytic 
cells in the respiratory system (2,3). Infection can be asymptomatic, resulting in 
latent TB infection (LTBI), with a 10% chance of re-activation throughout life (4). 
Active disease can occur in any organ in the body but typically presents as a 
persistent pulmonary infection which is also the principle site of pathogen entry (2). 
The burden of disease falls disproportionately on low- and middle-income countries, 
primarily in Asia and Africa, which account for 85% of all cases worldwide (1). 
Nevertheless, TB remains a treatable disease although it requires a prolonged 
course of antibiotic therapy-over six months, with an 85% success rate (1). In high-
income countries, a combination of diagnostic methodologies including the tuberculin 
skin test (TST, also known as Mantoux test), chest X-rays, sputum culture and the 
ubiquitous sputum smear acid-fast stain, Interferon-gamma release assay (IGRA) 
and nucleic acid amplification test (NAAT), has enabled medical authorities to 
assess infection accurately and initiate treatment rapidly, hence preventing spread of 
infection (5,6). With additional resources to carry out contact tracing and treat LTBl, 
tuberculosis incidence is extremely low (5).  
 
However, in low-income countries, a lack of funding, infrastructure, and 
trained medical personnel severely limits the ability of their health care systems to 
deliver efficient and accurate diagnostic services and currently an estimated third of 





low-cost, infrastructure-independent, point-of-care diagnostic that requires minimal 
training to use and hence can be easily deployed in resource-poor settings. It has 
been estimated that such a diagnostic with 100% sensitivity and specificity could 
save 625000 lives annually (7). Antibody-based detection of Mtb derived biomarkers 
is ideal, but the utility of antibody based assays targeting Mtb proteins remains 
unproven (8). Mtb lipid biomarkers are another suitable class of targets due to their 
resistance to degradation and presence in a variety of clinical samples, but the lack 
of T cell help required for an effective B cell immune response and the insolubility of 
many lipid antigens has made the generation of highly specific, high affinity 
antibodies using traditional hybridoma technology challenging (9). The advent of 
recombinant antibody phage display allows for the selection of such antibodies in 
vitro without a requirement for an immune response (10,11). We have therefore 
explored antibody phage display for the generation of high affinity, highly specific 
antibodies against two potential TB lipid biomarkers: lipoarabinomannan (LAM), a 
soluble highly branched glycolipid reportedly found in patient urine; and mycolic acid, 
an insoluble long chain fatty acid present in high quantities in TB patient sputum 
samples (12,13). High affinity antibodies with diagnostic potential were generated 
against both targets. In this study, we detail their derivation and thorough 
characterization. Testing against clinical samples indicated that our anti-LAM 
antibody had significant sensitivity in the smear-negative, HIV negative cohort. We 
also describe our efforts to develop novel inexpensive production methodologies for 
these antibodies in E. coli as current methods rely primarily upon expensive 
mammalian expression.  
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1.1  Tuberculosis pathology, epidemiology, prevention and treatment 
 
 Tuberculosis (TB) is one of the oldest diseases known to man, with 
archaeological evidence from ancient Egypt and historical written records from 
classical Greece attesting to its presence in the ancient Near East; and in its most 
common form presents itself as a persistent pulmonary infection (14). It is currently 
the second most common cause of death due to an infectious disease, with an 
estimated 1.4 million deaths in 2011, and thus is a major public health concern (1). 
The causative agent, the bacteria Mycobacterium tuberculosis (Mtb) was discovered 
in the late 19th century by Robert Koch, and a number of species of the same genus 
have subsequently been associated with various skin and lung diseases (14). 
Pathogenic species of note include M. avium and kansasii, which are the two 
species frequently found in non-tuberculous pulmonary infections while M. marinum 
and ulcerans typically cause granulomatous lesions and chronic ulcerations of the 
soft tissue of the skin respectively (15,16). M. leprae on the other hand is well known 
for its association with the historical disease leprosy (17). However, there is a large 
group of mycobacterial species that are non-pathogenic as well e.g. M. smegmatis 
(18).  
 
Mtb is a non-motile, non-spore forming, aerobic rod-shaped bacillus and is an 
intracellular pathogen that infects humans as its primary host (2). It cannot be 
classified as either a true Gram-positive or negative bacteria but is generally termed 
acid-fast, due to its ability to resist decolourisation with mild acid after staining with 
various dyes (2). TB is typically acquired via inhalation of Mtb contaminated aerosol 





into the lung, the invading bacteria are taken up by resident phagocytic cells such as 
macrophages and dendritic cells. Mtb has evolved various methods for evading 
phagocytic killing including the prevention of phagosome maturation by inhibiting 
lysosome fusion or acidification, escaping into the cytosol or inactivation of host 
generated reactive oxygen and nitrogen species by enzymatic breakdown (19). This 
enables the survival and replication of Mtb in this intracellular niche. As the bacilli 
replicate, the growing infection with associated inflammation attracts additional 
mononuclear phagocytes which in turn can be infected. Sustained intracellular 
infection results in the formation of granulomas, which are aggregates of primarily 
macrophages, but also other immune cells such as neutrophils, monocytes, dendritic 
cells (DCs), B and T cells and natural killer cells, at the site of infection which seal off 
the infection and prevent further spread of the bacteria (20). The granuloma, while 
protecting the host from disseminated disease, also appears to provide the invading 
pathogen with an environment within which it can survive shielded from further host 
immune responses. It also impacts upon the penetrance and hence efficiency of 
antimycobacterial drugs (3).  
 
In most immunocompetent individuals, granuloma formation is the end stage 
of disease, producing an asymptomatic latent TB infection (LTBI), which is the case 
for over 90% of infections (4). Currently, it is estimated that one-third (approximately 
2 billion individuals) of the world’s population has LTBI (1). However, there is a 5% 
chance of active disease within the first 18 months of infection and a further 5% 
chance of disease reactivation over the person’s remaining lifetime (21). The 
symptoms of active TB include prolonged coughing, weight loss, fever and night 





individuals and is due to release of bacilli from containment in the granuloma (22). 
This enables further spread in the body and aerosol transmission to other individuals 
by coughing and expectoration of infectious bacteria. It is unclear what the 
contributing immunological mechanisms are but two known triggers are depletion of 
CD4 helper T cells due to HIV infection and TNFα blocking therapy with monoclonal 
antibodies; and is also associated with anti-inflammatory steroid treatment, 
malnutrition and diabetes (22).  
 
Prior to the development of antimycobacterial drugs, treatment of tuberculosis 
was limited to providing rest, good nutrition and fresh air in various spas and 
sanatoriums (15). Drug treatment of tuberculosis started with the development of 
streptomycin in 1946, although frequent use has led to drug resistance and hence its 
discontinuation from first-line usage (23). Currently, four drugs are recommended by 
the World Health Organization (WHO) for first line use: rifampicin, which interferes 
with bacterial RNA synthesis; isoniazid, which interferes with mycolic acid synthesis; 
pyrazinamide, which accumulates in and acidifies the interior of the bacterium; and 
ethambutol, which inhibits cell wall synthesis by blocking of arabinosyl transferase 
(23). A combination of all four is given for the first two months and subsequently only 
rifampicin and isoniazid for next four months to treat active infection(4). Isoniazid is 
given alone for nine months to treat LTBI. With such a long treatment regime, 
compliance is important to limit the development of drug resistance; therefore 
patients are usually required to take their drugs in the presence of an observer, 






Due to lack of compliance, various multi-drug resistant TB (MDR-TB) strains 
have appeared which are defined as resistance to at least rifampicin and isoniazid. 
Nonetheless, MDR-TB remains treatable through the careful use of a combination of 
at least four second line antimycobacterial drugs, which include aminoglycosides 
(Kanamycin/Amikacin) and fluoroquinolones (ofloxacin/levofloxacin/moxifloxacin) 
(24). Of greater concern has been the recent appearance of extensively-drug 
resistant TB (XDR-TB), which is defined by resistance to both rifampicin and 
isoniazid plus at least one drug in each of the two classes of second line drugs 
above. XDR-TB is harder to detect and treat due to the need to test for resistance to 
multiple drugs and find appropriate drugs combinations that are effective, which has 
led to poorer outcomes associated with such infections (25). It also raises the 
possibility of the development of TB strains that are totally resistant to current 
therapy. 
 
The principle vaccine available for TB is based on an attenuated strain of 
Mycobacterium bovis, Bacille Calmette-Guérin (BCG) which is injected as a live 
vaccine into new-borns and children (26). While moderately protective (73-77% 
reduction in risk) against severe disseminated TB infection in infants and young 
children, it offers poor protection (50% average reduction in risk) against pulmonary 
infection in adults with a wide variation in efficacy from nil to 80% (27,28). The 
geographic latitude where the individual vaccination studies were conducted 
accounted for a significant (66%) proportion of the variation, with vaccine efficiency 
decreasing towards the equator (28). This has been attributed to exposure to 
environmental non-tuberculosis bacteria, which is more prevalent in lower latitudes, 





effect of BCG immunization, or alternatively, limiting the multiplication of the live 
BGC vaccine and hence development of specific immunity to TB (29,30). 
 
Despite the apparent treatability of both active and latent TB infection, disease 
transmission remains significant, with an estimated 8.7 million new cases alone in 
2011 (1,31). This can primarily be attributed to delayed or missed diagnosis due to 
the inadequacy of current diagnostic tests, resulting in sustained spread of disease 
by untreated TB sufferers. A systematic review of TB cases from the pre-antibiotic 
era indicated an estimated average mortality rate of 70% and 20% within 10 years of 
infection for sputum smear-positive and negative cases respectively, indicating the 
deadly outcome of non-treatment which arises from missed diagnosis (32). The 
World Health Organization (WHO) and other groups have estimated the number of 
undetected cases, based on actual reported cases and estimated incident rates to 
be one-third of all TB cases, suggesting that there is an urgent requirement for 
improvement in TB diagnosis particularly in the early stages of active disease (1,33). 
An additional confounding factor is the increasing proportion of TB patients co-
infected with HIV (Human Immunodeficiency Virus), which is estimated to be 13% 
globally and above 50% in parts of sub-Saharan Africa (1). TB/HIV co-infection leads 
to a more rapid progression to the fatal disease manifestations and thus requires 
better early diagnosis; it also reduces the efficacy of a number of widely used 
diagnostic tools such as sputum smear, X-ray and tests relying on immunological 
responses such as the tuberculin skin tests (34). As a result, deaths due to TB/HIV 
make up approximately half of all deaths due to TB despite only comprising a 






1.2  Methods for TB diagnosis 
 
A wide variety of methods are currently used and recommended for the 
diagnosis of TB or LTBI and can be divided into two general categories: firstly, direct 
microbiological detection of the pathogen via acid-fast staining, microbial culture or 
more recently nucleic acid amplification tests (NAATs). Alternatively, diagnosis can 
be made via detection of specific immune responses, either measuring T cell 
responses to TB antigen with the tuberculin skin test (TST, also known as Mantoux 
test) or interferon gamma release assay (IGRA), or formation of granulomatous 
lesions via chest X-ray (31,35-37). Detection of T cell responses are more typically 
used to screen for LTBI, as they cannot distinguish between active disease and 
latent infection (4,38). In resource-rich first world countries, a combination of the 
above tests have been successfully used to detect and treat both active disease and 
latent infection and incidence rates are typically in the order of less than25 per 
100,000 in North America and Western Europe in contrast to rates greater than 300 
per 100,000 in the most severely afflicted regions of sub-Saharan Africa (1). 
However, each method has drawbacks in terms of cost, requirements for 
infrastructure and trained manpower, rapidity and accuracy. While this has minimal 
effect in resource-rich countries due to well-developed medical infrastructure and 
manpower, availability of funds for medical diagnostics and ready medical access for 
the vast majority of the population, these drawbacks, which we describe in detail 
below, has severely impacted the ability of resource-poor countries to detect, control 







1.2.1 Detection of host immune responses- X-rays, TST and IGRA 
 
Chest X-rays are only useful for the detection of the pulmonary form of TB 
and relies on radiographic visualization of lung granulomatous lesions which appear 
opaque on film. While X-rays have long been used in first-world countries due to its 
rapidity and reasonable sensitivity in HIV negative individuals, they have a high false 
positive rate especially in low burden populations due to its lack of specificity and 
vulnerability to observer error (31,39). This is evidenced by a cross-sectional study in 
which 36% of patients with X-rays suggestive of TB could not have their diagnosis 
confirmed by microbial culture, the most sensitive direct detection method, and 20% 
of culture-positive patients were not picked up by X-rays (40). This has led to 
recommendations that any radiological diagnosis of TB be confirmed by direct 
microbiological detection (35,36).  
 
The tuberculin skin test (TST) is the oldest test that is capable of detecting 
LTBI, in addition to active TB, and is based on measuring the skin hypersensitivity 
reaction to subcutaneously injected purified protein derivative (PPD) of Mtb. 
However, as the antigens which are used to trigger the skin reaction can also be 
found in related mycobacteria, populations vaccinated with BCG often have high 
false-positive rates (31,41). Also, due to its dependence on a functional immune 
system, responses are depressed in the HIV positive cohort resulting in a higher 
false negative rate (42,43). It also requires a repeat visit within a short timeframe to 






A recent improvement is the IGRA, which measures the cytokine response of 
patients’ T cells to TB specific protein antigens based on interferon gamma 
secretion. Unlike the TST, it relies on TB specific antigens such as ESAT-6 (Early 
Secreted Antigenic Target-6kDa) and CFP-10 (Culture filtrate protein-10kDa) and so 
is not likely to trigger a response from individuals vaccinated with BCG or exposed to 
other mycobacteria. It has shown promise especially on extra-pulmonary samples 
from which T cells can be isolated, where sensitivity in other rapid assays such as 
acid-fast staining and NAATs are low (44). However, similar to the TST, it cannot 
distinguish between latent TB and active disease and also exhibits the same 
reduced response in the HIV cohort (41,45). Due to these drawbacks, WHO has 
recommended that the TST and IGRA not be used to diagnose active TB in low and 
medium income countries, where HIV incidence is higher, although IGRAs remain 
widely used in high income countries to detect latent TB infection due to their better 
performance characteristics versus TSTs (38). 
 
1.2.2 Direct microbiological detection – Acid-fast stain, microbial culture and 
Nucleic acid amplification tests 
 
Direct microbiological detection is regarded as the only means for confirming 
a case of TB and highly recommended before deciding to initiate therapy (1). This is 
primarily due to the logistical difficulty and toxicity of treatment (six months of 
antibiotic therapy) and the lack of specificity for active TB for diagnosis on the basis 
of symptomology, X-rays or TST/IGRAs alone (35). This is evidenced by the low 
proportion of microbiologically confirmed TB cases (7-15%) present in a population 





direct microbiological detection test most widely employed globally (and also the 
oldest TB diagnostic in use for over 100 years) is the acid-fast stain, where collected 
specimens are smeared directly onto a slide and stained with Ziehl-Neelsen or 
Auramine-O dyes to highlight mycobacterial bacilli which are counted under an 
optical microscope (31). The dyes employed for this assay stain surface mycolic 
acids-a family of hydrophobic long chain fatty acids highly enriched in mycobacterial 
cell walls (47). Staining of sputum samples (sputum smear) is the most common 
form of this assay and is used to confirm a diagnosis of pulmonary TB. However, due 
to the presence of mycolic acids in all mycobacteria as well as a variety of related 
actinomycete species, this test cannot directly confirm the presence of Mtb (48). 
However, in high-prevalence areas, the presence of such high concentrations of 
acid-fast bacilli is considered highly suggestive of TB and sufficient to confirm 
diagnosis (35).  
 
The sensitivity of sputum smears has been reported to range from 80% to as 
low as 20%, although the use of centrifugation or sedimentation of liquefied sputum 
to concentrate the sample or magnetic beads to separate out the tuberculosis bacilli 
has been shown to increase sensitivity (49-51). This low sensitivity is the primary 
drawback of this method, with a detection limit of between 5,000-10,000 bacilli/ml of 
sputum (31). Furthermore, this approach does not allow the identification of drug 
resistant strains of Mtb and also has reduced sensitivity for the HIV positive patient 
cohort (52). This reduced sensitivity is due to the reduced granuloma cavity 
formation and sputum production caused by the weak immune response to Mtb 






 The current gold standard for TB diagnostics remains the microbial culture 
test in which the sample is cultured on either specialist solid or liquid media 
optimized for mycobacterial growth e.g. Löwenstein–Jensen agar or Middlebrook 
D7H9 broth. It has the highest sensitivity of all current methods with a detection limit 
as low as 10 bacilli/ml of sputum and is relatively low cost (31). However, there are a 
number of factors that make this test problematic for TB management. Mtb is a slow-
growing microbe and thus culture is time consuming, taking typically over one month 
for a confirmed diagnosis (31). While automated liquid culture systems such as the 
Bactec MGIT 960 can shorten the time to diagnosis to two weeks with improved 
sensitivity, it is still much slower than other direct detection methods such as NAATs 
and acid-fast staining (53,54). Another drawback is that culture cannot immediately 
determine species as a variety of non-tuberculous mycobacteria can grow in the 
same media. However, where liquid culture methods do stand out is as follow up 
tests for drug resistance in combination with the microscopic observation drug 
susceptibility assay, where mycobacterial growth and cording behaviour is examined 
under a microscope to rapidly determine drug susceptibility within a week (55,56). 
Due to their accuracy, such tests are still recommended over DNA based assays for 
the diagnosis of extensively drug resistant tuberculosis (XDR-TB) (1).  
 
In recent years, nucleic acid amplification tests (NAATs) have been 
introduced into TB diagnostics and have been shown to be capable of almost 
equivalent sensitivity and specificity to sputum culture tests (57-60). Its primary 
disadvantage is its high costs, which make it unsuitable for use in developing 
countries (31). It also has high infrastructure requirements in terms of lab equipment 





out to diagnose TB infections due to their ability to accurately and rapidly (same-day) 
diagnose both standard and multi-drug resistant tuberculosis (MDR-TB) and is 
recommended for use alongside culture and acid fast staining (5,36). In particular, 
line probe assays, in which labelled amplified DNA is hybridized to DNA probes 
along a strip membrane, are fast and highly accurate (57,61). This has led to WHO 
recommending these assays for the identification of mycobacterial species and 
rifampicin and/or isoniazid resistance directly from sputum samples or cultures from 
smear-negative samples (62). 
 
1.3 TB diagnostics in resource-poor settings 
 
The various methods described above all have significant drawbacks: 
detection based on host response e.g. X-rays/TST/IGRA suffers from poor 
specificity, while acid fast staining is insensitive. Culture and NAATs are both 
sensitive but are slow or expensive respectively. Furthermore, all require significant 
infrastructural support e.g. electrical power, refrigeration as well as lab equipment 
e.g. microscopes, incubators, thermal cyclers, and trained medical personnel to carry 
out the tests and interpret the results. As a result, these tests while readily 
accessible to the wider public in first-world countries are often limited to the level of 
the national or regional reference lab in resource-poor third world countries (Fig. 1-
1). Even acid-fast staining, which is considered to have the lowest requirements for 
resources, is not considered to be a true point-of-care test due to its need for trained 
microscopists and lab equipment and is estimated to be not readily available to up to 








Figure 1-1: Location of the various current direct detection TB diagnostics 
in a typical health care system.  
 
The ideal point-of-care test would be portable, have no infrastructure or 
electrical requirements, rapid and sensitive and require little training to operate. 
No existing test currently meets these requirements. (Adapted from WHO, 
2006) 
 
1.3.1 Improving current diagnostics for resource-poor countries 
 
Despite the limitations of these diagnostics, efforts have been made to 
improve these methodologies for use in resource-poor settings. Recently, the WHO 
has introduced a global rollout of the Xpert MTB/RIF NAAT platform for simultaneous 
detection of TB infection along with rifampicin resistance for MDR-TB (1,63). It is a 
self-contained automated disposable cartridge system that combines sputum sample 
processing, PCR amplification and detection of Mtb and rifampicin resistance 





required and this enables the deployment of the system into more rural areas in third 
world countries where highly trained personnel and sophisticated infrastructure is not 
available. It has virtually equivalent specificity and sensitivity to sputum culture while 
allowing for same-day diagnosis with performance better or equal to other 
commercially available NAATs (64-67). However, it has poorer performance for 
extra-pulmonary TB diagnosis with sensitivity as low as 25% for lung pleural fluid 
samples (68).  
 
By recommending a world-wide introduction of a single platform, the 
Foundation for Innovative New Diagnostics was able to negotiate a reduced price for 
developing countries at approximately USD$10 per test in contrast to a price of 
USD$65 in the European Union, thus reducing the prime disadvantage of such tests 
which are high costs (63). Nonetheless, it has been estimated that implementation of 
this assay in high burden, low-income countries will still require additional funding in 
spite of the reduced prices given current spending rates on TB healthcare, as 
implementation of this test to diagnose all suspected TB cases would consume over 
80% of the national TB budget of these countries alone (69). This could limit the use 
of this assay in these countries. 
 
 Similarly, efforts to improve the sensitivity of acid-fast staining have led to the 
development of portable battery powered light emitting diode (LED) fluorescent 
microscopes. WHO has advocated switching from light to fluorescent microscopy 
(using Auramine-O dye) as it offers an incremental increase in sensitivity (10%) and 
also reduces the assay time taken due to the reduction in number of visual fields 





with a recommendation to only test two rather than three samples (due to negligible 
reduction in sensitivity) has facilitated the introduction of same-day microscopy 
where diagnosis and initiation of therapy can be carried out in a single visit (73). This 
is an important factor in third world rural settings when patient access to medical 
care is limited and inconvenient. However, the increase in sensitivity is not 
comparable to that achievable by culture and NAATs, and also cannot provide 
species identification, while the requirements for trained microscopists remain. As 
such, even in its optimized format, acid-fast stain remains unsuitable as a point-of-
care test.  
 
1.3.2 Potential point-of care diagnostics for resource-poor countries 
 
What is required is a point-of-care test that is rapid i.e. sample collection, 
processing and testing completed in a few hours and allow for same-day treatment, 
cheap, accurate (>95% specificity and >90% sensitivity) and have minimal 
infrastructure and training requirements for operation i.e. no need for refrigeration or 
additional instrumentation, portable and no need for specialized personnel (31). It 
has been estimated that such a test with 100% sensitivity on pulmonary samples 
would cut annual deaths by 625000 (or 36% of deaths globally), excluding deaths 
due to HIV co-infection, drug resistant TB and inadequate drug availability (7). 
Various diagnostic methodologies have been evaluated to determine if they can 
meet these requirements.  
 
 Serology, which relies on detection of the antibody response against the 





Hepatitis B (74). Despite the large number of commercially available serological 
assays available, a recent meta-analysis of published data on their efficacy has 
reported no significant improvement over sputum smear microscopy (75). Due to the 
poor reproducibility of data and lack of improvement in sensitivity over sputum 
smear, WHO has issued a rare blanket recommendation not to use commercial 
serological assays for the diagnosis of TB (76).  
 
In spite of this, various groups have continued to evaluate new antigens or 
new combinations of antigens to improve sensitivity and specificity. Recently, a 
group identified four TB lipolytic enzymes as potential serological markers, out of 
which one showed 93% and 87% sensitivity for smear-positive and smear-negative 
culture-positive patient serum samples respectively with over 95% specificity against 
the negative control population which included both BCG vaccinated and latent TB 
infected individuals (77). Another group showed that a combination of six novel 
antigens expressed in combination as fusion proteins could achieve 93% sensitivity 
(78). However, these studies did not include large numbers of HIV positive 
individuals, in which assay sensitivity might be lower due to a deficient immune 
response and thus this platform remains un-validated. 
 
Another diagnostic technology platform that is widely used for other diseases, 
but has not been developed into a suitable TB diagnostic test is that of antibody-
based assays (79). These have been developed in a variety of formats such as 
plate-based or membrane dot blot ELISAs, lateral flow dipstick tests, and more 
recently handheld enzymatic electroimmunosensor-type assays (8,80,81). Antibody-





of use, rapidity and low infrastructure requirements; provided sufficient sensitivity 
and specificity is achieved with the right antibody-detector and antigen-target pair. 
The range of TB antigen targets include specific single antigens such as 
lipoarabinomannan, ESAT-6, and MPT64 as well as antibodies raised against 
antigen mixtures such as culture filtrate protein precipitate, whole cell bacilli or a mix 
of known TB specific proteins (8,55,81-90) . However, while Mtb protein targets have 
been widely explored, lipid targets found in the bacterial cell envelope have not been 
as thoroughly investigated for their diagnostic potential in antibody-based assays; 
principally due to their insolubility in aqueous solution, as well as difficulty in 
obtaining specific high affinity antibodies. Some advantages of lipid targets include 
their resistance to extreme temperatures and pH which allows for sterilization of 
clinical samples in contrast to proteins which are prone to denaturation, and their 
general high abundance in comparison to individual protein targets, due to the thick 
glycolipid-based cell envelope of Mtb. These represent an interesting source of novel 
biomarkers for the diagnosis of TB provided suitable antibodies can be identified and 
developed. 
 
In addition to application of the above methodologies which are widely used 
for other diagnostic applications, various novel techniques have been developed 
which may have potential for point-of-care diagnostics in resource-poor settings. One 
example is loop-mediated isothermal amplification (LAMP), which relies on DNA 
polymerases with high strand displacement activity and requires no melting step. 
This obviates the need for a thermal cycler as PCR can be carried out at a single 
temperature, while also allowing for easy visual readout via fluorescent double 





(91). Nonetheless, LAMP assays have been successfully carried out in resource-
limited settings with minimally trained personnel and achieved sensitivities equivalent 
to in house PCR assays and better than sputum smears, though still poorer than 
sputum culture (91-93). Another option that is still in the early stage of technology 
demonstration and feasibility testing is the detection of volatile Mtb derived organic 
compounds released in breath (94).  
 
1.4 Anti-lipid antibodies 
1.4.1 Lipids as disease biomarkers 
 
 A number of lipids have been found to be associated with infectious and other 
diseases which can be detected in patient clinical samples and used as biomarkers. 
In oncology, elevated levels of plasma lysophospholipids have been associated with 
ovarian cancer, while oxidized low density lipoprotein and cholesterols in plasma 
have been associated with atherosclerosis and systemic lupus erythematous 
respectively (95-97). In infectious disease, Mtb membrane lipids such as 
lipoarabinomannan (LAM) and mycolic acid have been reportedly found in patient 
urine and sputum samples respectively (12,13). Current methods for the analysis of 
lipids include mass spectrometry or high performance liquid/gas chromatography. 
While these methods are extremely sensitive, accurate and capable of generating 
detailed data on the various lipid species present, they are also expensive and 
require sophisticated equipment and data processing (98). As such, they are not 
ideal for point-of-care diagnostics especially in third world countries. However, they 
provide important lipidomic profiles which can be used to identify lipid biomarkers 






 Antibodies are ideal diagnostic reagents due to their high affinity and 
specificity. However, the traditional method for producing antibodies, whether for 
production of polyclonal sera or monoclonal development relies on an efficient in vivo 
B cell immune response to the antigen to produce high affinity IgGs and requires the 
involvement of T helper cells to support affinity maturation and class switching in the 
germinal centre (99,100). This in turn requires presentation of peptide epitopes and 
as such is only efficacious for proteinaceous targets, which have been extensively 
exploited for the development of rapid antibody tests (100). For non-proteinaceous 
biomolecules e.g. carbohydrates, lipids, and small molecules such as drugs and 
steroids, conjugation to protein carriers can increase the immunogenicity (termed a 
hapten in these cases) as this enables B cells that bind and endocytose these 
haptens to concurrently engage T cell help via the protein carrier epitopes displayed 
on MHC class II molecules (9).  
 
Antibodies have also been successfully generated against lipids through 
animal immunization when delivered as part of an intact bacterial cell or in the 
presence of an adjuvant such as lipid A. These are typically soluble glycolipids such 
as bacterial lipopolysaccharide or amphipathic membrane lipids such as 
phosphatidylinositol (101-105). Analysis of the epitopes targeted indicates that the 
generated antibodies primarily bind the phosphate or carbohydrate headgroup 
portion of these lipids, which indicate that the non-polar lipid tails are generally not 
immunodominant. Furthermore, the antibodies generated are usually of the IgM 





maturation (101,106). As such, immunization has limited value for generating high 
quality antibodies for diagnostic use against lipid or glycolipid targets. 
 
1.4.2 Recombinant phage display 
 
In vitro antibody phage display technology, first developed by Winter et al, 
enabled antibody selection without the need for prior animal immunization (107). By 
engineering the display of a diverse antibody repertoire on the surface of filamentous 
bacteriophage with each individual phage carrying both the functional antibody and 
its particular DNA sequence packaged within, antibody specificity and genotype were 
coupled together and could now be selected in tandem. This was achieved by 
cloning variable domain antibody sequences, extracted from B cells via PCR, into a 
plasmid vector in-frame with the gene III phage coat protein to create a polyclonal 
library of antibody sequences. Transformation of the library into a suitable bacterial 
host along with the genome of the phage, typically M13 bacteriophage, resulted in 
expression of a polyclonal collection of antibodies displayed on phage. The genome 
of the phage could be delivered either as part of the library plasmid vector or 
separately through a helper phage. The second method is generally preferred as it 
results in a smaller library vector allowing for easier manipulation.  
 
 Non-immune, immune and synthetic antibody libraries (with randomized 
CDRs) have been created from both human and animal sources. They are displayed 
on both phage as well as alternative display platforms such as ribosome, yeast, 
bacteria and mammalian cells, all of which rely on the principle of coupling of 





variety of targets (108-110). In particular, the ability to recover a diverse range of 
antibody sequences from human B cells through the use of degenerate primer sets 
or the construction of semi-synthetic libraries using germline human frameworks and 
CDRs comprised of randomized amino acids enabled the production of extremely 
diverse and unbiased fully human antibody libraries with the ability to target both 
foreign and self-antigens (11,111). A considerable advantage of in vitro antibody 
screening via phage libraries is the ability to bias selection for antibodies with 
specific properties such as binding at pH or temperature extremes, or for fast or slow 
on and off-rates respectively, or to incorporate negative selection to remove cross-
reactive epitopes; all of which is not possible in an in vivo system as binding always 
occurs under physiological conditions (109). This lack of constraint on selection 
conditions has allowed phage display to be used for the selection of non-polar lipids 
that are insoluble in aqueous medium such as oxidized cholesterols, long chain fatty 
acids and prostaglandins (10,112,113). 
 
1.4.3 Recombinant antibody expression 
 
 While recombinant antibody offers a comprehensive antibody selection 
methodology, the end result is typically just the genetic sequence of the variable 
heavy and light chains of identified antigen-specific antibodies encoded on the library 
vector. As such, the complete antibody molecule must be expressed using a 
separate methodology. This is in contrast to hybridomas in which the selected clone 
continues to secrete the whole antibody in culture (99). Expression of recombinant 
antibody has been carried out in a variety of hosts, including mammalian cell culture, 





has the advantage of being the original expression environment of the protein, as 
well as being able to provide post translation modification such as N-linked 
glycosylation of the N297 residue on the constant domain of IgG, which is required 
for Fc receptor (FcR) binding and complement fixation (114-116). The disadvantages 
of mammalian cell culture however are reduced speed due to slower growth in 
culture and increased costs (117,118). An alternative eukaryotic expression system 
that lacks both these disadvantages is yeast, which as a eukaryotic system has 
advanced protein folding machinery and secretory apparatus and has been used to 
produce full length soluble antibodies (119). However, unmodified strains of yeast 
produce highly mannosylated N-linked glycosylation, which target proteins for rapid 
clearance in vivo in mammals. Using glyco-engineering, proprietary strains of Pichia 
pastoris have been developed which produce more mammalian type glycosylation to 
overcome this limitation, though access to these strains is limited (120).  
 
 For antibodies where effector function is not required, such as those intended 
for diagnostic use, prokaryotic systems may be used to produce antibodies or 
antibody fragments, which offers significant reduction in speed of production and 
costs (117,118). While expression of full length monomeric IgM was achieved in the 
bacterial host Escherichia coli soon after the development of monoclonal 
hybridomas, it required refolding of the antibody from the insoluble protein fraction 
(121). Instrumental for the expression of soluble antibody fragments was the 
development of expression constructs with the ability to direct protein translation into 
the periplasm by addition of a heterologous signal peptide at the N-terminus of the 
protein coding sequence. Export into the periplasm enables proper formation of inter 





compared to the cytoplasm and hence allows for proper assembly of the antibody 
molecule (122).  
 
 E. coli is not ideal for the periplasmic expression of antibodies or antibody 
fragments due to the limited ability of the bacterial host to ensure proper polypeptide 
pairing, folding and disulphide bond formation of the antibody molecule, resulting in 
poor yields of soluble protein due to aggregation and/or degradation of improperly 
folded protein (123). As such, considerable effort has been made to optimize 
bacterial hosts for antibody and antibody fragment expression. Engineering of 
oxidizing cytoplasmic environments, co-expression of molecular chaperones, use of 
periplasmic protease deficient strain of E. coli and balancing of heavy and light chain 
expression have all enabled increased yield (123-126). More recently, various 
groups have used a combination of specially engineered protease-deficient E. coli 
strains and reduced rates of expression to produce full length aglycosylated 
antibodies to appreciable levels (110,125).  
 
1.5 Lipid biomarkers for TB diagnostics 
 
The development of recombinant antibody technology has made the 
development of high specificity and affinity diagnostic antibodies against lipid and 
carbohydrate targets viable. Mtb has a wide variety of lipid and glycolipid targets 
which are typically found in the cell wall of the microbe (Fig. 1-2). Insoluble lipids 
include sulfolipids, phthiocerol dimycocerosate (PDIM), mycolic acid- both free and 
covalently bound to the peptidoglycan layer of the cell wall and mycolic acid 





are comprised of phosphatidylinositol mannosides, lipomannan and 
lipoarabinomannan (LAM) (127). Of particular interest as biomarkers are mycolic 
acid and LAM, due to their reported presence in sputum and urine clinical samples 
respectively (12,13). 
 
Figure 1-2: Structure of the mycobacterial cell wall 
LAM and mycolic acids can be seen integrated into the cell wall. The majority of 
the mycolic acids are covalently attached to the arabinosyl residues of the 










1.5.1 Lipoarabinomannan  
 
 Lipoarabinomannan (LAM) has become a target of particular interest in TB for 
two principle reasons; first, unlike most lipids it is soluble and immunogenic and 
hence generating antibodies in animals is straightforward; and second, it has 
purportedly been found in the urine of TB patients, which is easier to sample / collect 
and less likely to be biohazardous compared to the collection of sputum (129). LAM 
has a core structure consisting of a mannosyl-phosphatidyl-myo-inositol lipid anchor 
attached to a highly branched polysaccharide with a repeating α1-6 mannose 
backbone and α1-5 arabinose branches which are decorated with secondary 
arabinose branches with α1-3,5 and β1-2 linkages (Fig. 1-3) (130). The core lipid 
anchor has up to four fatty acid chains which are thought to anchor the LAM in the 
plasma membrane of the bacterium. LAM can be extracted from a crude cell wall 
fraction using ethanol solvent or boiling with SDS, indicating that it is tightly 
integrated but not covalently bound to the cell wall (131). However, the ability of 
antibodies to bind LAM on the surface of intact mycobacteria and the role of LAM in 
mannose receptor driven phagocytosis suggests that a portion of it at least is 






Figure 1-3: Structure of lipoarabinomannan 
Red boxes highlight the three different capping motifs found on mycobacterial 
LAM. The core of the LAM structure is formed from α1-6 mannose and α1-5 
arabinose residues (Adapted from Nigou et al, 2003). 
 
  
Investigations into the cell wall components of mycobacteria have indicated 
that LAM is present in all mycobacterial species studied to date although the wide 
variety of mycobacterial species discovered has precluded an exhaustive search for 





of actinomycete species of related genera such as Amycolatopsis sulphurea, 
Corynebacterium diphtheriae, Rhodococcus ruber, Tsukamurella paurometabolum 
and Turicella otitidis, although the majority of these lack the arabinose branches and 
instead have individual monosaccharide arabinose and mannose residues 
decorating the main oligomannose backbone (130,132-135). As such, there is a high 
chance that anti-LAM antibodies could cross react with these species. Interestingly, 
there is variation in the LAM structure across different mycobacterial species which 
occurs primarily at the capping motifs at the end of the secondary arabinose 
branches. These are thought to coincide with the phylogenetic organization of the 
various species and are believed to be responsible for much of the biological activity 
of this molecule. At least three different LAM variants with different capping motifs 
have been described (Fig. 1-3): PILAM – with a phosphoinositide cap in fast growing 
mycobacteria such as M. fortuitum and M. smegmatis; ManLAM – with a mannose 
cap with up to three α1-2 linked mannose residues in slow-growing mycobacteria, 
which include all major pathogenic species such as M. tuberculosis, M. bovis, M. 
leprae and M. avium. Lastly, the fast growing mycobacterial species M. chelonae has 
been found to have no sugar caps on its secondary arabinose branches (AraLAM) 
(130). An antibody specific for these α1-2 mannose motifs could therefore distinguish 
the pathogenic slow-growing mycobacteria from the non-pathogenic fast-growing 
mycobacteria. 
 
 α1-2 mannose-capped LAM (ManLAM) has been found to be involved in the 
phagocytosis and entry of virulent M. tuberculosis into host macrophages and 
suppression of their immune response. A comparison of phagocytosis of beads 





mannose caps for binding and uptake via the mannose-receptor (136,137). This 
receptor is a major point of entry for mycobacterial infection and ManLAM mediated 
entry via the mannose-receptor has been associated with the inhibition of fusion of 
the lysosome with the phagosome and enhanced survival of intracellular bacteria 
(136). Reduction in the availability of surface exposed mannose residues due to 
variation in the degree of mannose capping among different M. tuberculosis strains 
correlates with reduced uptake of mycobacteria and infectivity, thus confirming its 
key role in macrophage infection (138).  
 
 Mtb is known to interfere with phagocytosis progression by inhibiting 
phagosome-lysosome fusion, as well as blocking apoptosis of infected 
macrophages, thus ensuring its intracellular survival (139,140). While the effector 
mechanisms have not been completely elucidated, ManLAM has been shown to 
have inhibitory effects on phagocytosis-related signalling pathways such as blockage 
of cytosolic Ca2+ release via inhibition of sphingosine-1-kinase activity and insertion 
of the endosomal marker EEA1 into the phagosome (139,141). These effects may 
be mediated by the incorporation of free LAM into the cell membrane of the infected 
host cell (142). In addition, other immunosuppressive effects of ManLAM have been 
observed, including modulation of cytokine secretion from a stimulatory to inhibitory 
phenotype, inhibition of T cell activation and blockage of dendritic cell maturation 
(143-145). These effects have not been noted with LAMs carrying other capping 
motifs, indicating that these mannose caps on the termini of the LAM molecule are 






 More recently, evidence arguing against the mannose caps of LAM as 
virulence factors was reported. A mutant strain of BCG expressing a LAM lacking 
mannose caps was found to survive equally well in a mouse infection model and 
produce a similar cytokine profile as the non-mutant strain, although it had slightly 
reduced uptake and increased phagosome-lysosome fusion (146). The same 
mutation in Mtb similarly had no effect on its survival and cytokine induction in mice 
in vivo and well as in macrophage in vitro (147). 
 
1.5.2 LAM diagnostics  
 
The first LAM test was developed in 1990 as a sandwich ELISA using a 
monoclonal antibody detector and anti-BCG polyclonal antibodies to detect LAM 
from the centrifuged sputum pellet and showed intermediate sensitivity between 
sputum smear and culture (82). Another similar study was carried out using liquefied 
sputum supernatant, but tested primarily smear-positive patients and thus did not 
provide a representative patient cohort (84). A separate study on serum samples 
using cohaemagluttination of S. aureus Cowan strain incubated with anti-Mtb 
polyclonal indicated high specificity, but used a laborious method of processing 
serum requiring several rounds of ethanol precipitation to remove interfering serum 
proteins and antibodies (148). Subsequently, two groups explored urine as a 
potential clinical sample for testing of LAM. Both groups used a rabbit polyclonal 
raised against the crude Mtb cell wall fraction and affinity purified against LAM as 
opposed to previous groups which used unpurified polyclonals. Their data showed 






 The initial success of urinary LAM diagnostics led to the development of two 
commercial LAM ELISA kits (Clearview TB ELISA, Inverness Medical Technology & 
Determine TB LAM Ag Test, Alere) based on those studies’ protocols, which was 
extensively tested in a variety of clinical studies but failed to show significant utility 
above sputum smear microscopy due to low sensitivity (6-51%) in urine samples 
(139,149-153). In sputum samples, sensitivity was better but this was further 
complicated by low specificity due to cross-reactivity with other microbacterial flora 
present in the patients’ sputum such as Nocardia and Tsukamurella species (154). 
Sensitivity was also not enhanced by the use of induced sputum (155). This low 
sensitivity was confirmed by a recent meta-analysis combining all available clinical 
data on commercial LAM assays and has been attributed to either low levels of LAM 
in the urine or modification of LAM by the host leading to reduced binding and 
detection (13).  
   
A recent paper suggested that low levels of excreted urinary LAM in 
immunocompetent individuals could be due to retention of LAM in the circulation 
caused by formation of immune complexes with anti-LAM antibodies; alternatively, 
high levels of LAM in immunodeficient individuals could be due to spread of infection 
to the urinary tract (156). However, more recently, Lawn et al has shown that a LAM 
lateral flow type urinary assay (Determine TB LAM Ag Test, Alere) which is both 
rapid and cheap, in combination with sputum smear microscopy, can achieve 
detection sensitivities approaching that of the Xpert MTB/RIF assay in HIV patients 
with low CD4 levels (157,158). As the test has increased sensitivity in patients with 
lower CD4 levels whom are more likely to progress rapidly towards severe disease 





test to identify TB/HIV co-infected patients at high risk of fatal disease (159). Given 
that the main drawback for urinary LAM assays are their lack of sensitivity, use of 
more sensitive technologies or targeting alternative forms of clinical material from 
patients (such as serum) may potentially yield better outcomes. 
 
1.5.3 Mycolic acid 
 
Unlike LAM, mycolic acid is extremely hydrophobic and insoluble in aqueous 
solution and therefore more difficult to manipulate in a diagnostic assay. However, it 
is highly abundant in the cell wall of Mtb, consisting of around 40% of the dry weight 
of the cell and therefore should be one of the most abundant targets for detection 
(47). The majority is covalently anchored to the arabinogalactan-peptidoglycan cell 
wall and can only be released by alkaline hydrolysis (Fig. 1-2). Free mycolic acids 
are also present interspersed between the anchored mycolic acids and can be 
extracted just with organic solvents (127). These are either unmodified or conjugated 
to carbohydrates to from dimycolates such as trehalose dimycolate (TDM, also 
known as cord factor) and phthiocerol dimycocerosate. To date, there is no method 
devised that allows for the detection of mycolic acid directly from clinical samples. 
Instead, analysis of mycolic acid must be carried out on lipid extracts of culture or 
sputum using a combination of organic solvent extraction and alkaline hydrolysis to 
liberate both free and covalently bound mycolic acid (12,160). Identification of 
mycolic acid can then be performed using high performance liquid chromatography, 
electrospray ionization mass spectrometry, thin layer chromatography or nuclear 






The general structure of mycolic acid can be described as a β-hydroxyl fatty 
acid with an α-alkyl branch (Fig. 1-4) (48,165). The α-alkyl is the shorter branch and 
does not contain any functional groups while the longer fatty acid tail, referred to as 
the meromycolate branch can have unsaturated double bonds, cyclopropane and 
various other functional groups which enable mycolic acids to be classified as 
follows: alpha mycolic acids, which only has the aforementioned functional groups, 
as well as keto, methoxy, epoxy and wax ester mycolic acids which carry their 
named functional groups respectively.  
 
 
Figure 1-4: Structure of the three main classes of mycolic acid in Mtb.  
The longer chain is the meromycolate chain with the functional methoxy and 
keto groups circled in red. The cyclopropane groups are represented by 
triangles. The folded W configuration of mycolic acid is shown with the 
functional groups exposed at the edges of the structure. (Adapted from 






Mycolic acids can be found in all mycobacterial species and also in the related 
actinomycete genera Corynebacterium, Gordona, Nocardia, Rhodococcus, and 
Tsukamurella (48,166,167). Within these genera and among the individual species 
and strains, there are characteristic variations in the types of mycolic acid found and 
the length of the α-alkyl and meromycolate branches and the locations of the 
functional groups therein (165,168). These can be used as diagnostic indicators for 
identification of the mycobacterial species (160,161). There are also overall mycolic 
acid characteristics that can be attributed to particular genera; mycobacteria are 
notable for having mycolic acids with the longest carbon chains with a total of 60-90 
carbons atoms and an α-alkyl of 20-26 carbon atoms followed by Tsukamurella 
mycolic acids with a total of 64-78 carbon atoms (48,167). Corynebacterium on the 
other hand has the smallest mycolic acids with a range of 22-40 carbon atoms 
(169,170). Similarly, individual mycobacterial species have different types of mycolic 
acid, with the methoxy mycolic acids being limited to the Mtb complex group of 
species (M. tuberculosis, africanum, bovis) and a few other pathogenic species 
including M. gordonae and M. marinum while alpha mycolic acids are found in all 
species (48). Mtb also contains keto mycolic acids but lack the wax ester and epoxy 
mycolic acids (164).  
  
Mycolic acid plays a vital role in the virulence of Mtb. Structurally, mycolic acid 
plays a major role in maintaining the impermeability of the mycobacterial cell wall 
due to its hydrophobicity with its long alkyl chains and immobile nature in covalent 
attachment to the peptidoglycan layer, which serves to limit drug access to the core 





extracellular Mtb biofilms, which are believed to enhance drug tolerance (171). It has 
also been found to have immunomodulatory properties; Mtb oxygenated mycolic 
acids were found to induce formation of foamy macrophages which act as nutrient 
reservoirs within which the intracellular mycobacteria can replicate (172,173). Loss 
of different cyclopropane functional groups within mycolic acid has various 
contradictory effects in mouse infection models with enhanced inflammation and 
cytokine production and either enhanced or attenuated virulence (57,174). Different 
classes of mycolic acids have also been shown to elicit differential immune 
responses when dosed intra-tracheally in mice: while alpha mycolic acids were 
relatively inert, cis-cyclopropane containing methoxy and keto mycolic acids elicited 
inflammatory responses. In contrast, trans-cyclopropane methoxy mycolic acid 
partially lost its inflammatory activity and keto mycolic acid exerted anti-inflammatory 
alternative activation of alveolar macrophages and counteracted effects of cis-
cyclopropane mycolic acids. Thus, the various functional groups of mycolic acid may 
exert both anti-inflammatory and pro-inflammatory effects so as to modulate the 
immune response to maximise chances of survival, such as triggering granuloma 
formation but not macrophage apoptosis (175). Mycolic acid specific CD1b+ T cells 
were also found to be present in the immune response of TB patients but not in 
healthy BCG vaccinated controls, suggesting that they may also have a significant 
role in driving host response to infection (176). However, mycolic acids are also 
targets of several widely used anti-mycobacterial drugs such as isoniazid, 







While mycolic acids can be readily detected by chromatographical techniques, 
their hydrophobicity renders them difficult to target with antibodies. Nonetheless, it is 
known that anti-mycolic acid antibodies can be produced during infection in humans 
and detected using mycolic acid-containing liposomes as the target for a serological 
assay (178). However, high cross-reactivity with control serum samples was 
observed, which was proposed by Verschoor to be due to mycolic acids adopting a 
cholesteroid like structure when in a lipid membrane (179). Studies with purified 
mycolic acid monolayers on aqueous medium have supported this theory by 
indicating that mycolic acids form a W-shaped configuration with the functional 
groups at the corners of the W and the alkyl chains running folded and parallel to 
each other and perpendicular to the membrane surface (180). In particular, the keto 
mycolic acids was found to prefer this configuration as the greater hydrophilic nature 
of the keto groups encourages solvent exposure and discourages burying of these 
functional groups within the hydrophobic core of the molecule (181). This theory is 
supported by the isolation of anti-mycolic antibodies from a chicken scFv phage 
display library that also had cross-reactivity to cholesterol (182). Nonetheless, the 
surface exposure of distinguishing hydrophilic functional groups suggests that 
developing highly specific ant-mycolic acid antibodies is a possibility.  
 
1.6 Aims of this project 
 
In this study we address key challenges in TB diagnostics. We aim to develop 
antibodies targeting lipids and glycolipids enriched in the TB cell envelope and we 
will combine this with developing technology platforms that allow for the production 





the basis for the development of a low cost diagnostic platform for TB that will be 
applicable in the developing world. Specifically, our aims are to: 
 
1.6.1 Optimize expression of full length IgG in E. coli 
 
Expression of IgG in bacterial culture is one way of reducing costs of antibody 
production. This may be important in ensuring that the costs of antibody-based 
assays are kept to a minimum. Current methods of bacterial IgG expression rely on 
specially optimized strains not available to general laboratories (125). Alternatively, 
studies have shown that balancing translation rates to ensure that the protein 
secretory machinery is not overloaded can improve yields of heterologous proteins 
(183). Using a generally available E. coli expression strain, we aim to optimize 
bacterial IgG expression using simple methods for reducing translation rates.  
 
1.6.2 Develop antibodies targeting the Mtb lipids Lipoarabinomannan and 
mycolic acid 
 
Previous studies on LAM based diagnostic assays have primarily relied on 
polyclonal antibodies, which may have batch to batch variation and have been 
shown to exhibit cross-reactivity to non-pathogenic mycobacteria and non-
mycobacterial actinomycete species (154). By using antibody phage display 
selection on ManLAM coupled with negative selection with a non-mannose capped 
LAM to drive selection towards the α1-2 mannose caps, we aim to isolate a ManLAM 






Similarly, while antibodies have been previously generated against purified 
mycolic acid, these are in the scFv format which may lose affinity when converted to 
full IgG and are also cross-reactive to cholesterol (184). We therefore aim to isolate 
a mycolic acid-specific Fab from the same antibody phage display library that can be 
readily converted to an IgG for use in a diagnostic assay. 
 
1.6.3 Thoroughly characterize anti-LAM/anti-mycolic acid antibodies 
 
Antibodies isolated from the library will be tested for their specificity for 
ManLAM and mycolic acid, limit of detection and cross-reactivity to other antigens in 
a variety of immunoassays. One advantage of recombinant antibody expression is 
the ability to switch constant regions; we will explore the use of different human and 
murine constant regions to improve the clinical utility of our antibodies.  
 
1.6.4 Determine the diagnostic utility of the antibodies 
 
We will employ clinical samples from healthy controls spiked with the target 
biomarkers as well as actual clinical samples (urine, sputum and serum) to 
determine the diagnostic utility of the antibody. We also aim to optimize the antibody 




















Chapter 2: Materials and methods 
  




2.1 Buffers and solutions 
 
1xPBS & 1xPBS/T wash buffer 
200ml of 10x PBS buffer (1st Base, Singapore, Cat.No. BUF-2040) was topped up to 
2L with deionized water. Tween-20 detergent (Sigma-Aldrich, United States, Cat. No. 
P1379) was added at 1:2000 dilution for PBS/T (0.05% Tween). Filter sterilization 
was carried out with a 0.22µM bottle-top filter.  
 
Bacterial periplasmic extraction buffer 
Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 100 mM Tris pH 8.0 (1st Base, 
Singapore, Cat.No. BUF-1415-1L-pH8.0), 150 mM NaCl, 1 mM EDTA (Duchefa, 
Netherlands, Cat. No. E0511), 0.5 M sucrose (Sigma-Aldrich, United States, Cat. No. 
S0389), 1 mM PMSF (Sigma-Aldrich, United States, Cat. No. P7626), 1 µg/ml 
pepstatin A (Sigma-Aldrich, United States, Cat. No. P5318), 10 mM iodoacetamide 
(Sigma-Aldrich, United States, Cat. No. I6125) 
 
Bacterial Lysis buffer 
Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 20 mM sodium phosphate pH 7.4, 300 
mM NaCl, 1 mM EDTA (Duchefa), 0.5 mM PMSF (Sigma-Aldrich), 1 µg/ml pepstatin 
A (Sigma-Aldrich), 10 mM iodoacetamide (Sigma-Aldrich) and Complete EDTA-free 
protease inhibitor (Roche, Switzerland, Cat. No. 05056489001, 1 tablet/50ml 
solution)  
 




Protein L binding buffer 
Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 100 mM sodium phosphate buffer pH 
7.2, 150 mM NaCl 
 
IMAC (Immobilized metal affinity chromatography) wash buffer 
Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 50mM sodium phosphate buffer pH7.4, 
500mM NaCl 
 
IMAC elution buffer 
Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 50mM sodium phosphate buffer pH7.4, 
500mM NaCl, 250mM imidazole (Sigma-Aldrich, United States, Cat. No. I01250) 
 
5x Sodium dodecyl sulphate loading buffer 
11.25ml of 1M Tris-HCl pH 6.8 (1st Base, Singapore, Cat. No. BUF-1415-1L-pH6.8), 
2.5g of sodium dodecyl sulphate (SDS) (Bio-Rad, United States, Cat. No. 161-0302), 
25ml glycerol, 25mg of bromophenol blue (Bio-Rad, United States, Cat. No. 161-
0404) were mixed and made up to a final volume of 50ml with deionised water. 
Dithiothreitol (Sigma-Aldrich, United States, Cat No. D9163) was added to a final 









Reagents were made up to the following final concentrations in Milli-Q water and 
filter sterilized with a 0.22µM bottle top filter: 20mM Tris pH7.4 (1st Base, Singapore, 
Cat.No. BUF-1415-1L-pH7.4), 150m NaCl 
 
PEG solution for phage precipitation 
73.05g of NaCl and 100g of polyethylene glycol-6000 (Sigma-Aldrich, United States, 
Cat. No. 81260) was dissolved in deionized water to a final volume of 500ml (final 
concentration 2.5M NaCl, 20% w/v PEG) and autoclaved to sterilize. The hot 
autoclaved solution was cooled rapidly by shaking in a water bath to mix 
polyethylene glycol and aqueous layers which are immiscible at high temperatures. 
 
Alkaline hydrolysis buffer 
Solid potassium hydroxide (BDH, United Kingdom, 102104V) was dissolved in 100% 
methanol (VWR, United Kingdom, Cat. No. 20864-320) to give either 1 or 3M 
methanolic potassium hydroxide solution. 
 
Concentrated hydrochloric acid 
Concentrated hydrochloric acid (Fluka, United States, Cat. No. 84435) was added to 
distilled water to give a final solution of 4 or 8M hydrochloric acid. 
 
TMB stop solution 
97% concentrated sulphuric acid, approximately 18.3M, (Sigma-Aldrich, United 
States, Cat. No. 07208) was added to distilled water to give a final solution of 2M 
sulphuric acid.  




2.2 Construction of antibody expression vectors 
2.2.1 Construction of mammalian expression vectors 
 
All mammalian expression vectors were constructed on the pTT5 vector 
(Fisher Scientific, United States, Cat. No. 50-148-474) backbone which contains an 
Epstein-Barr virus oriP origin of replication for episomal persistence in cell lines 
expressing the EBNA1 protein and an improved cytomegalovirus-based expression 
cassette (185). Separate expression vectors were created for the heavy and light 
chain. For both vectors, a mammalian signal peptide was inserted upstream of the 
cloning site to direct antibody expression into the secretory pathway for disulphide 
bond formation, glycosylation and convenient harvesting from the culture 
supernatant. Either an SfiI or ApaLI restriction site was introduced at the signal 
peptide C-terminus to allow the heavy or light chain antibody sequence to be cloned 
in-frame. For the heavy chain vector, the IgG constant region sequence with an N-
terminal BsmBI restriction site (human G1, G3 or mouse G2a CH1-3 sequence for 
full length IgG; human G1 CH1 sequence up to the heavy-light chain disulphide 
bridge cysteine, followed by a myc and 6xHis-tag for Fab) was inserted downstream 
of the signal peptide. An XbaI site was added after the stop codon to allow for 
swapping of different constant region sequences. Heavy chain variable region 
sequences could then be sub-cloned directly in-frame from the phage library vector 
via the SfiI/BsmBI restriction sites. For the light chain expression vector, an AscI site 
was added downstream of the signal peptide to enable the sub-cloning of the 
complete light chain sequence (both variable and constant, including the stop codon) 
into the light chain expression vector in-frame. 
  




2.2.2 Construction of bacterial expression vectors 
 
The backbone of the antibody expression plasmid for employment in E. coli 
was derived from pASK-IBA2 (IBA GmbH, Germany, Cat. No. 2-1301-000), which 
contains a tetracycline based promoter and an OmpA leader sequence for export 
into the periplasm. To introduce the antibody sequences, the bicistronic expression 
cassette consisting of the light chain sequence, the intercistronic ribosomal binding 
site, and the heavy chain variable region with the PelB leader sequence was cloned 
in as a complete construct from the phage display library vector via ApaLI and 
BsmBI cloning sites with the light chain in-frame with the plasmid OmpA leader 
sequence. The heavy chain constant region of human G1 was cloned in from the 
mammalian IgG expression vector to be in frame with the variable heavy region. 
During the course of plasmid construction, deletion of a backbone restriction enzyme 
site situated within the origin of replication had created a reduced copy number 
plasmid in addition to the normal high copy number plasmid. For cloning in of the 
chimeric 4G2 antibody, the whole light chain and the heavy variable chain was 
cloned in via ApaLI/AscI and Mfe/Xho restriction sites respectively.  
 
2.2.3 Construction of chimeric antibody constructs 
 
Human G1 and G3 CH1 sequences and Mouse G2a CH2 and CH3 (Fc) 
sequences were amplified from previously constructed pTT5 expression vectors with 
primers designed to permit a second overlapping PCR of the human CH1 and 
mouse Fc sequences as follows, human G1 CH1: SEQ1B 5’-
CGGATCTCTAGCGAATTCC-3’ & HuG1MoG2aRev 5’-CCACCCAAGAG 




GTTAGGTGCTGGGCACGGTGGGCATGTG-3’; human G3 CH1: SEQ1B and 
HuG3MoG2aRev 5’- CCACCCAAGAGGTTAGGTGCTGGGCACCGTGGGCATGGG 
GG-3’; Mouse G2a: HuG1MoG2aFor 5’-CACATGCCCACCGTGCCCAGCACCTAA 
CCTCTTGGGTGG-3’ or HuG3MoG2aFor 5’-CCCCCATGCCCACGGTGCCCAGC 
ACCTAACCTCTTGGGTGG-3’ with MoG2aRev 5’-ATCCAGCTTCTAGACTATTTAC 
CCGGAGTCCGGGAGAAG-3’. The first round of PCR was carried out using Native 
Pfu polymerase (Stratagene, United States, Cat. No. 600135) with an initial melt at 
95°C for 5min, followed by 30 cycles at a melting temperature of 95°C for 30s, an 
annealing temperature of 56°C for 30s and extension at 72°C for 1min for CH1 
sequences and an annealing at 62°C for 30s and extension at 72°C for 2min for Fc 
sequences, followed by a final extension step at 72°C for 15min. PCR products were 
run on 1% agarose gel and the appropriate bands excised and DNA extracted 
(QiaQuick, Qiagen, Germany, Cat. No. 28704). 1µl of each purified PCR products 
were then combined in a second PCR using the same polymerase enzyme to 
overlap the human G1 or G3 CH1 and mouse G2a Fc sequences. Overlap extension 
PCR was carried for the first five cycles without primers with an initial melt at 95°C 
for 5min, followed by cycling at a melting temperature of 95°C for 30s at an 
annealing temperature of 62°C for 30s and extension at 72°C for 2min.1µl of each 
primer SEQ1B and MoG2aRev (at 10µM stock concentration) were then added and 
a further 25 cycles carried out at an annealing temperature of 56°C for 30s to amplify 
the final chimeric sequence before final extension at 72°C for 15min. The chimeric 
constant region PCR product were then purified on 1% agarose gel as above and 
cloned into the heavy chain mammalian expression vectors via the BsmBI and XbaI 
restriction sites.  
 




To create the chimeric light chain with a mouse light constant region for 
moG2afull, a reverse primer (LC-Rev) was designed that could anneal to the C-
terminal region of the variable light chain and also contained a short sequence of the 
N-terminal region of the mouse constant light chain (either kappa or lambda to match 
the isotype of the human variable light chain). This reverse primer together with 
SEQ01B primer was used to amplify the human variable light chain sequence from 
the pTT5 mammalian expression vector using the first round PCR protocol above 
with an annealing temperature of 56°C. A mouse kappa or lambda constant light 
chain sequence was also amplified using the same PCR protocol from a pTT5 
expression vector carrying a complete mouse light chain. The reverse primer SEQ03 
(5-‘CCTTTATTAGCCAGAGGTCG-3’) was used along with a forward primer that is 
the reverse complement of LC-Rev, which anneals to the N-terminal region of the 
constant light chain. PCR products were purified on 1% agarose gel as above and 
1µl of each PCR product used for overlap extension PCR to join the human variable 
and mouse constant region. Overlap extension PCR was carried for the first five 
cycles without primers with an initial melt at 95°C for 5min, followed by cycling at a 
melting temperature of 95°C for 30s at an annealing temperature of 56°C for 30s and 
extension at 72°C for 2min.1µl of each primer SEQ1B and SEQ03 (at 10µM stock 
concentration) were then added and a further 25 cycles carried out to amplify the 
final chimeric sequence before final extension at 72°C for 15min. The PCR product 
was purified on 1% agarose gel and sub-cloned back into the pTT5 light chain 
expression vector via the ApaLI/AscI restriction sites. 
 
 




2.2.4 Sub-cloning of antibody heavy and light chains by restriction digest and 
ligation 
 
Individual heavy chain variable region or complete light chain sequences were 
digested from selected monoclonal plasmid minipreps of the phage library vector 
(see section 2.8.4) using the pairs of restriction enzymes SfiI/BsmBI or ApaLI/AscI 
respectively (New England Biolabs, United States: SfiI – Cat. No. R0123, BsmBI - 
Cat. No. R0580, ApaLI – Cat. No. R0507, AscI – Cat. No. R0558) at the 
recommended digestion temperature and buffer. Cut DNA fragments were isolated 
by running on 1% agarose gel and the appropriate DNA band excised and gel 
extracted (QiaQuick, Qiagen). Vectors were cut similarly with the exception of the 
light chain vector where BsmBI was used to generate an ApaLI overhang due to the 
presence of multiple ApaLI sites in the vector. Cut insert and vector were ligated 
together with T4 DNA ligase (New England Biolabs, United States, Cat. No. M0202) 
and transformed into chemically competent XL1 blue E. coli (Stratagene, United 
States. Cat. No. 200249). Clones containing the inserted sequences were identified 
by restriction digest with of the same pairs of enzyme and grown up in 400ml of LB 
broth (BD, United States, Cat. No. 244610) with 100µg/ml carbenicillin (Novagen, 
United States, Cat. No. 69101-3) in a shaking incubator at 37°C and DNA extracted 
using a Endo-free Maxiprep kit (Macherey Nagel, Germany, Cat. No. 740426.50) for 
transfection into mammalian cell culture. 
 
2.3 Expression and purification of bacterial lgG 
2.3.1 Initial periplasmic expression in BL21 or HB2151 
 




The low copy number 4G2 expression plasmid was transformed into either 
HB2151 or BL21(DE3) E. coli (Stratagene, United States, Cat. No. 200131) and 
grown up in 2YT (BD, United States, Cat. No. 244020) broth with 100 µg/ml 
carbenicillin (Novagen). Induction was carried out at OD600 1.0 with 1/10 normal 
inducer concentration (final concentration of 20ng/ml). Periplasmic extraction was 
carried out by resuspending the pellet in 1/40 volume chilled periplasmic extraction 
buffer, sonicating briefly on ice and then gently rotated at 10 rpm for 1 hr at 4 °C. 
Cells were collected at 40000 g for 30min at 4 °C and the supernatant was retained.  
 
2.3.2 Small scale optimization of bacterial IgG expression conditions 
 
Expression plasmids were transformed into E. coli strain HB2151 and grown 
up as a starter culture. 50 ml of 2YT (BD) broth with 100 µg/ml carbenicillin 
(Novagen) was inoculated with 1/50 volume of starter culture and grown at 30 °C at 
220 rpm. Induction was carried out as indicated and cultures transferred to room 
temperature and grown overnight at 120 rpm. The bacterial pellet was weighed and 
resuspended in chilled lysis buffer at a ratio of 1 ml per 200 mg wet cell mass and 
sonicated on ice. Lysates were clarified by centrifugation at 16000 g for 30 min at 
4°C. All cultures were grown up in non-baffled shake flasks and cytoplasmic 
extraction carried out as described above for all subsequent experiments.  
 
2.3.3 Large-scale expression and purification of bacterial IgG 
 
 Expression was carried out in 2x 800 mL of 2YT broth (BD) with 100 µg/ml 
carbenicillin (Novagen) in 2L non-baffled shake flasks as described above with the 




following optimized conditions: high expression construct was used and induction 
was carried out at OD600 1.0 using 20ng/ml or 50ng/ml final inducer concentration. 
The cell pellet was weighed and resuspended in lysis buffer at the same volume to 
wet cell mass ratio as above, sonicated and clarified by centrifugation at 20000g for 
30min at 4°C. The cell lysate was passed through a 0.22µm filter before purification 
on a 1 ml recombinant Protein A FF column (GE Healthcare, United Kingdom, Cat. 
No. 17-5079-01) fitted to a AKTAprime Plus or Explorer FPLC system (GE 
Healthcare, United Kingdom). Lysate was passed through the column at a flow rate 
of 0.5 ml/min, then the column washed with 30 ml 1x PBS before elution in 0.5 ml 
fractions with IgG elution buffer (Pierce Thermo Scientific, United States, Cat. No. 
21004). Fractions were neutralized with 1/10 volume 1 M Tris pH 8.0. Peak fractions 
were pooled and buffer exchanged into 2 ml Protein L binding buffer with an Amicon 
30000 MWCO concentrator (Merck Millipore, United States, Cat. No. UFC903024) 
and then bound to 400μl Protein L agarose bead 50% slurry (Pierce Thermo 
Scientific, United States, Cat. No. 20512) overnight at 4°C. The beads were washed 
with ten column volumes of 1x PBS in column and antibody eluted with IgG elution 
buffer (Pierce, United States) and neutralized as above. Eluate was buffer 
exchanged into 1x PBS/20 % glycerol and concentrated down to 150 µl volume.  
 
2.4 Expression and purification of mammalian IgG and Fab 
 
Paired antibody heavy and light chain plasmids were transfected into HEK293-
6E cells (ATCC, United States, ) which stably expresses the EBNA1 protein using 
branched polyethyleneimine (Sigma-Aldrich, United States, Cat. No. 408727) as a 
transfection reagent. Cells were cultured in suspension at a density of 106cells/ml in 




complete serum-free F17 medium (20 ml GlutaMAX-I - Invitrogen Gibco, United 
States, Cat. No. 35050-061; 0.5 ml 50mg/ml Geneticin - Invitrogen Gibco, United 
States, Cat. No. 10131-027; 9 ml Pluronic F68 – Invitrogen Gibco, United States, 
Cat. No. 24040-032; 1 L F17 medium - Invitrogen Gibco, United States, Cat. No. 
A13835-01). 10µg (equal amounts of heavy and light chain plasmids by mass) of 
total DNA and 30µg of PEI were mixed in 1ml of filter sterilized 150mM NaCl solution 
(per 10ml of cell culture) and incubated for 15min before addition to the cell culture. 
Cells were incubated in a shaking incubator at 37°C in 5% CO2, 125rpm and 
tryptone-N1 (Organotechnie, France, Cat. No. 19553) added to a final concentration 
of 0.5% the following day. The cell culture was maintained for one week before 
harvesting the supernatant to recover the antibody. 
 
One week old cell culture was centrifuged at 8000g for 20min and the 
supernatant passed through a 0.22µM filter before affinity purification on a 1ml 
recombinant Protein A FF column (GE Healthcare, United Kingdom, Cat. No. 17-
5079-01) fitted to a AKTAprime Plus or Explorer FPLC system (GE Healthcare, 
United Kingdom) at a flow rate of 1ml/min. The column was washed with filter 
sterilized 1xPBS and bound antibody was eluted in 1ml fractions with IgG elution 
buffer (Pierce Thermo Scientific) and neutralized with 1/10 volume 1 M Tris pH 8.0. 
Peak fractions were pooled and buffer exchanged into 1xPBS with an Amicon 30000 
MWCO concentrator (Merck Millipore) and stored at -80°C after flash freezing with 
liquid nitrogen. For Fab, supernatant was passed through a 1ml IMAC column (GE 
Healthcare, United Kingdom, Cat. No. 17-0920-03) charged with 0.1M cobalt 
chloride and rinsed with deionized water. The column was then washed with IMAC 
wash buffer and then eluted in 1ml fractions with IMAC elution buffer. Peak elute 




fractions were buffer exchanged into 1xPBS and stored at -80°C as above for 
purified IgG. 
 
2.5 Polyacrylamide gels and western blot 
 
SDS-PAGE gels were cast from 40% 37.5:1 acrylamide-bisacrylamide solution 
(Bio-Rad, United States, Cat No. 161-0148) polymerised with 10% APS and TEMED. 
Samples taken during extraction and purification of bacterial or mammalian 
antibodies were resolved on 8 or 10% SDS-PAGE gels. Samples were heated in 
SDS loading buffer with or without addition of the reducing agent dithiothreitol for 
5min at 95°C and chilled on ice before running. For western blot, gels were 
transblotted to a Hybond-C nitrocellulose membrane (GE Healthcare, United 
Kingdom, Cat. No. RPN137E). IgG was detected using anti-Human Fc-HRP 
conjugated polyclonal secondary antibody (Pierce Thermo Scientific, United States, 
Cat. No. 31413) alone or in combination with anti-human Kappa-HRP conjugated 
polyclonal secondary antibody (Invitrogen, United States, Cat. No. AHI1804) diluted 
1:2500 or 1:5000 respectively in 5 % skim milk (Sigma-Aldrich, United States, Cat. 
No. 70166) in 1xPBS/T. Blots were washed four times with 1x PBS/T and once with 
1x PBS for five minutes each wash and then signal developed with SuperSignal 
West Pico Substrate (Pierce Thermo Scientific, United States, Cat. No. 34080). 
 
2.6 Measurement of protein concentration 
 
To measure protein concentration, purified antibody was measured by the 
Bradford method. 300µl of Coomassie Plus reagent (Pierce Thermo Scientific, 




United States, Cat. No. 23236) was added to 10µl of sample or protein standards in 
a flat-bottom 96-well plate and incubated for 10min at room temperature before 
reading absorbance at 595nm. Protein standards were used to generate a standard 
curve plotted on a log-log axis to determine sample concentration.  
 
2.7 Bacterial strains and culture 
 
Mycobacterium smegmatis was a kind contribution from Dr Ayi Teck Choon, 
DSO National Laboratories and Mycobacterium bovis Bacille Calmette-Guérin (BCG) 
was a kind contribution from Dr Sylvie Alonso, National University of Singapore. All 
other mycobacterial species were provided by Dr Seah Geok Teng, National 
University of Singapore. Nocardia cyriacigeorgica (ATCC BAA-1517) and 
Tsukamurella paurometabolum (ATCC 8368) was purchased from American Type 
Culture Collection, United States. Live mycobacterial culture was grown up to log-
phase growth in Middlebrook 7H9 media (BD, United States, Cat. No. 271310) at 
37°C in shake flasks with the exception of M. bovis (BCG) which was cultured in 
100ml of Middlebrook 7H9 broth at 37°C with 5% CO2 in T175 cell culture flasks for 
two weeks. Nocardia cyriacigeorgica and Tsukamurella paurometabolum were 
cultured in Brain-Heart Infusion Broth (BD, United States, Cat. No. 237500) while 
Escherichia coli strain XL1 blue was cultured in LB broth (BD), at 37°C in flasks in a 
shaking incubator. Heat killed inactivated Mtb (H37Rv strain) was kindly provided by 
Dr Sylvie Alonso and carried out by heating bacterial suspension at 90°C for 30min.  
 
To standardize mycobacterial cultures by colony-forming units (CFU) for 
subsequent experiments, bacteria were pelleted by centrifugation at 4000g for 15min 




in a 50ml Falcon, weighed and re-suspended in PBS containing 50% (v/v) glycerol to 
OD600 of 1.0 and then serially diluted 1:10 six times. 100µl of each dilution was 
plated onto Middlebrook 7H11 (BD, United States, Cat. No. 283810) agar plates 
supplemented with 10% OADC enrichment (BD, United States, Cat. No. 212351) 
and incubated at 37°C (with 5% CO2 for BCG) for 3 and 21 days for M. smegmatis 
and BCG respectively before the colonies were enumerated. The procedure was 
performed in duplicate and the average CFU per unit OD600 was calculated to 
determine the appropriate dilutions for subsequent experiments. 
 
2.8 Phage display 
2.8.1 Negative selection panning against ManLAM 
 
A non-immune human Fab-antibody phage display library (Humanyx Pte Ltd, 
Singapore) constructed by the method of Hans de Haard et al was screened for anti-
LAM antibodies after multiple rounds of selection on Mannose capped 
lipoarabinomannan (ManLAM) from Mycobacterium tuberculosis Ayoma-B strain 
(Nacalai Tesque, Japan, Cat.No. 02449-61) coupled with negative depletion on 
Phosphoinositide capped lipoarabinomannan (PILAM) from M. smegmatis 
(Invivogen, United States, Cat. Code TLRL-LAMS) (11). Cross-reactive LAM 
antibodies were first depleted from the library by pre-absorption to 100μg PILAM 
coated onto a Maxisorp immunotube for 1½ hr at room temperature (Nalgene Nunc, 
United States, Cat. No. 470319). Remaining cross-reactive antibodies were blocked 
in solution by the addition of 100μg of soluble PILAM. The phage library was then 
applied to an immunotube coated with 100μg of ManLAM to pull out anti-ManLAM 
antibodies by binding for 1½-2hrs at room temperature. Coated tubes had been 




washed twice with 1xPBS after coating and pre-blocked with 4% skim milk in 1xPBS 
for 2hrs at room temperature prior to application of the library. Unbound phage were 
removed by repeated washing with 2% skim milk block in 1x PBS/T, followed by 
1xPBS/T and 1xPBS washes. Three skim milk washes, three PBS/T washes and two 
PBS washes were carried out for the first pan and for subsequent pans the number 
of skim milk and PBS/T washes was increased to seven. Solid surface pre-
absorption with PILAM on an immunotube was carried out only for the first two 
rounds of selection and a total of four rounds of selection were carried out. Phage 
was then recovered after each round of selection on immunotube to produce an 
enriched polyclonal library as described below in section 2.8.3.  
 
2.8.2 Lipid panning against mycolic acid 
 
The same non-immune human phage Fab antibody phage display library 
(Humanyx Pte Ltd, Singapore) used for generating anti-LAM antibodies was panned 
against mycolic acid based on a previously developed protocol for generating anti-
lipid antibodies (10). Briefly, the Maxisorp immunotube (Nalgene Nunc) was coated 
by evaporating 200μg of Mtb-derived mycolic acid (Sigma-Aldrich, United States, 
Cat. No. M4537) dissolved in 0.5ml n-hexane overnight at 4°C, washed twice with 
1xPBS and then blocked with 4% skim milk in 1xPBS for 2hrs at room temperature. 
The phage library was then panned against the lipid coated immunotube as 
described above in section 2.8.1 without any negative depletion and a modified 
washing protocol. After the library was allowed to bind, the immunotube was washed 
four times with 2% skim milk in 1xPBS and eight times with 1xPBS for the 1st pan. 
The number of washes was doubled for subsequent pans. Phage was then 




recovered after each round of selection on immunotube to produce an enriched 
polyclonal library as described below in section 2.8.3.  
 
2.8.3 Phage recovery after each round of panning 
 
 Bound phage was recovered by enzymatic elution with 500µl of 2mg/ml 
trypsin (Sigma-Aldrich, United States, T9935) in 1xTBS with 2mM CaCl2 at 37°C for 
30min and re-infected into 5ml of freshly cultured TG1 E. coli at OD600 0.5 for the 
library recovery. After the second round of selection, a 1.2ml portion was set aside, 
spun down and resuspended in 2YT/50% glycerol and stored at -80°C for 
subsequent isolation of monoclonal phage.  Phage infected TG1 was further infected 
with M13KO7 helper phage (New England Biolabs, US, Cat. No. N0315S) at an MOI 
of 1:20 and grown overnight at 30°C on 2YT (BD) with 100µg/ml of ampicillin and 
25µg/ml of kanamycin (2YTAK) agar plates to produce polyclonal phage. Expressed 
phage was recovered the next day by scrapping the bacterial lawn with 5ml of Tris-
buffered saline (1xTBS, pH7.4) per plate and centrifuging the bacterial suspension at 
4000g for 20min. Phage in the recovered supernatant was precipitated by adding a 
1/5 volume of PEG solution (2.5M NaCl/20% polyethylene glycol 6000), incubating 
on ice for 1hr and then centrifuging for 15min at 10000g. Precipitated phage was 
resuspended in 2ml of 1xPBS, clarified by centrifugation at 16000g for 2min to 
remove any insoluble particles and then precipitated with PEG solution as above and 
pelleted with centrifugation at 16000g for 5min The purified phage pellet was finally 
resuspended in a final volume of 1.5ml in 1xPBS and centrifuged one last time at 
16000 for 1min to remove any remaining insoluble debris or phage. 100µl of this 
enriched polyclonal library was then mixed with 900µl of 4% skim milk in PBS and 




blocked for 1hr before binding to a freshly coated immunotube for the next round of 
selection. Recovered polyclonal phage was also used in phage polyclonal ELISA to 
test for enrichment against the target antigen. 
 
2.8.4 Screening of phage libraries 
 
Phage libraries were screened by producing monoclonal phage culture as 
follows: infected TG1 glycerol stock (from an appropriately enriched pan as 
determined by polyclonal phage ELISA) was diluted 1:10 from 10-3 to 10-6 in 2YT 
broth and the dilutions plated out on 2YT with 100µg/ml of ampicillin and 2% glucose 
(Sigma-Aldrich, United States, Cat. No. G8270)-2YTAG agar plates to obtain single 
colonies. Approximately 400 individual colonies were picked and each inoculated 
into 300µl of 2YTAG media in a 2ml deep well plate (Nalgene Nunc, United States, 
Cat. No. 278752) and grown overnight at 37°C shaking at 700rpm for starter culture. 
10µl of starter culture was inoculated the next day into 200 µl of fresh 2YTAG media 
in a new deep well plate and grown up by shaking at 37°C at 700rpm until a culture 
density of OD600 0.5 was reached. M13KO7 helper phage (New England Biolabs) 
was then added at an MOI of 1:20 and the culture incubated for a further 1hr. The 
culture was pelleted by centrifugation at 4000g for 10min and supernatant discarded. 
The pellets were resuspended in 300µl of fresh 2YTAK media and then grown at 
30°C overnight at 700rpm for monoclonal phage production. Monoclonal phage 
secreted into the culture supernatant was tested by ELISA as described below in 
section 2.13.2 to identify target-specific clones.  
 




Subsequently, positive clones were screened for unique clones by BstN1 
digestion of the amplified heavy and light chain coding region. Clones with different 
sequences would have different digestion patterns. The antibody coding region was 
amplified by colony PCR using HotStarTaq PCR Master Mix (Qiagen, Germany, Cat. 
No. 203443) according to manufacturers’ protocol from 1μl of bacterial culture in a 
20μl reaction volume with 1μl each of the following primers at 10μM concentration: 
HX01-F (5’-AGCGGATAACAATTTCACACAGG-3’)/HX01-R (5’-.TGATTGCAGACCT 
TTCTGCTGTTT-3’) The PCR reaction was run as follows: 95ºC initial melt for 15min, 
then 30 cycles of melting for 45s at 95ºC, annealing for 45s at 52ºC and extension 
for 1min 40s at 72°C, followed by a final extension step at 72°C for 10min. 10µl of 
the PCR mix was digested with 1µl of BstN1 (New England Biolabs, United States, 
Cat. No. R0168) for 3hrs at 60°C and run on a 3% agarose gel. Confirmation of 
unique sequences was done by Sanger sequencing using BigDye v3.1 (Applied 
Biosystems, United States, Cat. No. 4337455) of the Fab heavy and light chain 
sequences with the same primers used for colony PCR along with two additional 
primers that anneal in the intercistronic region (pCES-LR – 5’- 
ATGCCGTCGGCGACCTAACA-3’/pCES-HF – 5’-GGCGCGCCAATTCTATTTCAAG 
-3’) to provide overlapping coverage of the heavy and light sequences. Identified 
unique positive clones were grown up in 4ml of 2YT broth (BD) with 100µg/ml 
carbenicillin (Novagen) and 2% glucose at 37°C in a shaking incubator for recovery 
of the monoclonal plasmid DNA (prepared using plasmid miniprep kit, Qiagen 
Germany, Cat. No. 27104) for subsequent cloning into expression vectors. 
 
 




2.9 Carbohydrate microarrays 
 
Carbohydrate microarrays were fabricated as described previously (186). 
Gamma Amino Propyl Silane (GAPS) II slides (Corning, United States, Cat. No. 
40003/4) were submerged in dimethylformamide containing 2% 
diisopropylethlyamine and 0.5 mg/mL maleimido-N-hydroxysuccinimide hexanoic 
acid for 14hrs at room temperature. Functionalized slides were washed three times 
with methanol, dried and stored under an argon atmosphere. The functionalized 
oligosaccharides were synthesized as described previously (187). The 
oligosaccharide compounds with 1M equivalent tris(2-carboxyethyl)phosphine to 
reduce disulphides were dissolved to the desired concentration in PBS. Per spot, 1nl 
of the solution was printed onto the maleimide functionalized slides using an 
automated printing robot in replicates of ten at four different concentrations (2 mM, 
0.4 mM, 80 µM and 16 µM). Slides were incubated in a humid chamber to complete 
reaction for 24hr and stored in a dessicator until usage. Printed carbohydrate 
microarray slides were washed three times with water and quenched in 0.1 % (v/v) 
β-mercaptoethanol in PBS for 1 h at room temperature. Afterwards, slides were 
washed three times with water and two times with ethanol. Slides were blocked by a 
solution of 2.5% BSA in Tris buffer with calcium (20mM Tris, 150 mM NaCl, 1 mM 
CaCl2, pH 7.4 for 1 h at room temperature, washed three times with Tris buffer with 
calcium and centrifuged. The antibody (50µg/mL) was incubated on the slides in in 
20mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.4, washed three times with the 
same buffer and centrifuged. For inhibition, mannan, PILAM or ManLAM (each at a 
final concentration of 30 µg/mL) was added to the incubation solution. A 
fluorescence-labelled anti-human antibody (10µg/mL in 20mM HEPES, 150mM 




NaCl, 1mM CaCl2, pH 7.4; Invitrogen, United States) was incubated on the slide in a 
similar fashion. Afterwards, slides were scanned using a fluorescence microarray 
scanner (GenePix 4300A, Molecular Devices). 
 
2.10 Immunofluorescence and acid fast-staining 
 
Cover slips were rinsed with deionized water and 100% ethanol and then 
dried on a heating block at 60°C. Bacterial cultures were grown up as described 
above in section 2.7 and 20µl of bacteria re-suspended in filter sterilized deionized 
water to a density of OD600 0.1(approximately 10
6 CFU) was pipetted onto the cover 
slip and allowed to dry onto the cover slip on the heating block at 60°C. The cover 
slips were then transferred to a 24-well plate and fixed with 500µl of 1:1 mix of 
methanol-acetone for 30min at -20°C for immunofluorescence or 5% phenol-70% 
ethanol solution for 15min at room temperature for acid fast staining respectively. 
Cover slips were then taken out of the fixative and allowed to dry. For 
immunofluorescence, fixed cover slips were washed once with 1xPBS and then 
blocked with 2% foetal calf serum in 1xPBS, washed again with 1xPBS and then 
incubated with primary antibody, either 5µg/ml my2F12 chimeric antibody or 1:200 
rabbit anti-LAM polyclonal (Acris Antibodies, Germany, Cat. No. PAB14007) in 
blocking solution. Cover slips were then washed with two 5-min incubations in 
1xPBS/T and rinsed in 1xPBS before incubation with secondary antibody, either anti-
rabbit or anti-mouse polyclonal (Invitrogen, United States, Cat. No. A-21207 and A-
11001) conjugated to Alexa Fluor 594 and 488 respectively, at 1:100 dilutions in 
blocking solution. The cover slips were washed again as above, rinsed in deionized 
water before mounting with Mowoil on glass slides. All washes were done in 24-well 




plates and incubations done on parafilm with 50µl of reagent for 30min at room 
temperature. Mounted slides were viewed using a Confocal Laser Microscope 
system (Leica SP5, Germany). For acid fast staining, fixed slides were stained with 
TB Quickstain (BD, United States, Cat. No. 212315) according to manufacturer’s 
instructions in 24-well plates. The slides were stained with carbolfushin for 5min, 
rinsed liberally with deionized water then flooded with TB Quickstain Methylene Blue 
to counterstain for 3min and then rinsed again with deionized water. Cover slips 
were allowed to dry and then fixed to glass slides and viewed under a light 
microscope (Leica, Germany). 
 
Common throat bacterial smears on glass slides were provided heat fixed and 
formalin activated by Dr Timothy Barkham, National University of Singapore. These 
were incubated with 5µg/ml my2F12 chimeric antibody in blocking buffer (5%BSA in 
1x PBS) for 1hr, washed and probed with Alexa Fluor 488 anti-mouse polyclonal 
(Invitrogen) and washed again as above. After washing, DAPI mounting medium 
(Invitrogen, United States, Cat. No. P-36931) was added and the smear covered with 
a glass slip and visualized at 100x power using a fluorescence microscope (Olympus 
BX51, United States) under UV and 488nm illumination for detection of DAPI and 
secondary antibody respectively.  
 
2.11 Collection and processing of bacterial cultures for ELISA 
2.11.1 Bacterial supernatants and whole cell suspension for LAM ELISA 
 
To harvest the supernatant, fresh mycobacterial cultures at stationary phase 
growth were spun down at 4000g for 20min and the supernatant harvested and 




sterilized by passing through a 0.22µM syringe filter. To adjust for differences in 
culture density, the OD600 of each culture was measured prior to harvesting and the 
supernatant diluted with fresh Middlebrook 7H9 broth media (BD) at a ratio 
equivalent to produce a culture density of OD600 1.0. For testing whole bacteria 
suspensions, the pellet was re-suspended in filter sterilized 1xPBS and adjusted to 
OD600 0.5.  
 
2.11.2 Lipid extraction from bacterial cultures for mycolic acid ELISA 
 
1ml of OD0.1 M. smegmatis (5.8x107 CFU/ml) were centrifuged from pure 
culture at 16000g for 15min in 2ml Eppendorf tubes and the pellet was re-suspended 
in 1mL of n-hexane (Sigma-Aldrich, United States, Cat.No. 27050-4). The mixture 
was vortexed for 15 minutes, incubated on a rotator at room temperature overnight, 
then centrifuged and the organic layer was recovered. To enhance the effectiveness 
of solvent extraction, a second methodology was tried where the sample was heated 
for two hours at 70°C before vortexing. To lyse the bacteria to improve extraction, a 
third protocol was carried out where the same amount of mycobacteria was re-
suspended in 1mL of Milli-Q water and incubated at 99°C for 30 minutes using a 
Thermomixer heating block (Eppendorf, United States, Cat.No. 5355-000.011). 1mL 
of n-hexane was then added and processed as above without heating. A fourth 
protocol was also done where the bacteria was pelleted after incubation in boiling 
water and then re-suspended in 1ml of n-hexane as above.  
 
For the fifth method of alkaline hydrolysis, the pellet was re-suspended in 
500μL of 1M potassium hydroxide (KOH) in methanol at 80°C for 1 hour, then 




neutralized with 100μL of 4M hydrochloric acid (HCl). 500μL of n-hexane was added 
to each sample, which was then vortexed for 15 minutes, centrifuged, and the upper 
organic layer was recovered for experimentation and made up to 1ml in n-hexane. 
100µl of extract was used for monoclonal IgG ELISA.  
 
For determination of CFU limit of detection and species specificity, fresh 
overnight bacterial cultures were adjusted to the appropriate concentration (106 to 
109 CFU/ml for limit of detection, OD0.1 for species specificity) by pelleting at 
16000g for 15min and resuspension in the appropriate volume of filter sterilized 
1xPBS. 1ml of this bacterial suspension was pelleted again as above and treated by 
the alkaline hydrolysis method described above and the recovered lipid extract 
standardized to 1ml with n-hexane. 100µl of extract was used for monoclonal IgG 
ELISA. 
 
2.12 Collection of clinical samples for ELISA 
2.12.1 Spiked whole blood and serum samples for LAM ELISA 
 
Venous blood was drawn from healthy Singaporean adult volunteers with 
informed consent (DSRB No. 08-171) using a 10ml Vacutainer-red cap serum tube 
(BD, United States, Cat.No. 366430) and ManLAM (Nacalai Tesque) was added to 
whole blood at indicated concentrations prior to coagulation and then the blood was 
allowed to clot at room temperature. Serum was harvested by centrifugation at 
2000g for 15min of a portion of the spiked whole blood. Spiked serum or clotted 
whole blood was treated with Proteinase K (20mg/ml dissolved in 1xPBS, Sigma-
Aldrich, United States, Cat.No. P2308) at a final concentration of 1mg/ml for 1hr or 




1.5hr respectively at 56°C on a Thermomixer heating block (Eppendorf) to digest 
serum proteins and antibodies. A final heating step for sterilization and inactivation of 
Proteinase K and any remaining active antibodies was carried out by incubation at 
95°C for 30min and then the sample was centrifuged at 2000g for 15min to pellet 
precipitate. Untreated serum underwent standard heat inactivation for 30min at 56°C. 
 
2.12.2 TB patient selection criteria and sample collection procedure 
 
Adult volunteers were recruited from patients presenting with symptoms 
suggestive of pulmonary TB infection (persistent fever, night sweats, cough of more 
than 2 weeks duration, haemoptysis, chest pain, loss of weight and/or appetite, and 
generalized fatigue) at the National Centre of Tuberculosis and Lung Diseases, 
Tbilisi, Georgia according to the following inclusion criteria: >18 years of age, HIV 
negative, no recent illness or hospitalization within the last two weeks, not a re-
treatment case. After informed consent was given, sputum, serum and urine samples 
were collected and stored. A duplicate sputum sample was taken for standard 
clinical diagnosis via light microscopy acid-fast sputum smear and culture. Patients 
were then classified into four groups as follows based on the diagnostic results: non-
TB (smear and culture-negative), TB smear-negative (smear-negative but culture 
positive), TB smear grade 1+ only and TB smear grade 2+ and above. 15 samples 









2.12.3 Clinical patient serum samples for LAM ELISA 
 
Venous blood was drawn using a 4ml Vacutainer-red cap serum tube (BD, 
United States, Cat.No. 367812) and allowed to clot at room temperature. Serum was 
recovered by centrifugation at 2000g for 15min, heat inactivated by incubation at 
56°C for 30min and then stored at -80°C until further processing in 1.5 ml Eppendorf 
tubes. Serum was digested by addition of Proteinase K (Sigma-Aldrich) to a final 
concentration of 1mg/ml and incubation at 56°C in a drying oven for 2hrs followed by 
the final inactivation and sterilization step at 95°C for 30min. Processed samples 
were then allowed to cool at room temperature and stored at -20°C before testing by 
ELISA. 
 
2.12.4 Clinical patient urine samples for LAM ELISA 
 
 Approximately 5ml of mid-stream urine was collected and incubated in a 
plastic sample container at 95°C for 30min in a drying oven. Samples were then 
allowed to cool at room temperature and stored at -20°C before testing by ELISA 
 
2.12.5 Clinical patient sputum samples for LAM ELISA 
 
Approximately 6ml of purulent sputum was collected in a 50ml Falcon tube 
and liquefied by addition of 10% N-acetyl L-cysteine (Sigma-Aldrich, United States, 
Cat.No. A7250) dissolved in 1xPBS, to a final concentration of 0.25%, and 
incubation at 37°C for 2hrs in a drying oven. 2ml of liquefied sputum was transferred 
into a 15ml Falcon tube and Proteinase K (Sigma-Aldrich) added to a final 




concentration of 2mg/ml and incubated for a further 2hrs at 56°C in a drying oven 
before sterilization at 95°C for 30min. Samples were then allowed to cool at room 
temperature, centrifuged at 4000g for 10min to pellet debris and stored at -20°C 
before testing by ELISA. 
 
2.12.6 Clinical patient sputum samples for mycolic acid ELISA 
 
2ml of sputum liquefied by addition of N-acetyl L-cysteine (Sigma-Aldrich) as 
described above in section 2.12.5 was transferred to a second 15ml Falcon tube. 
Alkaline hydrolysis for the release of mycolic acids was carried out by addition of 1ml 
of 3M potassium hydroxide (KOH) in methanol and incubation at 80°C for 2hrs in a 
drying oven. Samples were cooled to room temperature and then 300µl of 8M 
hydrochloric acid was then added to neutralize the alkali. 1ml n-hexane (Sigma-
Aldrich) was added and mixed by repeatedly inverting the Falcon tube. The mixture 
was allowed to stand for separation of the lower aqueous and upper organic layers 
and the lower aqueous layer removed carefully with a micropipette. 1ml of 10x PBS 
(1st Base) was added and mixed to neutralize any remaining acid. The upper organic 
layer was recovered by centrifugation at 1000g for 10min and 300µl of extract was 
used for monoclonal IgG ELISA. 
 
2.13 ELISAs 
2.13.1 Comparison of functional IgG levels in bacterial lysate and 
determination of purified bacterial IgG affinity curves by indirect ELISA 
 




For ELISAs, 96-well Maxisorp ELISA plates (Nalgene Nunc, United States, 
Cat. No. 442404) were coated with 20µg/ml of protein antigen or 5µg/ml ManLAM 
(Nacalai Tesque) in 1x PBS overnight at 4°C, washed twice with 1xPBS and blocked 
with 380µl/well of 4% skim milk in 1xPBS for 2hrs at room temperature and then 
washed twice with 1xPBS/T prior to addition of antibody. For ELISAs with the anti-
dengue antibody 4G2, 50µl of live dengue-2 virus (strain ST) virus was captured with 
incubation for 1hr at room temperature in wells coated with 5µg/ml mouse 4G2 and 
blocked and washed as above. Wells were subsequently washed twice with 
1xPBS/T to remove unbound virus. For comparison of functional IgG levels, clarified 
cell lysate was used while either purified bacterial or mammalian expressed IgG was 
used to plot their respective affinity binding curves. Clarified cell lysate (at dilutions 
from 1:2 to 1:64) or 100µl of purified antibody (diluted at a 1:2 ratio from 5µg/ml to 
0.076µg/ml) diluted in 4% skim milk block in 1xPBS was added. Binding of IgG was 
detected using 1:5000 anti-Human Fc HRP conjugated polyclonal secondary 
antibody (Pierce Thermo Scientific, United States, Cat. No. 31413 ) diluted in 2% 
skim milk block in 1xPBS. All steps except the blocking step were carried out in 
100µl volumes and for 1hr at room temperature except for ELISAs involving dengue 
virus which were done at 50 µl volumes. ELISA plates were washed four times with 
1x PBS/T between after primary antibody incubation and three times with 1xPBS/T 
and once with 1xPBS after secondary antibody incubation prior to addition of TMB 
(Pierce Thermo Scientific, United States, Cat. No. 34021). Reaction of TMB was 
stopped with 2M sulphuric acid. For ELISAs with 4G2 only two 1x PBS/T washes 
were carried out except for the last prior to addition of TMB where an additional 1x 
PBS wash was done and for ELISAs with my2F12 1xPBS was used in place of 
1xPBS/T. 




2.13.2 Indirect phage polyclonal and monoclonal ELISAs 
 
For phage polyclonal and monoclonal indirect ELISAs, 96-well Maxisorp 
ELISA plates (Nalgene Nunc) were coated with 10µg/ml of LAM antigen (ManLAM, 
Nacalai Tesque; PILAM, Invivogen) in 1xPBS or 25 µg/ml of Mtb-derived mycolic 
acid (Sigma-Aldrich) or cholesterol/phosphocholine in a 1:2 w/w ratio (Avanti Polar 
Lipids, United States, Cat Nos. 700000 and 850345) in n-hexane (Sigma-Aldrich) 
and incubated overnight at 4°C to bind or evaporate respectively. ELISA plates were 
then washed twice with 1xPBS and blocked with 380μl per well of block at room 
temperature for 2hrs. For ELISAs involving LAM, Casein in PBS block (Pierce 
Thermo Scientific, United States, Cat. No. 37528) was used while for ELISAs 
involving mycolic acids and other lipids 4% skim milk in 1xPBS was used as a 
blocking agent. The plates were washed and then polyclonal phage at 1:10 dilution 
or monoclonal phage at 1:2 dilution in block was added. Plates were washed and 
then bound phage detected with HRP-conjugated anti-M13 polyclonal antibody (GE 
Healthcare, United States, Cat. No. 27-9420-01) diluted 1:5000 in block. Plates were 
washed again before colour development with TMB (Pierce Thermo Scientific) for 
10min. All incubations and reactions were carried out for 1hr at room temperature 
with 100μl volume per well and washes between incubations were done four times 
with 1xPBS (for LAM ELISAs) and 1xPBS/T (for lipid and mycolic acid ELISAs) 
unless indicated. The last wash for lipid ELISAs prior to incubation of TMB is with 








2.13.3 Indirect monoclonal IgG ELISA against LAM or lipids 
 
LAM (ManLAM, Nacalai Tesque; PILAM, Invivogen) and lipids were coated 
and blocked as described for indirect ELISAs in Section 2.13.2 on 96-well Maxisorp 
ELISA plates (Nalgene Nunc). Commercial synthetic lipids or purified lipid extracts 
for determination of antibody specificity were purchased from Sigma-Aldrich, United 
States (Mtb-derived mycolic acid, Cat. No. M4537; M. bovis-derived trehalose 
dimycolate, Cat. No. T3034, β-hydroxylmyristic acid, Cat. No. H4148) or from Avanti 
Polar Lipids, United States (cholesterol, Cat. No. 700000; 7-ketocholesterol, Cat. No. 
700015; 15-ketocholestene, Cat. No. 700008;15-ketocholestene, Cat. No. 700009; 
15-hydroxycholestene, Cat. No. 7000010; 15-hydroxycholestane, Cat. No. 700013; 
dimyristoyl phosphatidic acid, Cat. No. 830845 ; dimyristoylphosphosphocholine, 
Cat. No. 770345; C-80 alpha mycolic acid, Cat. No. 791280; keto mycolic acid, Cat. 
No. 791281; methoxy mycolic acid, Cat. No. 791281). Lipids extracts of various 
bacterial species or from mycobacteria at different concentrations were processed as 
described above in section 2.11.2. 
 
Detector antibody in the appropriate block (Casein for anti-LAM antibodies, 
4% skim milk for anti-mycolic acid antibodies) was added at 1µg/ml. The plates were 
washed and binding detected with anti-human Fc HRP conjugated polyclonal 
secondary antibody (Pierce Thermo Scientific) at 1:5000 dilution in the appropriate 
block). The plates were washed for a final time and colour developed with TMB 
(Pierce Thermo Scientific) and stopped with 2M sulphuric acid. All incubations and 
reactions were carried out for 1hr at room temperature with 100ul volume per well 
and washes between incubations were done four times with 1xPBS (for LAM 




ELISAs) or 1xPBS/T (for lipid and mycolic acid ELISAs) unless indicated. The last 
wash for lipid ELISAs prior to incubation of TMB is with 1xPBS in order to reduce 
bubble formation from the Tween-20 detergent. 
 
2.13.4 Determination of chimeric antibody affinity binding curves  
 
96-well Maxisorp ELISA plates were coated with ManLAM (Nacalai Tesque) 
at 10µg/ml in 1xPBS or 25µg/ml Mtb-derived mycolic acid (Sigma-Aldrich), washed 
and blocked with either Casein or 4% skim milk in PBS as described for indirect 
ELISA in section 2.13.2 and then washed again. Each of the six antibody variants, 
serially diluted to various standardized molar concentrations (taking into account 
their molecular weight) in the appropriate block was added, 100µl per well, and 
incubated for 1hr at 37°C. The plates were then washed and 100µl of a mix of anti-
human Fc and anti-mouse Fc HRP-conjugated secondary polyclonal antibodies 
(Pierce Thermo Scientific) each at 1:5000 dilutions in the appropriate block was 
added to each well and incubated 1hr at 37°C. The plates were washed for a final 
time and colour developed with TMB (Pierce Thermo Scientific), incubated for 15min 
at 37°C and stopped with 2M sulphuric acid. Incubation at 37°C was done to ensure 
the antibody binding and TMB substrate reactions had reached equilibrium. Washes 
between incubations were done four times with 1xPBS (for LAM ELISAs) and 
1xPBS/T (for lipid and mycolic acid ELISAs) unless indicated. The last wash for lipid 
ELISAs prior to incubation of TMB is with 1xPBS in order to reduce bubble formation 
from the Tween-20 detergent. Raw absorbance values were converted to 
percentage of maximum signal and plotted on a XY graph for subsequent data 
analysis (section 2.15) 




2.13.5 Determination of limit of sensitivity for anti-mycolic acid antibodies 
 
Purified mycolic acid extract (Sigma-Aldrich) or synthesized mycolic acid 
alpha, keto and methoxy subclasses (Avanti Polar Lipids) was serially diluted in n-
hexane (Sigma-Aldrich) to indicated concentrations and evaporated overnight onto 
96-well Maxisorp ELISA plates (Nalgene Nunc) at 4°C. The next day, plates were 
washed, blocked with 4% skim milk in 1xPBS and washed again as described in 
section 2.13.2 for indirect ELISA. 100µl of each anti-mycolic acid antibody at 1µg/ml 
concentration in 4% skim milk block was added to each well and the remainder of 
the ELISA was carried out as described in section 2.13.3 for indirect IgG ELISA with 
lipids. 
 
2.13.6 Indirect sandwich ELISA on purified LAM, bacterial suspensions and 
culture supernatants  
 
For sandwich ELISA, 96-well ELISA plates (Nalgene Nunc) were coated with 
5µg/ml capture antibody (either Fab or HuG1) in 1xPBS overnight at 4°C, washed 
twice in 1xPBS, blocked with 380µl per well of Casein in PBS block (Pierce Thermo 
Scientific) for 2hrs at room temperature and washed twice again with 1x PBS before 
adding antigen. Bacterial suspensions, culture supernatants and spiked serum 
samples were prepared as described above in section 2.11.1 and 2.12.1 respectively 
while purified PILAM or ManLAM or H37Rv LAM (a gift from Dr. Patrick Brennan, 
Colorado State University) was spiked into 1xPBS at indicated concentrations. After 
antigen binding, the plate was washed and detector antibody (either HuG1 or 
hG3mG2a) added at 1µg/ml in casein block. The plates were washed again and the 




appropriate HRP-conjugated anti-human or anti-mouse Fc (Pierce Thermo Scientific, 
United States, Cat. Nos. 31413 and 31439 respectively) secondary polyclonal 
antibody (depending on the detector antibody used) added at 1:5000 dilution in 
Casein block. After incubation, plates were washed and signal was developed using 
TMB and stopped with 2M sulphuric acid. ELISA with polyclonal anti-LAM was 
carried out using pre-coated plates and HRP-conjugated antibody from Clearview 
commercial LAM ELISA kit (Inverness Medical Innovations, UK) used according to 
manufacturer’s instructions as follows: 100µl of sample was added to ELISA plates 
already pre-coated with polyclonal anti-LAM and pre-blocked for 1hr at room 
temperature. Plates were washed four times with the manufacturer’s buffer solution 
(PBS/T) and the detector antibody (same as capture, rabbit polyclonal anti-LAM pre-
conjugated with HRP) added at 100µl per well and incubated for 1hr at room 
temperature. Plates were washed again four times and colour developed with 
manufacturers’ TMB solution and stopped with 2M sulphuric acid. ELISA with live 
bacterial suspensions was carried out in a Biological Safety Cabinet and washes 
done with a multichannel pipette dispenser vacuum aspirator. All incubations and 
reactions were carried out for 1hr at room temperature with 100μl volume per well 
and washes between incubations were done four times with 1xPBS unless indicated.  
 
2.13.7 Determination of anti-LAM antibody titres in healthy serum samples 
 
ManLAM (Nacalai Tesque) and PILAM (Invivogen) was coated at 10µg/ml 
onto 96-well Maxisorp ELISA plates (Nalgene Nunc), washed, blocked and washed 
again as described in section 2.13.2 for indirect ELISA. Serum samples serially 
diluted in Casein block (Pierce Thermo Scientific) as indicated were added at 100µl 




per well and incubated for 1hr at room temperature. Plates were then washed four 
times with 1xPBS and then the binding of human serum IgG detected with anti-
human Fc HRP-conjugated polyclonal secondary antibody as described in section 
2.13.3 for monoclonal IgG ELISA against LAM. This protocol was also used to 
confirm loss of binding of endogenous anti-LAM serum IgG after heat and proteinase 
K inactivation. 
 
2.13.8 Indirect sandwich ELISA on spiked or patient clinical samples 
 
Indirect sandwich ELISA was carried out as described in section 2.13.6 on 
patient samples processed as described in section 2.12, with capture and detector 
antibody concentrations varied as indicated. Spiked or patient clinical samples were 
added at either 100µl or 300µl per well as indicated and antibody and TMB volumes 
used as 100µl or 200µl per well respectively. 100µl of 2M sulphuric acid was used to 
stop all reactions after the indicated incubation time. For calibration and as a positive 
control, ManLAM (Nacalai Tesque) in 1x PBS at indicated concentrations was added 
at the same volume per well as the sample.  
 
2.13.9 Indirect ELISA on patient lipid extracts 
 
Indirect ELISA was carried out on 300µl of sputum lipid extracts (extracted as 
described in section 2.12. evaporated onto 96-well Maxisorp ELISA plates (Nalgene 
Nunc).  
 




2.14 Mass spectrometric profiling and quantification of mycolic acids. 
 
Mycolic acid profiles were determined by means of high-resolution tandem 
mass spectrometry. Lipid extract from M. smegmatis prepared by alkaline hydrolysis 
as described in section 2.11.2 were diluted to 2:1 (v/v) with isopropanol: methanol: 
chloroform 4:2:1 containing 2mM ammonium acetate. 10μl samples were infused 
into a LTQ Orbitrap XL mass spectrometer (Thermo Scientific, United States) using 
nanomate interface (Advion, United States). The nanospray voltage was -1.35kV 
(negative ionisation) and mass spectra were acquired in duplicate at a resolution of 
30,000 and 100,000. α-alkyl chains were identified by product ion scans, using 
collision energies between 35 and 45eV. Once the mycolic acid profile of the 
samples was determined, individual mycolic acid molecular species were quantified 
by multiple reaction monitoring (MRM) analysis. A comprehensive set of MRM 
transitions was set-up, including all mycolic acid species and α-alkyl chains identified 
by HR-MS/MS. A total of 90 mycolic acid species were analysed. 5μl of lipid extract 
were diluted to 50μL in chloroform:methanol 1:1 containing two internal standards 
(I.S., keto- and methoxy- mycolic acids, m/z 1266 and 1254, final concentration: 
0.5μg/ml each, Avanti Polar Lipids) and injected into a 4000QTrap mass 
spectrometer (ABSciex, United States). These two mycolic acids were not detected 
in the samples during HR-MS/MS analysis and could then be used safely as internal 
standards. The carrier solvent was chloroform:methanol 1:1 containing 10mM 
piperidine, flowing at 250μl/min. Each sample was injected in duplicate (injection 
volume: 20μl). The MS parameters were as follows: negative ESI, capillary voltage -
4.5kV, source temperature 250°C, DP -120, EP -10, CE -90, CXP -5. For 




quantification, the signal intensity of each MRM transition value was normalised to 
the internal standard transition intensity. 
 
2.15 Data analysis and statistics 
 
Tests for significant difference were carried out using 1 or 2-way ANOVA with 
Bonferroni corrections for multiple T-test comparisons for discrete and grouped data 
sets respectively while affinity binding curves were plotted using non-linear 
regression with a single-binding site specific binding model, using Prism 5.0 software 
(GraphPad Software, United States). ROC analysis was carried out using the same 
software. Test for significant differences between percentages of positive patient 
samples was carried out using multiple Z-test for independent groups 
(http://www.mccallum-layton.co.uk/stats/ZTestTwoTailSampleSize.aspx). 
  















Chapter 3: Optimization of IgG expression in bacteria 
  






The bacterial host Escherichia coli has been widely used for the production of 
heterologous proteins with over several thousand eukaryotic proteins successfully 
expressed and purified, along with thousands more bacterial and viral proteins (188). 
This is typically achieved using T7 or lac promoter driven expression systems carried 
on a plasmid vector and induced with an exogenously delivered chemical signal such 
as isopropyl-β-D-thiogalactoside. This has enabled the expression of proteins 
including complex multimeric polypeptides such as IgG at high yield but at low cost, 
in contrast to expression in mammalian cell culture which is expensive (118). 
Published work on soluble IgG expression has so far relied on methodologies that 
are technically challenging, such as refolding of denatured antibodies from inclusion 
bodies, modification of promoter regions to balance light and heavy chain 
expression; or using reagents and equipment that may not be readily available such 
as optimized bacterial expression strains and large scale fermenters 
(121,125,183,189). A methodology that can be easily replicated using commercially 
available vectors and strains would be very useful for the low-cost production of 
diagnostic antibodies for research and clinical use.  
 
Previous work on expression of antibody fragments and antibodies has 
demonstrated the importance of an oxidizing environment for the proper formation of 
disulphide bonds (190). We have therefore modified a commercial tetracycline (tet) 
promoter-based vector (pASK-IBA2, IBA GmBH) previously used for the expression 
of soluble Fab in the periplasm, for the expression of soluble full length IgG. (Fig. 3-
1). Studies had also previously shown that expression of heterologous secretory (i.e. 




periplasmic) proteins in E. coli could be enhanced by reducing translational rates, 
which is thought to reduce the demand on the limited protein chaperone, folding and 
secretion machinery (183). We therefore sought a promoter system that allows for 
homogenous modulation of translation rates. The tet promoter/inducer system does 
not rely on repressor/operator elements endogenous to the host and functions 
independently of host-strain background and metabolism as the tet repressor gene is 
encoded on the plasmid vector backbone itself (190). This allows for tight and 
regulated control of protein expression levels independent of host growth or protein 
expression rates and as such is ideal for this purpose (191,192). 
 
Figure 3-1: Design of the bacterial IgG expression vector 
The backbone of the vector was derived from pASK-IBA2 plasmid using a tet 
promoter. The appropriate restriction sites for cloning in of the light and variable 
heavy chains, leader sequences (OmpA, PelB) and the constant heavy chain 
sequence (CH) were added. Light (LC) and variable chains (VH) were cloned in 
as a complete construct together with the intercistronic ribosomal binding site 
(RBS) from the phage display vector or as separate constructs from the 4G2 
mammalian IgG expression vector.  
 
 
3.2 Preliminary expression in two common E. coli bacterial strains 
 
 We initially decided to try expression in two different E. coli strains commonly 
used for protein expression: BL21(DE3), which is deficient in the cellular proteases 
Lon and OmpT, to reduce any potential protein degradation; and HB2151, an E. coli 
strain commonly used for periplasmic expression of antibody fragments, to 
determine which is more suitable for antibody production. Rather than whole cell 




lysis, we tried extraction of only the periplasm so as to limit the release of 
unassembled heavy and light chain. Analysis of the periplasmic extract after 
overnight expression of a control antibody: chimeric 4G2, an anti-dengue E protein 
antibody, showed fully assembled IgG with both HB2151 and BL21(DE3) along with 
significant amounts of partially assembled IgG (Fig. 3-2A). Surprisingly, reduction of 
the extracts to allow resolution of the heavy and light chains revealed the presence 
of increased degradation of the heavy chain with the protease deficient BL21(DE3) 
compared to HB2151, suggesting that proteolysis of the heavy chain is not due to 
Lon or OmpT proteases and that HB2151 is more suitable for IgG expression as 
compared to BL21 (Fig. 3-2B). Despite the reduced degradation, purification of 4G2 
on protein A did not give any measurable level of purified protein as measured by 
Bradford assay.  
 
Figure 3-2: Periplasmic extract of bacterial IgG expressed in two different 
E. coli strains 
Non-reducing (A) and reducing (B) western blot of periplasmic extract from 
overnight expression of 4G2 in HB2151 (HB) and BL21(DE3) (BL) E. coli 
strains, respectively. All blots were probed with anti-Human Fc HRP conjugated 
secondary antibody.  




3.3 Optimization of expression in small scale culture 
 
 We subsequently explored various methods for reducing translation rates as 
this had been known to improve yields for secretory proteins (183). Previous 
experiments using the tet system had shown that below 50ng/ml, the concentration 
of inducer becomes limiting although the relationship between expression yield and 
inducer is not completely linear (191,192). We therefore carried out induction at the 
manufacturer’s recommended concentration of 200ng/ml, and at 50ng/ml and 
20ng/ml. Other methods which can reduce translation rates include induction of 
expression when the bacteria are approaching late exponential growth phase and 
was used in a method by Mazor et al for the production of full-length IgG (110). 
Accordingly, apart from induction at the standard time point, when the culture optical 
density at 600nm reaches 0.6 (OD600 0.6), we also tested using induction at OD600 
1.0. Use of low copy number plasmids has also been shown to decrease translation 
rate (191). In the course of constructing our expression vector, we also generated 
both a low copy and high copy version of our expression plasmid, by addition of a 
single base pair mutation in the origin of replication. The difference in copy number 
between the high and low copy plasmids, based on miniprep DNA yields, is 
estimated to be approximately eight- to ten- fold and the low-copy variant is expected 
to significantly reduce production of mRNA and hence translation rates.  
  
 In order to ensure that the results would be generally applicable to all 
antibodies, we expressed PA38 and PA64, two antibodies against the Protective 
Antigen component of anthrax toxin; ET21 and ET149, two antibodies against 
epsilon toxin of Clostridium perfringens along with chimeric 4G2 (184). With the 




exception of 4G2, all other antibodies were isolated from panning with the Humanyx 
phage display library. Expression of these five antibodies were carried out first in 
small scale shake cultures with various combinations of different concentrations of 
inducer, induction at different OD600 and using either high or low copy expression 
vector, as indicated. Standard induction conditions (200ng/ml inducer, high copy 
plasmid & induction at OD600 0.6) were also used as a comparison. Levels of fully 
assembled and functional IgG in the clarified cell lysate were then determined by 
Western blot and indirect ELISA respectively (Fig. 3-4). In order to prevent leakage 
of expressed antibody into the culture media, which commonly occurs during 
periplasmic expression in the HB2151 E. coli strain, protein expression was carried 
out in non-baffled flasks at a slower shaking speed of 120rpm to reduce agitation. 
Extraction was carried out by whole cell lysis as described by Mazor et al for 
bacterial IgG expression (110). 
 
 Initial experiments indicated that variation of inducer concentration resulted in 
significant differences in wet cell mass yields (Fig. 3-3), which could have a 
significant influence on overall yield. Therefore, in order to distinguish whether 
improved yield is due to an increase in wet cell mass or an increase in levels of fully 
assembled IgG per cell (unit yield), pellets were weighed after harvesting and 
resuspended in a volume of lysis buffer adjusted for wet cell mass thus ensuring that 
subsequently derived lysate samples are equivalent. There was little variation in wet 
cell mass when the low copy plasmid was used, regardless of inducer concentration 
or induction OD600 although the mass obtained was higher compared to standard 
induction concentrations. However, when the high copy plasmid was used, there was 
a significant increase in wet cell mass when the lowest inducer concentration 




(20ng/ml) was used as compared with the two other concentrations with up to 
approximately two-fold increase over the standard induction concentrations. This 
pattern was consistent for all five antibodies tested.  
Figure 3-3: Variations in wet cell mass under different inductions 
conditions  
Wet cell mass of the pellet was weighed after overnight induction at indicated 
inducer concentrations, plasmid copy number and induction OD600. Red box 
represents standard conditions 
 
The levels of fully assembled and functional IgG as measured by immunoblot 
and indirect ELISA respectively appear to correlate well for all antibodies expressed, 
as the intensity of the full sized IgG bands (≈200kDa, black arrow) on the 
immunoblot approximately corresponded to the signals by ELISA (Fig. 3-4A-E). 
However, the highest unit yields were not always given by the same induction 
conditions for each antibody. When low copy plasmid was used, unit yields were 
generally higher or similar to that obtained under standard conditions with the 
exception of ET149. They also appeared not to be influenced by varying inducer 
levels or induction OD600, a pattern similar to that observed earlier for wet cell mass. 
However, they did not give the best unit yields, which were obtained using high copy 
number plasmids. 




 On the other hand, when high copy number plasmid was used, there was 
significant variation with inducer concentration. Three different patterns were 
observed. Firstly, with antibody PA38, no significant changes were observed with 
inducer concentrations, although induction at the later time point of OD600 1.0 
increased yield (Fig. 3-4A). A second pattern was observed in which unit yield 
increased with a reduction in inducer concentration, which was observed in 
antibodies 4G2 and PA64 (Fig. 3-4B-C). For PA64, induction at OD600 1.0 also 
increased yields. The third pattern observed with ET21 and ET149 was increased 
yield with increased inducer concentration (Fig. 3-4D-E). Induction at different OD600 
did not appear to significantly affect the pattern of yield and in fact for ET149 the best 
unit yield was at standard conditions of 200ng/ml inducer, induction at OD600 0.6 with 
high copy plasmid.  





Figure 3-4: Levels of fully assembled or functional bacterial IgG obtained 
under different induction conditions 
Left and middle panels: Non-reducing western blot of 7.5μl clarified cell lysate 
from small scale overnight expression of bacterial IgG in shaking culture. All 
blots were probed with anti-Human Fc-HRP and adjusted to ensure equal 
intensity. Right panel: Indirect ELISA indicating levels of functional IgG. 
Background binding signal was negligible for all cell lysate samples at the 
indicated dilution or neat. Expressed antibodies were PA38 (A), 4G2 (B), PA38 
(C), ET21 (D), ET149 (E). Red arrows indicate original standard induction 
conditions while black arrows indicate size of fully assembled IgG. 
Low copy plasmid      High copy plasmid 




3.4 Comparison of yield by large scale expression 
 
 We then sought to determine the potential yield of bacterial IgG from a large 
scale production. Based on the small scale expression, the best unit yields for PA38, 
PA64 and 4G2 would be given by using high copy plasmid, 20ng/ml inducer 
concentration and induction at OD600 1.0. The yield would also be enhanced further 
by the greater wet cell mass obtained under this condition. For ET21 and ET149, 
50ng/ml inducer concentration appears to be best in comparison to 20ng/ml (with 
high copy plasmid and induction at OD600 1.0) for giving the best unit yield, but 
overall yield would be affected by the reduction in wet cell mass. To determine likely 
overall yields, we therefore carried out large scale expression in 1.6 litres of culture 
on one antibody of each group, 4G2 and ET149 respectively. All were induced at 
OD600 1.0 with high copy plasmid and at inducer concentrations of 20 and 50ng/ml 
respectively.  
 
Purification was carried out on a 1ml Protein A HPLC column and elution of 
IgG was tracked using absorbance at 280nm. Analysis of the individual peak 
fractions indicated successful expression of full length IgG (2H2L) for both 4G2 and 
ET149 (Fig. 3-5A & B). Protein bands of other sizes were also observed in the elute 
peak fractions. Analysis of selected 4G2 and ET149 fractions by western blot (Fig. 3-
5B) indicated that some of these protein bands were not antibody heavy or light 
chains as they were not detected with anti-human Fc or Kappa polyclonal antibody 
and hence are probably bacterial proteins that co-purify with the bacterial expressed 
IgG. This non-specific elution of bacterial proteins was unexpected, as previous 
papers had reported clean elution of bacterially expressed full-length IgG from 




Protein A (110,125). Some degradation of the heavy chain was also observed as 
bands larger than the full sized light chain but smaller than the full sized heavy chain 
was observed on the reducing western blot (Fig. 3-5B).  
 
Figure 3-5: Purification of bacterial IgG on Protein A and Protein L 
(A) Non-reducing Coomassie gel of peak fractions from Protein A HPLC 
purification of cell lysate of 4G2 and ET149. A wash sample (LW) was run and 
shows no contaminants present indicating the column was washed sufficiently 
to remove non-binding proteins. 2H2L indicates fully assembled IgG. (B) 
Reducing Coomassie gels and adjacent western blots (I) showing 
representative fractions from each Protein A elution (indicated with * on panel 
A). Blots were probed with both anti-IgG Fc and anti-Kappa chain polyclonals 
showing that majority of protein bands in the fraction are neither IgG heavy 
chain nor light chain. A separate reducing Coomassie gel shows 2μg of pooled 
elute (EL) after Protein L purification showing successful removal of the 
contaminating proteins and degraded heavy chain fragments. The equivalent 
amount of mammalian cell culture-derived IgG (IgG) was loaded for 
comparison. Individual heavy (HC) and light (LC) chains are indicated although 
the light chain for ET149 appears as two separate species. 30μl sample was 
loaded for Coomassie and 3.75μl for western blot. 




 Due to the impurity of the Protein A eluate, it was decided to carry out an 
additional purification step using Protein L, which binds the antibody light chain. 
Sequential purification on first Protein A and then Protein L should enable isolation of 
only antibody that contain both heavy and light chain, thus eliminating any unpaired 
heavy or light chain along with degraded fragments and contaminating bacterial 
proteins. Indeed, the higher molecular weight contaminants as well as the heavy 
chain degradation products were removed by Protein L purification of 4G2 and 
ET149 (Fig. 3-5B). Final yields of antibody were 12.6µg and 6.3µg for these 
antibodies respectively.  
 
3.5 Comparison of bacterial and mammalian expressed IgG 
 
 Following removal of the bacterial contaminant proteins and heavy chain 
degradation products through protein L purification we next decided to check for the 
presence of fully assembled tetrameric IgG. Analysis of the protein L eluate on non-
reducing SDS-PAGE indicated that a large proportion of the purified chimeric 4G2 
and ET149 IgG was present as fully assembled IgG (2H-2L, Fig. 3-6). However 
partially assembled IgG representing 2H-1L and 1H-1L was also evident. The 
increase of partially assembled IgG seen with expression in E. coli could be due to 
inefficient disulphide bond formation during assembly within the bacterial periplasm.  
 
   
 
 




Figure 3-6: Coomassie gel of purified bacterial IgG 
Non-reducing SDS-PAGE of 2μg of pooled bacterial IgG eluate after protein L 
purification (EL) and mammalian cell culture-derived IgG (IgG) indicates that the 
majority of purified IgG was fully assembled IgG (2H2L) although partially 
assembled IgG (2H1L, 1H1L) are also present 
 
To determine whether the bacterially expressed IgG retained the same 
binding avidity as those expressed in mammalian cell culture, an indirect ELISA of 
serially diluted purified IgG expressed from both bacterial and mammalian cell 
cultures was carried out against Dengue-2 and epsilon toxin using 4G2 and ET149 
respectively. A slight decrease in avidity was observed for both 4G2 and ET149 
bacterially expressed IgG in comparison to mammalian cell culture derived IgG (Fig. 
3-7). This could be due to an increased percentage of partially assembled IgG in the 
bacterially expressed antibodies as observed in the SDS-PAGE gels (Fig. 3-6). 
These partially assembled IgGs would have reduced avidity due to the presence of 









Figure 3-7: Comparison of mammalian and bacterial culture expressed 
IgG affinity 
Indirect ELISA of serially diluted bacterial (-■-)- and mammalian cell culture (-●-) 
-derived IgG against Dengue serotype-2 virus and epsilon toxin showing similar 





 From our initial experiments, it was clear that IgG expression in E. coli 
laboratory strains using general expression protocols gave poor yields and highly 
degraded product and the use of the protease-deficient BL21 strain was unable to 
reduce degradation (Fig. 3-2). Previous studies suggested that overload of the 
protein secretory and folding system was responsible for the poor yield and we 
therefore undertook optimization of expression conditions to minimize load via 
reduction of translational levels. We have demonstrated on the basis of expression 
of three different antibodies (PA38, PA64 and 4G2) against two separate antigens 
that reduction of translational levels can improve unit yields of full-length IgG (Fig. 3-
4). This was achieved by using either low copy plasmid, reducing inducer 
concentrations or induction at a later time point. However, the effects of these 
changes is antibody dependent and may negatively impact unit yields for certain 




antibodies as seen in the effect of reducing inducer concentrations for antibodies 
ET21 and ET149. This could be because they are more efficiently processed by the 
E. coli secretory and folding machinery and thus can be translated at high rates 
without any significant impact on final yields. Lowering translation rates hence 
decreases yields instead. This is supported by our observation that two antibodies 
appear to be have the best unit yields overall, as they have the most intense band on 
western blot and also require a greater dilution, 1:64 compared to 1:16, 1:8 or 1:2, to 
obtain an equivalent signal by ELISA (Fig. 3-4). 
 
 The effect of varying inducer concentration and induction OD600 on wet cell 
mass and unit yields was minimal when low copy plasmids were used. It may be that 
the low copy number results in a low baseline translation level which cannot be 
further reduced by delayed induction or inducer concentration. This low baseline 
translational level could also enable the E. coli host to redirect more of its 
metabolism into replication rather than protein expression, which explains the 
uniform increase in wet cell mass obtained (Fig. 3-3). This redirection of energy 
towards growth may also be the reason for the increase in wet cell mass observed at 
the lowest inducer concentration. Hence, wet cell mass yield is either unaffected or 
improved by reducing translational levels and as such antibodies which can have 
their unit yields improved by reducing translational levels, such as 4G2, PA38 and 
PA64, also benefit from a simultaneous increase in wet cell mass yield.  
 
 Purification of the cell lysate with Protein A was insufficient to give pure full-
length IgG with bacterial proteins and heavy chain fragments co-purifying in the 
eluate and as a result subsequent Protein L purification was required (Fig. 3-5). The 




inability of Protein A purification alone to give purified antibody, in contrast to 
previously reported findings, could be due to the extremely low yield of IgG resulting 
in non-specific binding of bacterial proteins to unoccupied Protein A binding sites. 
This could also be due to the binding of chaperone and heat shock proteins to the 
hydrophobic surfaces of unfolded expressed antibody (193) .However, due to the 
large volume of lysate required to be processed for reasonable antibody yields, a 
sufficiently large Protein A column must be used for efficient antibody capture and 
hence having empty binding sites is an unavoidable consequence of the low yield of 
fully assembled IgG.  
 
 The ability of our bacterial IgGs to bind both Protein A and Protein L indicates 
that the binding sites on the antibody are presented on the surface and suggests that 
the IgG is properly folded. Crucially, the purified 4G2 and ET149 antibodies were 
able to bind their respective antigens albeit with slightly reduced avidity as compared 
to mammalian cell expressed antibody and indicates that bacterially expressed IgG 
could substitute for mammalian derived IgG (Fig. 3-7). E. coli expressed IgG1 has 
been found to bind the neonatal Fc receptor (FcRn) and have the same 
pharmacokinetic parameters in the circulatory system as mammalian cell expressed 
IgG2 and IgG4b, but was unable to bind complement (C1q) or FcγRI (125). This 
suggests that E. coli derived antibodies lack effector functions as expected for 
aglycosylated antibodies. The inability of aglycosylated antibodies to bind Fcγ 
receptors has also been demonstrated in mammalian derived aglycosylated 
antibodies (194). However, this function is not required for diagnostic antibodies and 
hence should not hinder the use of bacterially expressed antibodies for this purpose.  
 




We have therefore evaluated the effect of reducing translational rates using 
simple mechanisms such as delayed induction or reducing induction concentrations 
to improve yields. Use of a combination of both methods clearly improved yields for 
several antibodies (4G2, PA38, PA64) due to both increased unit yield and increased 
wet cell mass. This is reflected in the levels of recoverable full length IgG which in 
4G2 was improved to 7.87µg/L of culture while previously no full length antibody 
could be purified or even detected on western blot (at standard conditions, Fig. 3-4).  
 
Previous studies on improvement of yields have often focused only on unit 
yields (as comparisons were based on percentage of total protein) or on overall 
yields per volume of culture (125,183) . Here we show that reducing translational 
rates can improve yields, but this occurs due to two separate processes. We also 
show that for certain antibodies, unit yield can occasionally be increased at the 
expense of wet cell mass yield and therefore both have to be taken into account 
during optimization. We use only commercially available plasmid vectors, inducer 
and E. coli strains and do not rely on extensive molecular biology reengineering of 
the promoter or coding regions, or expression of additional chaperones. Our 
methodology should therefore be readily applicable in the majority of laboratories to 
produce bacterial IgG that have virtual identical performance to their mammalian cell 
culture expressed counterparts in terms of avidity.  
  















Chapter 4: Generation of anti-ManLAM antibodies by phage display 
  






Lipoarabinomannan (LAM) is a Mtb membrane glycolipid that is currently the 
subject of significant research for the purpose of TB diagnostics due to its reported 
presence in patient urine, an easily sampled clinical specimen (13). However, 
although initial studies were promising, with sensitivity and specificity above 80%, 
subsequent studies showed poor performance due to low sensitivity which ranged 
from 13% to 59%, although sensitivity remained high at above 83% 
(13,83,85,87,151,153,154,195). Sensitivity has been shown to be improved in HIV 
positive patients and especially in the cohort with low CD4 counts and has been 
attributed to spread of Mtb infection to the urinary tract resulting in higher levels of 
LAM excretion, or alternatively, formation of immune complexes in the blood due to 
anti-LAM antibodies resulting in reduced excretion in the urine in immunocompetent 
individuals (156,157). The paucity of LAM in the urine has led to studies on the 
possibility of LAM detection in other clinical material such as sputum or serum. 
However, a study on detection of LAM in sputum using a commercial polyclonal 
antibody had improved sensitivity (86%) but very poor specificity (15%) (154). Low 
specificity was shown to be due cross-reactivity to non-mycobacterial species that 
reside in the oral cavity such as Nocardia and Tsukamurella species.   
 
LAM is present in all mycobacterial species as three different structural 
variants (ManLAM, AraLAM and PILAM), as well as in other actinomycete species 
including those mentioned above (130,132-135,196). It is therefore highly likely that 
polyclonal anti-LAM antibodies, which bind multiple epitopes on the LAM molecule, 
would recognize non-mycobacterial LAM along with all mycobacterial species. In 




addition, monoclonal anti-LAM antibodies may also not be able to distinguish 
between mycobacterial LAM variants. This has been shown to be the case for well 
characterized anti-LAM monoclonals, as they recognize mycobacteria from both the 
fast-growing group such as M. smegmatis and M. fortuitum that carry PILAM as well 
as slow-growers such as Mtb, or been shown to bind the core LAM oligosaccharide 
(84,197). An antibody that is capable of recognizing only the α1-2 mannose caps of 
ManLAM would have high specificity for the slow-growing highly pathogenic group of 
mycobacteria which includes Mtb. This would potentially improve the specificity of 
LAM based diagnostic assays and allow for testing of clinical samples that may have 
high concentrations of LAM (such as sputum) but are also contaminated with other 
microbiota that express related glycolipids without the specific mannose caps.  
 
4.2 Panning of the Humanyx phage library  
 
 Phage display allows for the application of antibody selection techniques not 
possible with traditional animal immunization. As the mannose caps comprise only a 
small proportion of the entire LAM molecule, we considered it unlikely that a 
straightforward selection against LAM would produce antibodies against the 
mannose caps. We therefore developed a novel method of phage display screening 
that used a related antigen, PILAM, to deplete antibodies against epitopes common 
to all LAM species (negative selection) from a non-immune human antibody phage 
display library (Humanyx) in order to drive antibody selection towards the targeted 
unique region of the desired antigen, the α1-2 mannose caps of ManLAM (Fig. 4- 
1A). Depletion was achieved by binding the phage library to PILAM prior to binding 
against ManLAM. Using this method, we were able to demonstrate ManLAM-specific 




enrichment of the polyclonal phage library preparations from Pan 1 to Pan 4 as 
measured by indirect phage ELISA (Fig. 4-1B). No increase in binding for PILAM 
was observed from Pan 1 to Pan 4, indicating that there was no enrichment of 
antibodies against the common backbone of LAM. While Pan 4 had the highest 
polyclonal signal, Pan 3 only had a slightly lower signal, indicating that the proportion 
of ManLAM-specific phage were probably only slightly reduced in Pan 3 versus Pan 
4. Since repeated panning can result in loss of antibody diversity due to competition 
for limited antigen, Pan 3 was expanded into monoclonals for screening so as to 
capture as wide a diversity of ManLAM specific antibodies as possible. 
 
 
Figure 4-1: Panning of Humanyx antibody phage library against ManLAM 
(A) Procedure for phage panning with negative selection. (B) Selective 
enrichment of Humanyx library for ManLAM-specific binders as indicated by 










4.3 Monoclonal screening and identification of my2F12 
 
Three hundred and eighty (380) monoclonals from Pan 3 were screened for 
ManLAM specificity by indirect phage ELISA by testing against PILAM as the 
negative control. There were a significantly greater percentage of strong and 
moderate specific binders (ManLAM signal vs. PILAM signal > 5, 66.6%) as 
compared to weak and negative binders (ManLAM signal vs. PILAM signal < 5, 
33.3%), indicating that there was efficient selection for strong binders (Table 4-1). 96 
clones with highest specific signal against ManLAM were selected and their antibody 
sequence amplified via colony PCR. BstN1 digests were carried out on the PCR 
products and the digestion pattern compared. All 96 selected clones had identical 
digestion patterns suggesting that only one unique clone was present (Fig. 4-2). Six 
clones were sequenced which confirmed that only one unique clone (my2F12) 
present, the CDR sequence and germline variable gene source is given in Table 4-2. 
This was cloned into our mammalian expression vector carrying the huG1 constant 
region (198), and transiently expressed in HEK 293 cells as full length human IgG1. 
This recombinant antibody was specific for ManLAM of two different Mtb strains but 
did not shown any binding to PILAM from M. smegmatis thus verifying its specificity 
for ManLAM (Fig. 4-3). In contrast, a commercial rabbit polyclonal sandwich ELISA 
bound both the two ManLAMs and PILAM tested positive for all variants.  




Table 4-1: Binding characteristics of monoclonals from 3rd Pan 
Proportion of negative, weak, moderate and strong binding clones isolated from 
the 3rd Pan as determined by monoclonal phage ELISA.  
 
 
Figure 4-2: Diversity of monoclonals from the enriched 3rd Pan 
BstN1 digest of 96 selected highest binding clones. All clones had the same 














of Total (%) 
Negative (SNR < 2) 81 24.47 
Weak (SNR 2-5) 46 12.11 
Moderate (SNR 5-10) 160 42.11 
Strong (SNR > 10) 93 24.47 
 









Table 4-2: CDR sequences of isolated monoclonal my2F12 
Amino acid sequences of the heavy and light CDR regions and germline genes 
used in my2F12. Basic amino acids are in bold. 
 
 
Figure 4-3: ManLAM-specificity of isolated monoclonal my2F12 
Sandwich ELISA using my2F12 Fab fragment as capture and my2F12 HuG1 as 
detector or with Clearview commercial diagnostic assay using rabbit anti-LAM 
polyclonal on ManLAM and PILAM in PBS. Results are the average of three 
independent experiments with error bars showing standard error of mean.  
 
 
4.4 Characterization of my2F12 specificity 
 




To verify that specificity for the α1-2 mannose caps conferred the ability to 
distinguish LAM derived from fast growing mycobacteria from slow growing 
mycobacteria as predicted, we then tested our antibody via sandwich ELISA on 
secreted LAM-containing culture supernatants from various mycobacterial species 
grown in Middlebrook 7H9 broth. As predicted, antibody binding was only observed 
for the culture supernatants of slow-growing species (Fig. 4-4A, a phylogenetic tree 
of the mycobacterial species is given in Fig. 4-4B). In contrast, a commercial rabbit 
anti-LAM polyclonal was observed to bind all LAM variants and supernatants of all 
mycobacterial species. However, variability in signal for my2F12 binding was 
observed between the various slow-growing species. This is probably due to 
variation in levels of secreted LAM because of differences in length of time in culture 
and rate of growth. 
 
Figure 4-4: Mycobacterial specificity of ManLAM specific antibody my2F12 
(A) Sandwich ELISA using my2F12 Fab fragment as capture and my2F12 
HuG1 as detector or with commercial kit using rabbit anti-LAM polyclonal on 
LAM secreted by slow-growing versus fast-growing mycobacteria in culture 
supernatant my2F12 is only specific for ManLAM and LAM secreted by slow-
growers while the rabbit polyclonal binds all LAM variants. Results are the 
average of three independent experiments and error bars show standard error 
fast growers 
slow growers 




of mean (B) Phylogenetic tree of tested species based on 16s ribosomal RNA 
sequences. Adapted from Shinnick & Good, 1994 
 
 
To definitively identify the types of carbohydrates recognized by my2F12 we 
tested for antibody binding to various synthetic carbohydrates printed onto 
microarray slides (Fig. 4-5). The antibody was shown to bind only oligomannose 
carbohydrates containing α1-2 mannose linkages and did not bind those with only 
α1-4 or α1-6 mannose linkages such as PIM4 (phosphatidylinositol tetramannoside) 
hexamannan or trimannose. Binding was possible even with one α1-2 mannose 
linkage present (PIM5), which suggests that this is the minimal binding footprint of 
the antibody. No binding was observed to other saccharides consisting of other 
hexose or pentose monomers, such as maltotriose, fucose, rhamnose, lactose, 
galactose, and di- & hexa-arabinan (Fig. 4-6). This specificity of my2F12 for α1-2 
linked mannans, the only type of linkage found in the cap of ManLAM, thus clarifies 
and confirms our earlier results showing specificity for the mannose-caps of 
ManLAM.  
  





Figure 4-5: my2F12 specificity for α1-2 mannose linkages  
Carbohydrate microarray with oligomannose carbohydrates with α1-2 (red 
circles), as well as α1-4 and α1-6 linkages. my2F12 was only found to bind 










Figure 4-6: Lack of my2F12 binding to other oligosaccharides 
Other mono, di- and oligosaccharides were bound on microarray and tested for 
affinity to my2F12. No binding was observed 
 
4.5 Expression of my2F12 in bacteria 
 
In the previous chapter, we sought to determine if we could express full length 
IgG in a bacterial host. We were able to express limited quantities of full length IgG 
using simple methods to boost yields such as reducing inducer concentrations and 
induction at a later time point to reduce translation rates. The expressed bacterially 
IgG had virtually identical binding avidity compared to that of mammalian IgG and 
could potentially be used for as a diagnostic reagent. We therefore attempted to 
express my2F12 using this same methodology. We had previously shown that the 
optimal inducer concentration and induction OD needs to be determined for each 
individual antibody. We also showed that a generally high but not optimum yield can 




be obtained just by using low-copy plasmid. We therefore applied the same 
optimizations carried out in the previous chapter to my2F12 to determine whether 
this antibody could be successfully expressed in bacteria.  
 
my2F12 had a similar pattern of wet cell mass yield as compared to the other 
antibodies tested, with the highest yields given by the low copy number plasmid, 
which were not affected by other induction conditions, while the yields with high copy 
plasmid varied with inducer concentration as before with higher yields obtained with 
lower inducer concentrations (Fig. 4-7).  
 
Figure 4-7: Wet cell mass obtained during expression of my2F12 bacterial 
IgG 
Variation in wet cell mass for my2F12 (red bar) in comparison to the previously 
expressed five antibodies under different induction conditions. Red box 
represents yield under standard induction conditions 
 
 Like the other antibodies, levels of fully assembled antibody approximately 
correlated with the levels of functional antibody, as indicated by western blot and 
ELISA respectively, over the various conditions tested (Fig. 4-8). Unit yields of 
antibody under low copy plasmid conditions remained relatively unchanged when 
inducer concentrations and induction time point was varied, consistent with the 
pattern observed with other antibodies. When high copy number plasmid was used, 




reducing inducer concentration improved unit yields at induction at OD600 0.6 but 
decreased yields at OD600 1.0. This pattern had not been observed previously. The 
best unit yield was given by expression with high copy plasmid at OD600 1.0 with 
200ng/ml of inducer. 
 
Figure 4-8: Levels of fully assembled or functional my2F12 bacterial IgG 
obtained under different induction conditions 
(A) Left and right panels: Non-reducing western blot of 7.5μl clarified cell 
lysate from small scale overnight expression of my2F12 in shaking culture. All 
blots were probed with anti-Human Fc-HRPO and adjusted to ensure equal 
intensity. (B): Indirect ELISA indicating levels of functional IgG. Background 
binding signal was negligible for all cell lysate samples at the indicated dilution 
or neat. Red arrows indicate original standard induction conditions while black 
arrows indicate size of fully assembled IgG. 
 
 




Having determined the optimal conditions for highest unit yields, we then 
proceeded to determine potential yield from a large-scale purification. This was 
carried out in the same manner as in the previous chapter using sequential Protein A 
and Protein L purification. No protein band representing fully assembled IgG was 
detected on the Coomassie gel of the Protein A elute fractions or in the pooled 
eluate (Fig. 4-9). Consistent with the lack of full length IgG expression, purification on 
protein L on the pooled Protein A eluate of my2F12 eliminated all protein bands and 
the eluate had negligible amounts of protein (<1 µg) as measured by Bradford assay. 
This was unexpected given our success at achieving recoverable yields previously 
and the detection of fully assembled, functional IgG by Western blot and ELISA.  
 
Figure 4-9: Large scale expression and purification of my2F12 bacterial 
IgG 
Non-reducing Coomassie gel of peak fractions from Protein A HPLC purification 
of cell lysate of my2F12. 30μl of each fraction or pooled Protein L eluate (ProL) 
or 2µg of pooled Protein A eluate (ProA) was run. 2µg of mammalian culture 
expressed full length my2F12 was added as a control (ctrl) which is indicated by 
the arrow 2H2L. No protein bands were observed at that size for all peak 
fractions and pooled eluate indicating very low protein expression of full length 
IgG 






A ManLAM-specific antibody could be of great benefit to LAM-based TB 
diagnostics by improving the specificity of such assays for various types of clinical 
samples. Using a subtractive phage display technique, we have developed an 
antibody that can distinguish the mannose-capped LAM produced by slow growing 
mycobacteria from other forms of LAM produced by fast-growing mycobacteria. We 
have proven its specificity based on differential binding to both purified LAM as well 
as LAM secreted into culture supernatant from both groups of mycobacteria (Fig. 4-2 
& 4-3) As the major pathogenic species of mycobacteria such as M. tuberculosis, 
avium, bovis and leprae all fall within this group of slow-growers, our antibody is 
likely to be extremely useful for detecting infections arising from such pathogens.  
 
We also show using carbohydrate microarrays that our antibody’s specificity 
for ManLAM is its ability to only recognize the α1-2 mannose linkage while having no 
binding for other mannose linkages such as α1-4 and α1-6, or to other mono-, di-, 
and oligosaccharides, some with identical linkages. X-ray crystallography of another 
anti-LAM antibody (CS-35) specific for the secondary arabinose branches of LAM 
shows that the binding pocket of that antibody forms a surface that can uniquely 
recognize arabinofuranose residues in that branched configuration (199). Therefore 
it is not surprising that our antibody is capable of having such exquisite specificity for 
mannose residues in that particular linkage.  
 
While phage display libraries have previously been used to generate anti-
carbohydrate antibodies, this is the first time a subtractive depletion technique has 




been applied to focus antibody specificity to a particular antigenic region on the 
carbohydrate molecule (200). As the utility of diagnostic antibodies depends highly 
on their specificity, this methodology for generating highly specific, high-affinity anti-
carbohydrate antibodies could prove to be highly useful. Typically, panning of phage 
libraries produces multiple antibodies specific for the target antigen (200,201). 
Interestingly however, all isolated antibodies from our enriched library were clones of 
one unique high-affinity antibody, indicating that there are an extremely limited set of 
ManLAM-specific antibodies within our library, or that competition for limited antigen 
resulted in only one high-affinity antibody displacing all other weaker binding clones 
in the process of enrichment. Either possibility suggests that such a high affinity 
ManLAM-specific is extremely rare and may not be easily obtained through standard 
phage library panning or hybridoma techniques.  
 
 Given the diagnostic purpose of our antibody, functions such as complement 
and Fc receptor binding are not required and hence we sought to use the bacterial 
IgG optimization and expression methodology developed in the earlier chapter to 
determine if my2F12 can be expressed in bacteria in useful quantities. This would 
significantly reduce the cost of diagnostic assay production. However, although the 
small scale optimization experiments indicated that some functional, fully assembled 
antibody was successfully expressed and that reduction of translational rates by 
using induction at a later time point did enhance unit yields (Fig. 4-8), large scale 
expression and purification with those optimized conditions failed to recover a 
quantity of antibody sufficient for characterization and testing on additional diagnostic 
samples (Fig. 4-9). It must be noted that even at optimized unit yields, antibody 
expression levels were low as in order to obtain moderate levels of ELISA signal, a 




high 1:2 dilution of the lysate was required (Fig. 4-8). Furthermore, conditions that 
gave the best optimized unit yields significantly decreased wet cell mass yields, a 
pattern noted with some of the antibodies tested earlier (ET21 and ET149) and 
which would impact on overall yield. It may also be that my2F12 may just be prone to 
degradation in E. coli, as evidenced by multiple bands on the Western blot smaller 
than the full sized antibody. We therefore switched to mammalian expression of IgG 
for the subsequent further characterization and testing of this antibody. 
  
 Based on our data, my2F12 has exquisite specificity for ManLAM and 
presents a unique opportunity to develop highly specific point-of-care TB diagnostics. 
Subsequent characterization on a variety of assay formats and clinical material will 
be done in order to determine the diagnostic utility of this antibody. 
  















Chapter 5: Optimization of my2F12 antibody and sample 
processing for diagnostic use 
  






In the previous chapter, we described the isolation of a ManLAM specific 
antibody using a novel negative selection method on the Humanyx phage display 
antibody library. The antibody was shown to bind directly to α1-2 mannose linkages 
on synthetic oligosaccharides and recognized only the LAM secreted by the slow-
growing group of mycobacterial species such as Mtb as predicted based on its 
mannose linkage specificity. This is the first anti-LAM antibody characterized with 
such specificity and we therefore sought to determine its utility on a variety of 
antibody-assays that are applicable to TB diagnostics.  
 
 A common type of antibody assay used in diagnostics is the sandwich ELISA 
(enzyme-linked immunosorbent assay), in which antigen is captured from solution by 
surface adsorped antibodies coated onto an ELISA plate. The bound antigen is then 
subsequently detected by a second antibody added after the capture phase. This 
mode of ELISA is particularly useful for detecting antigen in a complex matrix without 
the need for prior purification or concentration, is capable of very high sensitivity and 
thus is ideal for the detection of LAM from clinical samples such as sputum, urine or 
serum (79). While sandwich ELISAs typically require a pair of antibodies that bind 
different epitopes so as to prevent competitive binding for a single epitope, the 
multiplicity of α1-2 mannose caps on a single LAM molecule (7-10 depending on 
species) allows for the same antibody to be used both as a capture and detector 
antibody without interference to the binding of either antibody, as seen in 
functionality of our monoclonal sandwich ELISA in the previous chapter (196,202).  
 




 However, in order to use the same antibody, it must be modified such that the 
binding of the detector antibody can be distinguished from the capture antibody 
which is already present on the ELISA plate. This can be accomplished either by 
direct labelling of the detector antibody with the signal generating enzyme (typically 
horseradish peroxidase), or modifying the detector antibody with a tag e.g. biotin that 
can be recognized by a secondary antibody (79,202). Detection with secondary 
antibody is generally preferred for diagnostics due to a generally lower background 
and higher amplification of signal (Michel, G., personal communication). Use of 
recombinant antibodies offers a third option in the ability to express chimeric 
antibodies with the same variable domain but with switched constant regions (203). 
Thus, an antibody with the same specificity can be expressed as a human or mouse 
isotype, which can be detected separately with an appropriate species-specific 
secondary antibody. This avoids having to chemically label the detector antibody. 
The use of anti-mouse secondary rather than an anti-human secondary also has the 
advantage of reduced cross-reactivity to endogenous antibodies found in clinical 
samples such as serum. 
 
 A second type of antibody assay is the immunofluorescence (IF) or 
Immunohistochemistry (IHC) assay, in which a sample on a slide is probed with 
fluorescently labelled or enzyme conjugated pathogen-specific antibodies. For IHC, 
antibody binding is followed by a development step where the slide is incubated with 
a dye that precipitates onto the slide in the presence of the enzyme conjugate, thus 
identifying the location of the antigen (204). Such techniques are particularly useful 
for the detection of extrapulmonary TB, where traditional methods such as culture, 
acid-fast staining and NAATs have shown low sensitivity while relying on cell 




histology alone is non-specific (205,206). IF can be also easily applied to sputum 
smear fluorescent microscopy, which can be now carried out in resource poor 
settings due to the development of battery powered portable light-emitting diode 
based fluorescent microscopes (71). This would enable slow-growing mycobacteria 
to be rapidly distinguished from other acid-fast bacilli and be useful in areas of low 
TB incidence. A chimeric antibody would also be of value in this assay for the same 
reasons described above. We therefore constructed chimeric variants of my2F12 
and verified that they retained similar avidity as the parent antibody. We also 
explored their potential utility in the two types of diagnostic assays described above 
by determining their specificity with regards to a wide range of mycobacterial and 
other bacterial species.  
 
5.2 Design and expression of my2F12 chimeric antibodies  
 
A traditional chimeric antibody consisting of a human light chain and heavy 
variable region and mouse constant regions would be suitable for diagnostic use as 
it minimizes the structural similarity of the domains not involved in direct antigen 
binding. However, making a chimeric antibody often results in significantly reduced 
affinity relative to the parental antibody (huG1full) as modification of constant regions 
and antibody isotype is known to affect avidity even if the equivalent murine 
homologs (in this case mouse G2a and kappa light chain) are used (207). We 
reasoned that a chimeric my2F12 consisting of the first heavy chain constant domain 
(CH1) and hinge of human IgG3 followed by the Fc of mouse IgG2a (hG3mG2a) 
would have near parental avidity, as the increased length and flexibility of the G3 
hinge would minimize the influence of the switch in Fc on the structure of the antigen 




binding fragment (Fab) (208). In addition a set of constructs was engineered to 
highlight the regions of the antibody that were important for retention of parental 
avidity; hG1mG2a contained the CH1 and hinge of human IgG1 coupled to the Fc of 
mouse IgG2a; and 2 more traditional chimeric antibodies which had the complete 
human heavy chain constant region replaced with that of mouse IgG2a, with a fully 
human or chimeric light chain, moG2a and moG2afull respectively. A fully human 
IgG3 version (huG3full) of my2F12 was also produced. The structural layout of these 
variants is shown in Figure 5-1A. 
 
Purified antibody was run on both reducing and non-reducing SDS-PAGE gels 
to verify that the antibodies were of the right size and properly assembled. On the 
reducing gel, the light chain, human G1/mouse G2a and human G3 heavy chains ran 
at the appropriate sizes of 25kDa, 50kDa and 60kDa respectively and the intensities 
of the heavy and light chain bands were balanced indicating equivalent amounts of 
both polypeptide chains as expected (Fig. 5-1B). All six antibodies ran as a single 
main band greater than 150kDa on the non-reducing gel although some minor bands 
were observed, indicating that the majority of the antibody molecules were fully 
assembled although small amounts of incompletely assembled antibody were also 
present (Fig. 5-1C). A western blot of the six variants with anti-human Fc secondary 
was also carried out to confirm that the chimeric variants did indeed carry mouse Fc 
and as expected only the huG1full and huG3full isotypes showed up on western 
while the mouse chimerics did not (Fig. 5-1D).  




Figure 5-1: Design and expression of my212 chimeric variants 
(A) Structural diagram of the six my2F12 antibody variants including the original 
huG1 my2F12 showing the human/mouse origins and isotypes of the various 
constant domains. (B) Reducing and (C) Non-reducing Coomassie of the six 
variants. 2µg of each antibody was run on 10% SDS-PAGE gel showing 
individual heavy and light chains (HC/LC) or fully assembled antibody (2H2L) 
(D) Western blot of the six variants with 1:5000 anti-Human Fc-HRP on 0.5µg of 
each antibody run on a reducing SDS-PAGE and transblotted to a nitrocellulose 









5.3 Characterization of my2F12 chimeric antibody avidity 
 
The relative avidities of these antibodies were analysed by binding of serially 
diluted antibody to a fixed concentration of ManLAM by indirect ELISA and plotting 
the logarithmic dilution curves (Fig. 5-2A). Expectedly, both of the more traditional 
chimeric antibodies moG2a and moG2afull displayed significant reductions in avidity 
with a greater than one-log shift in the dilution curve relative to huG1full. As was 
hypothesized, hG3mG2a retained near parental avidity, as the dilution curve of 
avidity was largely similar to huG1full. The suggestion that retention of avidity is due 
to the presence of the IgG3 hinge is supported by observation that there is a half log 
reduction in the avidity of hG1mG2a which only differs in this region and that 
huG3full has higher than parental avidity. Interestingly, the loss of avidity between 
the antibody pairs huG1full and hG1mG2a, along with huG3full and hG3mG2a, was 
similar, suggesting that the effects of switching hinge and Fc on avidity are additive 
and that despite increased flexibility of the hinge, it cannot completely isolate the Fab 
region from changes in the Fc structure. Having determined that huG3full has higher 
avidity that huG1full, we also evaluated its suitability as a capture antibody compared 
to huG1full at equimolar coating concentrations in an indirect sandwich ELISA using 
ManLAM at low concentrations (1-10ng/ml) (Fig. 5-2B). It performed significantly 
worse than huG1full giving poorer signal to noise ratios at all concentrations tested 













Figure 5-2: Variation in binding affinity of different my2F12 chimeric 
antibodies 
(A) Serial dilution of IgG against ManLAM on indirect monoclonal IgG ELISA 
showing relative affinities of different chimeric constructs. Red lines indicate 
parental antibody (huG1full) and engineered diagnostic (hG3mG2a) (B) 
Relative binding efficiencies of HuG1 and HuG3 represented by signal-to-noise 
ratio when used as capture antibody at 5.0µg/ml and 5.4 µg/ml (equimolar 
concentrations) with hG3mG2a at 1 µg/ml as detector at various low 
concentrations of ManLAM. ***: p<0.001, *: P<0.05, NS: not significant. Results 
are the average of three independent experiments and error bars show 
standard error of mean. 
 
 
5.4 Identification of pathogenic mycobacteria with chimeric my2F12 by 
immunofluorescence microscopy 
 
In order for the chimeric antibody to be diagnostically useful, we have to verify 
that it retained the same specificity as the parent human my2F12. We therefore 
evaluated the specificity of my2F12 for various mycobacterial and actinomycete 
species on slides of fixed bacterial culture via confocal IF microscopy using the 
chimeric mouse antibody (moG2a) and an anti-mouse fluorescently labelled 




secondary antibody to detect binding. For comparison, a commercial rabbit 
polyclonal αLAM IF and the traditional Ziehl–Neelsen acid-fast stain was also carried 
out on duplicates of these slides. We also included two additional non-mycobacterial 
actinomycete species that had previously been isolated from clinical sputum samples 
and cross-reacted with polyclonal anti-LAM antibodies and hence could potentially 
give false positives; Nocardia cyriacigeorgica and Tsukamurella paurometabolum 
(154). The Gram negative bacterium Escherichia coli was also included as a 
negative control. A classification of the species used, their pathogenicity and IF and 
acid-fast stain results is given in Fig. 5-3 
 
Figure 5-3: Phylogenetic distribution and diagnostic characteristics of 
various mycobacterial species 
Tree diagram showing classification of mycobacterial and non-mycobacterial 
species into fast and slower growers, their pathogenicity, antibody specificity 
and acid-fast staining. 




 Confocal IF microscopy with my2F12 gave clear fluorescence for Mtb bacilli 
previously heat killed and subsequently fixed by methanol–acetone onto slides (Fig. 
5-4A). This indicates that our antibody can probably be used for detection of TB 
infection via IF sputum smears. The Mtb bacilli were also positive on IF with the 
commercial rabbit polyclonal αLAM and also were stained strongly red (positive) by 
the acid-fast stain, as expected for a slow-growing mycobacteria species. Other 
slow-growing mycobacterial species were similarly positive for both my2F12 and 
polyclonal αLAM IF as well as the acid-fast stain (Fig. 5-4B).  
 
On the other hand, all fast-growing mycobacterial species such as M. 
smegmatis could not be detected by my2F12 IF but were uniformly positive for 
polyclonal αLAM IF as well as the acid-fast stain (Fig. 5-5A). For the non-
mycobacterial actinomycete species, all were negative for the acid-fast stain and 
my2F12 but positive for polyclonal αLAM IF with the exception of T. paurometabolum 
which bound both the my2F12 and polyclonal antibodies (Fig. 5-5B). To further 
determine the likelihood of additional cross-reactivity on sputum samples, we 
subsequently tested our antibody against common throat bacteria species such as 
Streptococcus, Staphylococcus and Pseudomonas aeruginosa using the same IF 









Figure 5-4: my2F12 immunofluorescent staining for slow-growing 
mycobacteria 
my2F12 chimeric staining for slow growing mycobacteria by confocal IF 
microscopy for fixed heat-killed Mtb (A) and fixed live cultures of other slow 
growing species (B) Staining was carried out with my2F12 or rabbit polyclonal 
αLAM with corresponding differential interference contrast (DIC) microscopy 










Figure 5-5: Lack of my2F12 immunofluorescent staining for fast-growing 
mycobacteria or non-mycobacterial species 
Lack of binding of my2F12 chimeric antibody to fast growing mycobacterial 
species (A) or non-mycobacterial species (B) with the exception of T. 
paurometabolum by confocal IF microscopy. Staining was carried out with 
my2F12 or rabbit polyclonal αLAM with corresponding differential interference 









Figure 5-6: Lack of my2F12 immunofluorescent staining for common 
throat bacteria 
Lack of binding of my2F12 chimeric antibody to Staphylococcal, Streptococcal 
and Pseudomonas bacteria as shown by double staining with DAPI and 
my2F12 coupled with an anti-mouse Alexa Fluor-488 secondary antibody (488) 
under confocal IF microscopy.  
 
 
5.5 Identification of pathogenic mycobacteria with chimeric my2F12 by 
sandwich ELISA 
 
Sandwich ELISA Is another potential TB diagnostic assay and one that has 
been previously used assay for LAM in urine (87). We therefore tested our chimeric 
antibody alongside the Clearview polyclonal anti-LAM based commercial sandwich 
assay in a sandwich ELISA using intact whole bacteria re-suspended in PBS as the 
test antigen instead of the filtered culture supernatant used in the previous chapter to 
reduce variability in LAM amounts as length of time grown in culture is no longer a 
factor. For this assay, the antibody showed identical specificity to that observed on 
confocal IF microscopy, binding only the slow-growing mycobacteria and T. 
paurometabolum but not the fast-growing mycobacteria as well as E. coli and N. 




cyriacigeorgica (Fig. 5-7). In contrast, the polyclonal anti-LAM antibody bound all 
mycobacterial and actinomycete species, which is consistent with the earlier studies 
and our IF microscopy results. Critically, Mtb gave a clear signal on my2F12 ELISA, 
again indicating the suitability of this antibody as a TB diagnostic reagent. However, 
the signal was lower than that of other slow-growing mycobacterial species, possibly 
due to the heat-killing treatment required for safe manipulation of the bacteria. The 
heat-treatment is likely to have disrupted some of the cell wall and leached a portion 
of the ManLAM, potentially reducing levels of ManLAM in intact bacilli. The higher 
signal of polyclonal αLAM is probably due to multiplicity of binding sites on the 













Figure 5-7 Specificity of chimeric my2F12 for various mycobacterial 
species 
Sandwich ELISA with my2F12 chimeric antibody as detector and my2F12 HuG1 
as capture or with commercial kit using rabbit anti-LAM polyclonal against whole 
bacteria at OD600 0.5. my2F12 is specific only for mycobacterial slow-growers 
and a unique actinomycete T. paurometabolum while rabbit polyclonal binds all 
mycobacterial and actinomycete species tested. Data are the average of three 
independent experiments and error bars show standard error of mean 
 
 
5.6 Enhancing the sensitivity of my2F12 ELISA on spiked serum samples 
 
Due to the potential for cross-reactivity in sputum due to the presence of other 
actinomycete species that express α1-2 mannose capped LAM, we decided to 
investigate alternative clinical sample types where the burden of environmental 
bacteria is likely to be much less, i.e. serum. We therefore tested serum samples to 
determine the sensitivity of serum ELISAs and whether serum anti-LAM antibodies 
could interfere with detection, which had been observed previously (209). Serum 
was obtained from three previously BCG vaccinated and one unvaccinated 




volunteers and analysed for antibodies against ManLAM and PILAM by indirect 
ELISA. While all serum samples were found to have both anti-ManLAM and anti-
PILAM antibodies, as expected, the non-vaccinated serum had the lowest titre (Fig. 
5-8A). The other BCG vaccinated serum had varying higher levels of anti-LAM 
antibodies and were classified into high, medium and low titre serum respectively. 
Interestingly, both the anti-ManLAM and anti-PILAM antibody titres were roughly 
equivalent in each serum sample, which is probably due to the majority of 
endogenous anti-LAM antibodies being cross-reactive and binding both types of 
LAM equally well. Therefore, we expected that the endogenous antibodies in serum 
would not be able to interfere with our antibody binding to the mannose-cap epitope. 
However, on testing LAM spiked serum on the same sandwich ELISA used 
previously, we found that sensitivity correlated with the level of endogenous anti-
LAM antibodies in the serum and that the limit of detection (defined as signal-to-
noise ratio of 2) in the highest titre serum was almost twenty-five-fold less than in 
non-vaccinated serum (100ng/ml vs. 4ng/ml, Fig. 5-8B) and one hundred-fold less 
than in LAM spiked into PBS (100ng/ml vs. 1ng/ml, Fig. 5-8B). This suggested that 
endogenous anti-LAM antibodies in serum interfered with detection of LAM. 
 





Figure 5-8: Influence of serum anti-LAM antibodies on my2F12 assay 
sensitivity 
 (A) Serial dilution of serum from BCG vaccinated and non-vaccinated 
volunteers showing range of titres of endogenous anti-LAM antibodies (non-
specific signal as determined by binding against PBS has already been 
subtracted). (B) Detection of spiked ManLAM in serum by sandwich ELISA 
showing increasing interference and reduced sensitivity with increasing levels of 
endogenous anti-LAM antibodies in serum as indicated by signal-to-noise ratio. 
A limit of detection is set at a ratio of 2 and noise is defined as the signal 
obtained with no LAM added. Figure data are the average of three independent 
experiments and error bars show standard error of mean  
 
 
 As a result, we investigated simple methodologies to remove endogenous 
antibodies. We developed a hybrid method that first used proteinase K to digest 
serum antibody and proteins, followed by a heating at 95°C to inactivate proteinase 
K and any remaining antibodies as well as to sterilize the sample. This was done for 
both the high titre serum and unvaccinated serum after spiking with LAM and the 
treated serum was subsequently tested by the above sandwich ELISA in comparison 
with the untreated LAM spiked serum to determine if sensitivity was improved. In 
addition, both were also tested by indirect ELISA against PILAM and ManLAM to 
confirm that endogenous antibodies had been denatured. Comparison of the serum 




antibody binding activity showed a significant drop in levels of IgG antibody binding 
against both ManLAM and PILAM to almost close to that of background for the high 
titre serum (Fig. 5-9A). A drop in the non-vaccinated serum was also observed but 
this was not significant as the levels of anti-LAM antibody were extremely low even 
before treatment. Treatment of both the high-titre serum and unvaccinated serum 
resulted in improvements in the limit of detection, from 3ng/ml to 0.5ng/ml in 
unvaccinated serum and from 50ng/ml to 2ng/ml in high-titre serum (Fig. 5-9B). As 
expected the improvement was much greater in the high-titre serum. In both cases, 
sensitivity in the treated serum was similar to that of LAM spiked into PBS (limit of 
detection at 3ng/ml). Specificity of the antibody was retained as the signal obtained 
with 1µg/ml of PILAM spiked into either treated or untreated serum ranged from 
97.5% to 112% that of the background noise signal (no LAM added). In addition, we 
also tested the same treatment process on whole blood to whether the coagulation 
step to obtain serum could be omitted. To ensure full digestion, incubation with 
Proteinase K was extended for 30min. However, the limit of detection was about 
6ng/ml for both high-titre and unvaccinated serum, which was an improvement for 
the high-titre sample but a decrease for the unvaccinated serum and compares 
poorly with both the PBS standard and treated serum (Fig. 5-9C).  





Figure 5-9: Improvement in assay sensitivity by heat and proteinase K 
denaturation of serum anti-LAM antibodies  
 (A) Significant reduction of levels of endogenous anti-LAM antibodies in serum 
(at 1:512 dilution) by simple Proteinase K and heat treatment. Changes in 
sensitivity of sandwich ELISA as indicated by signal-to-noise ratio after 
denaturation of endogenous anti-LAM antibodies in spiked serum (B) or whole 
blood samples (C) with proteinase K and heat treatment (+PK) as compared to 
untreated spiked (-PK) samples and PBS standards. Concentrations of 
ManLAM are that in whole blood spiked before coagulation. Treatment of serum 
improves sensitivity for both samples while treatment of whole blood only 
improves sensitivity in the high-titre sample. Figure data are the average of 
three independent experiments and error bars show standard error of mean. 
Concentrations of ManLAM are that in whole blood spiked before coagulation. 
  






The clinical utility of our antibody is dependent on whether it can be used in 
clinical diagnostic techniques such as immunofluorescence microscopy or ELISA to 
distinguish the relevant pathogens. Previous studies have shown that other 
monoclonal and polyclonal anti-LAM antibodies cannot distinguish between 
pathogenic and non-pathogenic mycobacterial species or even cross-react to other 
LAM producing actinomycete species such as Nocardia despite their high-affinity for 
the LAM molecule itself and thus have limited clinical value (154,210). On the other 
hand, our antibody, both the parental and chimeric versions, do not cross-react to 
fast growing mycobacterial species such as M. smegmatis, chelonae and fortuitum 
but was able to detect all slow-growing mycobacterial species tested using both 
immunofluorescence confocal microscopy and ELISA (Fig. 5-4, 5-7). 
 
The division of mycobacterial species into these two taxonomical groups was 
first based on the phenotypic difference of growth-rates, but was later supported by 
phylogenetic analysis of 16s ribosomal RNA (18). While the vast majority of slow 
growers are pathogenic in humans or animals, the majority of fast growers are 
environmental non-pathogenic bacteria with only a few exceptions that cause 
typically mild disease (18,211). Slow-growing mycobacteria include species such as 
M. malmonese, marinum, scrofulaceum, simiae and xenopi, which have not had their 
LAM structure and capping motifs characterized to date. Our study is the first to 
screen for α1-2 mannose capping motifs over such a wide variety of mycobacterial 
species. The observation that ManLAM capping motifs were present in all slow 
growing species tested but none of the fast-growing species that we tested makes it 




highly probable that these motifs are exclusive to the slow growers and could be 
considered one of the defining characteristics of their group. It is therefore likely that 
our antibody will be able to detect all slow-growing mycobacterial species and 
represents an improvement over other anti-LAM antibodies available for diagnostic 
purposes.  
 
The cross-specificity of my2F12 will also enable clinicians to detect other non-
tuberculous mycobacterial infections, but distinguishing these from TB may then 
depend on clinical presentation of the patient or other diagnostic tests. Testing of our 
antibody on clinical samples from TB positive and negative patients will therefore be 
required to confirm its utility and determine its predictive value in TB diagnosis. Our 
antibody was also shown to have affinity for a related actinomycete, T. 
paurometabolum. This is not surprising as this organism has been found to produce 
LAM with terminal α1-2 mannose linkages (135). Although this may lead to false 
positives as this species has been previously been found in sputum clinical isolates, 
such mannose linkages are thought to be a pathogenic determinant as they enable 
host cell invasion via the mannose receptor and suppression of immune cell 
responses through DC-SIGN in the case of mycobacterial infection (136,143,154). 
This antibody could hence potentially be used to determine if any particular 
mycobacterial or actinomycete strain carries such carbohydrate motifs and have 
pathogenic potential. 
 
 To adapt our antibody for diagnostic purposes, we have successfully 
engineered our antibody to a format with a murine Fc but retained avidity by 
switching to a human G3 hinge, thus enabling us to use an anti-mouse secondary 




instead of an anti-human and avoid undesirable cross-reactivity. The fact that there 
is minimal background on our ELISA with unspiked human serum samples validates 
this approach. While changes in affinity have been reported due to switch in antibody 
isotype or species origin (212), no general observation for an increase by switching 
to G3 from G1 has been made. Our findings nonetheless suggest a simple but 
effective method for improving avidity of diagnostic antibodies by switching to a G3 
isotype. We have also shown that our chimeric antibodies, both the moG2a and 
hG3mG2a variants, retain their specificity for slow-growing mycobacteria and thus by 
inference the α1-2 mannose linkage, as tested on IF and sandwich ELISA 
respectively. Interestingly, the huG3full was less sensitive compared to huG1full 
when used as capture antibody even though both were coated at equimolar 
concentrations. However, the efficiency of the capture antibody is also dependent on 
how it binds when it is immobilized onto the ELISA plate, which can be affected by 
the protein stability and structure. Binding in the wrong orientation may result in 
occlusion of the binding surface or structural alteration and loss of affinity (213). It 
may be that the increased flexibility or size of the huG3full antibody renders it less 
ideal as a capture antibody compared to huG1full. 
 
 Finally, by engineering a chimeric antibody (hG3mG2a) with near equivalent 
avidity to the parent human antibody, we are now able to test samples that have high 
concentrations of endogenous human antibodies but have low burden of 
environmental bacteria such as serum. A previous study showed that that heat and 
urea denaturation of serum improved sensitivity, but did not directly demonstrate the 
presence of anti-LAM antibodies in serum (209). Here, we extend their observations 
by showing that the higher levels of anti-LAM antibodies correlate with decreased 




sensitivity of the LAM sandwich ELISA and that denaturation of these antibodies by 
heat and proteinase K treatment restores sensitivity. While the previous study used 
urea for denaturation, which would not only denature endogenous serum antibodies 
but also potentially denature the assay antibodies, we used proteinase K which was 
subsequently inactivated by heat and thus unlikely to affect our assay. This is also 
one of the advantages of a lipid biomarker in its resistance to heat. This could 
explain why we were able to achieve a significant improvement in sensitivity (25-fold 
improvement in high-titre serum (Fig. 5-9B), compared to the previous study which 
only showed several-fold increase in signal.  
 
Our final limit of detection was approximately 0.5-2ng/ml in serum, which 
compares favourably with published data on the sensitivities of both polyclonal and 
monoclonal based anti-LAM sandwich ELISAs (0.8ng/ml, Boehme et al; 0.5ng/ml; 
Sakar et al, 1ng/ml, Hamasur et al) (83,85,209). As such, this antibody in the 
sandwich ELISA format, along with the procedure for heat treatment of serum, is a 
good candidate for a useful point-of-care test for TB diagnosis. Furthermore, while 
use of sputum as a clinical sample may have a higher risk for false positives, the 
exact rate needs to be defined by clinical testing. Our antibody’s higher specificity 
when used in IF microscopy compared to acid-fast dyes and the general higher 
sensitivity and rapidity of fluorescent microscopy over basic light microscopy 
indicates that it might be of use in areas where acid-fast staining alone is insufficient 
for confirmation of TB due to the presence of fast-growing mycobacteria. Use of this 
antibody would thus remove the need to conduct additional speciation tests such as 
line probe assays and enhance the utility of the battery powered light-emitting diode 
fluorescent microscopes now being introduced by WHO. 
















Chapter 6: Generation of anti-mycolic acid antibodies by phage 
display 
  






Mycolic acid is an attractive lipid biomarker for TB diagnosis due to its 
attested presence at high concentrations (>1µg/ml total average) in the sputum 
samples of TB patients and its abundance in the mycobacterial cell wall (40% of dry 
mass) (12,47). In contrast to lipoarabinomannan, no anti-mycolic acid antibody has 
yet been generated using traditional methodologies of animal immunization due to its 
insolubility in solution and lack of immunogenicity. However, using a semi-synthetic 
chicken scFv (single chain fragment variable) antibody phage display library, Beukes 
et al were able to successfully generate several antibodies against mycolic acid, 
although some showed cross-reactivity to cholesterol (182). They and others have 
shown that generating antibodies against highly hydrophobic lipids is feasible by 
panning phage libraries against pure lipid evaporated onto a solid surface, thus 
avoiding the need for in vivo immunization (10,112). The isolated anti-lipid antibodies 
have been shown to be able to recognize not just the purified target but also the 
same lipid when present in organic solvent extracts from biological materials and 
evaporated in the same manner. This raises the possibility that such antibodies 
could be used to detect the presence of lipid biomarkers in extracts from clinical 
samples such as sputum and hence enable cost-effective, rapid and easy detection 
that is amenable to point-of-care use. 
 
We have therefore used the same Humanyx Fab phage library used to 
generate the my2F12 antibody against ManLAM to screen for mycolic acid-specific 
antibodies. Fab libraries have an advantage over semi-synthetic scFv libraries in the 
ability of their antibodies to retain binding affinity when converted to IgG (184). We 




have applied a modified version of the panning strategy, leaving out the negative 
selection and panning against evaporated Mtb-derived mycolic acid instead of LAM 
which was coated by adsorption in solution. In order to determine the feasibility of 
anti-mycolic acid antibodies as a TB diagnostic, we also explored the ability of these 
antibodies to recognize mycolic acid in organic solvent extracts of mycobacteria and 
distinguish these from other mycolic acids species present in extracts from related 
actinomycete species, as well as means for rapid extraction of mycolic acid from 
bacterial samples.  
 
6.2 Isolation of mycolic acid-specific antibodies 
 
Purified Mtb-derived mycolic acid was coated onto solid polystyrene surface 
by evaporation from hexane, allowing the Humanyx Fab phage library to be panned 
against it. This was done for four successive rounds and the subsequent polyclonal 
ELISA indicated successful enrichment for binders to mycolic acid as shown by the 
increase in specific absorbance (Fig. 6-1). To verify that enrichment for high affinity 
Fab-phage clones occurs and to identify suitable high affinity monoclonal antibodies, 
376 individual clones from the fourth pan (the pan with the highest signal) were 
screened for binding activity by indirect phage monoclonal ELISA against mycolic 
acid and a 2:1 w/w mix of phosphocholine/cholesterol coated in the same manner as 
a negative control. The ELISA signals were classified by signal-to-noise ratio (SNR) 
as follows: negative binders (SNR<2), weak binders (SNR 2-5), moderate binders 
(SNR 5-10) and strong binders (SNR >10). The distribution of the various types of 
binders is given in Table 6-1. The strong binders formed the largest group with 51% 




of all sampled clones while the negative binders formed only 4% of all tested clones 
indicated clear preference for strong binders.  
 
Figure 6-1: Panning of Humanyx antibody phage library against mycolic 
acid 
Polyclonal phage ELISA showing enrichment of successive phage pans. Each 
ELISA plate was coated with either mycolic acid or phosphocholine/cholesterol 
in a 2:1 w/w ratio as a negative control at a final concentration of 25µg/ml. 










Table 6-1: Binding characteristics of monoclonals from 4th Pan 
Proportion of negative, weak, moderate and strong binding clones isolated from 










of Total (%) 
Negative (SNR < 2) 15 3.99 
Weak (SNR 2-5) 36 9.57 
Moderate (SNR 5-10) 132 35.11 
Strong (SNR > 10) 193 51.33 
 




The top 48 binders were sequenced to identify unique clones and the four 
best unique binders mc3, mc6, mc26 and mc47 were cloned into a mammalian 
expression vector, expressed as full length human IgG1 and purified from culture 
supernatant (Fig. 6-2). The heavy and light chain amino acid CDR sequences and 
germline genes are given in Table 6-2A and 6-2B respectively. Purified IgG was also 
run on four antibodies were retested for binding activity and all retained specificity to 
mycolic acid (Fig. 6-3).  
 
Table 6-2: CDR sequences of isolated anti-mycolic antibodies 
Light (A) and heavy (B) chain CDR sequences and germline genes of the four 
anti-mycolic acid antibodies. 
 





Figure 6-2: Expression of four unique antibodies from the 4th Pan 
Reducing (+DTT) and non-reducing (-DTT) 8% SDS-PAGE Coomassie gel of 
the four antibodies showing the individual chains (HC/LC) or the intact IgG1 
molecule (2H2L). 2µg of antibody was loaded.  
 
 
Figure 6-3: Confirmation of mycolic acid specificity of four isolated 
monoclonal IgGs 
Antibodies were tested by indirect ELISA. ELISA plate was coated with either 
mycolic acid or phosphocholine/cholesterol in a 2:1 w/w ratio as a negative 
control at a final concentration of 25µg/ml. Hexane was added as a negative 
vehicle control. 




6.3 Characterization of mycolic acid antibody specificity and sensitivity 
 
All four antibodies were subsequently tested against a panel of synthetic and 
purified lipids. Earlier studies had indicated that mycolic acid might have a similar 3D 
structure to cholesterol and evidence of cross-reactivity to cholesterol was observed 
in anti-mycolic acid antibodies previously isolated from a chicken phage display 
library (22, 23). We therefore tested all four antibodies against purified cholesterol 
and oxidized cholesterol derivatives. We also tested for cross-reactivity to common 
membrane lipids such as dimyristoyl phosphocholine (DMPC) and dimyristoyl 
phosphatidic acid (DMPA), as well as the structurally related β-hydroxyl lipids 
sphingosine and β-hydroxyl myristic acid. Finally, to determine the exact specificity of 
our antibodies, we tested for binding against synthesized subclasses of mycolic acid 
in Mtb, namely alpha, keto and methoxy mycolic acid, as well as purified extracts of 
trehalose dimycolate (TDM) and mannose-capped lipoarabinomannan (ManLAM) 
which are present in Mtb and the phosphoinositol-capped LAM (PILAM) found in M. 
smegmatis.  
 
No binding was observed to any other cholesterol lipid, membrane lipid, β-
hydroxyl lipid or mycobacterial lipid, even TDM which is comprised of two mycolic 
acid molecules attached to a trehalose sugar (Fig. 6-4A). All antibodies bound the 
original purified Mtb-derived mycolic acid as well as the synthesized methoxy 
mycolic acid strongly, but bound alpha mycolic acid weakly and not to keto mycolic 
acid at all. To ensure that negative signals were not due to lack of effective antigen 
coating, the ELISA wells were imaged under phase contrast light microscopy to 
visualize the adsorbed insoluble lipids prior to the blocking step. All wells except the 




hexane control clearly contained evaporated lipid droplets (Fig. 6-4B). ManLAM and 
PILAM could not be visualized as they are coated in aqueous solution and are not 
evaporated onto the well surface as droplets. Adherence of these glycolipids to the 
ELISA plates used had been previously verified using a rabbit anti-LAM polyclonal in 












Figure 6-4: Lipid specificity of four anti-mycolic acid antibodies 
(A) Indirect monoclonal ELISA showing specificity of isolated recombinant 
monoclonal IgGs mc3,6,26 and 47 for mycolic acid extract and methoxy mycolic 
acid in contrast to other synthetic cholesterol derivatives, membrane lipids, β-
hydroxyl lipids and mycobacterial lipids. All antibodies including the control 
antibody (anti-dengue E protein antibody 14C10) were at 1µg/ml concentration 
and the lipids were coated at 25µg/ml (B) Phase contrast light microscopy 
images of ELISA well bottoms indicating adherence of evaporated lipid onto the 
ELISA plate. Images are at 100x magnification. Results are the average of three 
independent experiments and the error bars show the standard error of mean. 
 
 




To determine the sensitivity of the antibodies, all four antibodies were tested 
against serially diluted concentrations of purified Mtb-derived mycolic acid and 
synthetic mycolic acid subclasses. All four antibodies had similar binding curves 
although mc3 and mc6 had the highest affinity as defined by signal-to-noise ratio. 
The limit of detection (defined by a signal-to-noise ratio of 2) for mycolic acid extract 
and methoxy mycolic acid was similar at about 45ng/ml for mc6 while the rest had a 
slightly poorer sensitivity of about 80-100ng/ml (Fig. 6-5A & 6-5D). The limit of 
detection range for alpha mycolic acid was 200ng/ml for the mc6 to 800ng/ml for 
mc26 and mc47 (Fig. 6-5B). Keto mycolic acid could only be detected weakly by 


















Figure 6-5: Limit of detection for various classes of mycolic acids 
Limit of detection curves for Mtb- derived mycolic acid (A), and synthetic alpha 
(B), keto (C) and methoxy (D) mycolic acids as determined by indirect ELISA. 
Antibodies were used at a concentration of 1µg/ml and lipids were coated in 
hexane at the indicated concentrations, both with a volume of 100µl/well. 
Results are given as signal-to-noise ratio and the limit of detection of a signal-to 
noise ratio of 2 is shown by the dashed line. Results are the average of three 








6.4 Optimization of mycolic acid extraction protocol  
 
In order for the antibodies to be useful for diagnostics, a simple method for 
extraction of mycolic acid from the mycobacteria in clinical samples is required. We 
therefore optimized the sensitivity and efficiency of the assay by introducing various 
heating and alkaline hydrolysis steps to the basic lipid extraction protocol of 
vortexing in hexane described by Minnikin et al (214). To ensure that enhancement 
of signal could be observed, we carried out this extraction at a low concentration of 
M. smegmatis bacteria (1ml of OD600 0.1, 5.8x10
7 CFU/ml). We tested incubation 
with or without prior heating in hexane to improve lipid extraction or boiling in water 
to lyse the bacteria. An additional alkaline hydrolysis protocol was also tested as the 
majority of mycolic acid is known to be covalently bound to the peptidoglycan cell 
which can be liberated by treatment with alkali (12,215). Lipid extraction via these 
various methods was carried out independently in triplicate and evaporated onto 
ELISA plates and tested with mc3 and mc6, the two antibodies with the best limit of 
detection.  
 
 At this low concentration of bacteria, simple vortexing did not give a significant 
signal over background (hexane only). However, lipid extracted by alkaline 
hydrolysis gave a strong signal compared to all other methods by a large and 
statistically significant margin. Extraction by heating in hexane also gave significantly 
higher signal for mc3 only over vortexing and background although the increase was 
slight (Fig. 6-6). Other methods showed no significant increase in signal over 
vortexing in hexane or background. Given that alkaline hydrolysis only requires 
several hours to complete as compared to the other methods which require overnight 




incubation in hexane, this is the method we selected to determine the limit of 
detection on standardized CFU amounts of mycobacteria.  
 
 
Figure 6-6: Determination of optimal lipid extraction method 
Various methods of extraction were tested using the two most sensitive IgGs 
mc3 & 6 and 1ml of OD600 0.1 (5.8x10
7 CFU) M. smegmatis as a test sample. 
Mycolic acid was extracted by either overnight incubation at room temperature 
with hexane after vigorous vortexing only (Vortex) or with additional prior 
heating (Heat in hexane). Two more methods using a lysis step with boiling 
water where hexane was added directly to the water after heating (Boil + 
Hexane) or sequentially following an intermediate centrifugation to pellet the 
bacteria (Boil, spin + Hexane) were also carried out. A fifth protocol involving 
rapid alkaline hydrolysis (KOH) to release covalently bound mycolic acid was 
also done. *** p<0.001, alkaline hydrolysis vs. all other methods *p<0.05 for 
heat in hexane vs. all other methods.  




To confirm that the alkaline hydrolysis procedure released mycolic acid from 
the bacteria and that our antibodies were indeed detecting mycolic acid, triplicate 
alkaline hydrolysis extracts were first analysed by high-resolution tandem mass 
spectrometry (HR-MS/MS). Identification was based on accurate mass measurement 
and product ion scans (Fig. 6-7A). Mycolic acids were ionised as [M-H]- ions and 
observed m/z were within 2ppm of expected values. Product ion analysis allowed for 
the identification of α-alkyl chains (the most abundant being C24:0, Fig. 6-7B). 
Identified mycolic acids were then quantified in the same triplicate extracts by 
multiple reaction monitoring (MRM) analysis, using Q1/Q3 transitions previously 
identified in mycolic extracts of mycobacterial species and adjusted based on an 
internal synthetic mycolic acid standard (8). Identified unique mycolic acid transitions 
were ranked by concentration and analysis of the top ten mycolic acids identified 
indicated that the majority of these were alpha mycolic acids and their total 
concentration was approximately 3.4µg/ml (Fig. 6-7C). The levels of methoxy 
mycolic acids were insignificant compared to alpha mycolic acid which was expected 
for the particular species of mycobacteria tested (M. smegmatis). Nonetheless, the 
concentration of alpha mycolic acid alone is well within the detection limit of our 
















Figure 6-7: Identification of mycolic acids in lipid extract by mass 
spectrometry 
Representative high-resolution mass spectrum of alkaline hydrolysis lipid 
extracts, showing measured m/z of mycolic acids, elemental formulae and mass 
accuracy (in ppm). (B) Product ion spectrum of mycolic acid at m/z 1150.2, 
showing a main fragment at m/z 367.3580 (C24H47O2, fatty acyl 24:0) (C) 
Detection of individual species of mycolic acid in M. smegmatis KOH extract by 
mass spectrometry in MRM mode, the concentrations of the top ten mycolic 
acids, identified by Q1/Q3 transitions, are indicated along with the subtype( A or 
KE for Alpha and Keto/Epoxy respectively). No methoxy mycolic acid was 
detected. Results are the average of three independent experiments and the 














6.5 Determination of species specificity 
 
Having optimized a methodology for mycolic acid extraction, we then 
proceeded to apply this method to two other actinomycete species found previously 
in sputum samples, Nocardia cyriacigeorgica and Tsukamurella paurometabolum as 
these actinomycete species are also known to contain mycolic acids (48,154). As a 
comparison, we also tested the unrelated gram negative bacteria Escherichia coli. 
Extracts from 1ml of OD600 0.1 were tested by indirect ELISA in the same manner as 
above. mc3 was specific for only M. smegmatis extract while mc6 was strongly cross 
reactive for T. paurometabolum but not N. cyriacigeorgica extract. No binding to E. 
coli was observed for either antibody, which is to be expected as it does not contain 
any mycolic acid.  
Figure 6-8: Bacterial species specificity of anti-mycolic acid antibodies 
Indirect monoclonal IgG ELISA showing specificity of IgGs mc3 and mc6 for M. 
smegmatis lipid extract (Msm) compared to lipid extract from other 
actinomycete genera (N. cyriacigeorgica-Ncy, T. paurometabolum-Tpa) and E. 
coli (Eco) and hexane as negative controls. Mycolic acid at 6.25µg/ml was 
added as a positive control. Results are the average of three independent 
experiments and the error bars show the standard error of mean. 





6.6 Determination of CFU limit of detection 
 
Various standard amounts of bacteria from 109 to 106 CFU/ml were treated 
using the alkaline hydrolysis method to extract lipids into 1ml of n-hexane and 100µl 
of lipid extract was evaporated onto ELISA plates and tested with mc3 and mc6. We 
tested both the non-pathogenic mycobacterium M. smegmatis as well as a less 
pathogenic (BSL2) close relative of Mtb- M. bovis BCG. Both antibodies were able to 
bind the lipid extract of both mycobacterial species (Fig. 6-9). As before, mc6 had 
superior sensitivity compared to mc3, giving higher signal at the same bacterial 
concentration. Based on the limit of detection of signal-to-noise ratio of 2, the range 
of detection for both antibodies was roughly similar at between 106 to 107 CFU of M. 
smegmatis and one order of magnitude better for BCG at 105 to 106 CFU. Given that 
the volume of lipid extract evaporated was 100µl, this translates into a lower 




















Figure 6-9: Sensitivity of anti-mycolic acid antibodies for whole mycobacteria 
Limit of detection of the two most sensitive IgGs mc3 and mc6 using the rapid 
alkaline hydrolysis extraction method for various CFU amounts of M. smegmatis (A) 
and M. bovis BCG (B) based on a signal-to-noise ratio of 2 (indicated by dashed 
line). Both antibodies mc3 and mc6 can detect between 106 to 107 CFU of M. 
smegmatis and 105 to 106 CFU of M. bovis BCG in a 100µl volume. All results are 
the average of three independent experiments and the error bars show the standard 
error of mean. 
  






Our isolated antibodies had specificity primarily for the methoxy subclass of 
mycolic acid, with weak binding to alpha mycolic acid and no binding to keto mycolic 
acid or any other lipid tested (Fig. 6-4A). This is despite the fact that Mtb contains 
mycolic acid species of all three subclasses. While keto and methoxy mycolic acids 
have a W-shaped configuration that exposes the charged functional groups that 
allow for interactions with antibodies via electrostatic and hydrogen bonds in an 
aqueous environment, keto mycolic acid has the greatest tendency to fold in this 
manner and it is therefore unexpected that the antibodies all bound methoxy well but 
not keto at all (180,181). Alternatively, it may be possible that keto has weaker 
adherence to the ELISA plate and lost during the washing process. This could be 
determined by re-dissolving the dried lipid with hexane after completion of the assay 
and measuring the levels of recovered lipid via mass spectrometry in the same 
manner as done for the lipid extract. 
 
However, serological studies have shown that anti-TDM antibodies produced 
in the course of TB infection in humans are generally methoxy mycolic acid specific 
(216). It may thus be that the human antibody repertoire is predisposed towards 
recognition of this particular subclass and may explain the tendency of our human-
derived non-immune library to produce methoxy mycolic acid antibodies. The ability 
of our antibodies to distinguish between similar lipids with only small changes in 
molecular structure has been shown previously for antibodies raised in the same 
manner against oxy-sterols and indicates the ability of antibodies to provide fine 
specificity for lipid detection (10). 





As some related bacterial genera such as Nocardia and Tsukamurella contain 
mycolic acid in their cell walls as well, we wanted to determine whether our 
antibodies could specifically recognize mycobacterial mycolic acid so as to reduce 
the potential for false negatives. We showed that our two best antibodies mc3 and 
mc6 strongly bound M. smegmatis lipid extract only and not extract from other non-
mycobacterial species with the exception of mc6 to T. paurometabolum lipid extract 
(Fig. 6-8). This could be because its mycolic acids in terms of fine structure such as 
total number of carbon atoms and fatty acid chain length more closely resemble 
mycobacterial mycolic acids as compared to some other genera such as Nocardia 
and Corynebacteria which have fewer carbon atoms and shorter chain length (9). A 
previous study had indicated that a phage display-derived antibody against methyl 
palmitate, a non-polar lipid, could distinguish between this lipid and others with 
similar structure but longer carbon aliphatic tail (112). Therefore, while it is generally 
assumed that antibodies principally target and recognize polar epitopes even on 
lipids, it is possible that our antibodies can differentiate apolar portions of the mycolic 
acid molecule as well, such as the fatty acid tail. This ability to discriminate 
mycobacterial mycolic acids is important for diagnostic purposes as the 
abovementioned species of actinomycetes have been identified in sputum samples 
from TB patients (154). 
 
 Our most sensitive antibody, mc6, was able to detect 4.5ng of total mycolic 
acid or methoxy mycolic acid by indirect ELISA (Fig. 6-5A & 6-5D). While this is the 
first time the sensitivity of an anti-mycolic acid antibody has been determined, this is 
not too dissimilar to other antibody-based TB diagnostic assays such as the urinary 




lipoarabinomannan test, which also detect in the low-to sub nanogram level at similar 
signal-to-noise ratios (83,85). In order to determine whether such sensitivity is 
sufficient for clinical use, we sought to establish a limit of detection based on 
bacterial count (CFU). However, to ensure that our assay was as sensitive as 
possible while remaining suitable for use as a point-of-care test in a resource poor 
setting, we first had to optimize the protocol for maximum efficiency of lipid extraction 
from the sample while minimizing time, reagents and equipment required.  
 
While the initial method of vortexing in hexane was the simplest and did not 
require heating or neutralization, it did not give the highest signal and presumably 
had very low lipid yield. The procedure is also lengthy and required an overnight 
incubation. A shorter two hour hexane incubation with heating improved the signal, 
but was still clearly inferior to alkaline hydrolysis (Fig. 6-6). The efficiency of the latter 
method is probably due to its ability to also release covalently bound mycolic acid 
(12,215). It is also the shortest method requiring only one hour and thus is ideal for a 
rapid point-of-care test although it will require additional reagents. A variant of this 
method, which utilized a more complex protocol requiring overnight incubation with 
organic solvent to inactivate and delipidate cells, had also been applied previously in 
combination with mass spectrometry to give a limit of detection of 104 CFU Mtb in 
spiked sputum and was also used to extract detectable levels of mycolic acid from 
patient samples, thus indicating its suitability for clinical use (12). We therefore chose 
the alkaline hydrolysis method to determine the CFU limit of detection for the two 
most sensitive antibodies mc3 and mc6 and verified its ability to extract mycolic 
acids through HR-MS/MS and MRM analyses of the lipid extract which confirmed the 
presence of mycolic acid. 





 To determine the equivalent CFU detection limit, we used both M. smegmatis 
as well as M. bovis BCG mycobacterial species. The choice of M. bovis BCG was 
due to fact that while these two mycobacterial species along with Mtb have alpha 
mycolic acids, both M. bovis BCG and Mtb but not M. smegmatis produce methoxy 
mycolic acids (48). Thus, they have a greater similarity in the subclasses of mycolic 
acids detected by our antibodies although the levels of methoxy mycolic acid in BCG 
have reported to be low (48,164). Our results indicate that mc3 and mc6 recognize 
M. bovis BCG at a limit of between 105 to 106 CFU (Fig. 6-9) and are less sensitive to 
M. smegmatis by an order of magnitude, which is not surprising given the partial 
dissimilarity in mycolic acid composition and the higher sensitivity of our antibodies 
to methoxy mycolic acid over alpha mycolic acid. This higher sensitivity would be an 
advantage if the antibodies are to be used for diagnostic purposes as there are only 
a very limited number of mycobacterial species other than the Mtb complex group of 
species (Mtb, M. bovis, M. africanum, M. microti) that contain methoxy mycolic acids 
(48).  
 
As this is a lipid antigen insoluble in aqueous solution, using a capture 
antibody in a sandwich ELISA to improve sensitivity is not possible. It is also unlikely 
that mc3 and mc6 can be used concurrently to bind separate epitopes as given the 
small size of the molecule and their similar specificity and affinity; they are likely to 
bind the same epitope. This could be confirmed by completion ELISA. While our 
assay is currently less sensitive than mass spectrometry which detects 104 CFU, this 
is not surprising given that mass spectrometry is generally far more sensitive than 
immunological assays and can detect as low as 1pg of pure lipid (12). Nevertheless, 




based on CFU alone, this result is still less sensitive as compared to current 
diagnostic methods such as sputum culture, which can detect levels as low as 10 
CFU/ml of mycobacteria and even sputum smear which requires 104 CFU/ml for 
reliable detection (217). However, both these methods require intact bacteria and in 
case of culture, live bacteria for successful detection. As our technique relies on 
antigen detection instead, it can also detect mycolic acids in sputum released by 
dead bacterial fragments and thus may be more sensitive than indicated based on 
CFU counts alone. Furthermore, the higher affinity of our antibodies for methoxy 
mycolic acid over other subclasses (45ng/ml limit vs. 200ng/ml) probably results in 
an artificially poor CFU limit of detection as our test species M. smegmatis and M. 
bovis BCG have no or low levels of methoxy mycolic acid respectively as compared 
to alpha mycolic acids as indicated by our own mass spectrometry data and previous 
publications (48). On the other hand, nuclear magnetic resonance analysis has 
indicated that the proportion of methoxy to alpha mycolic acid is at least 50% or 
above in various Mtb strains (164). Mass spectrometry data has also indicated that 
the most common species of methoxy and alpha mycolic acids are present in TB 
patient sputum at an average concentration of over 100ng/ml, although detection 
was extremely poor in the smear-negative cohort which suggests lower levels of 
mycolic acid (although exact amounts in this cohort were not described in the paper) 
(12). This is well within the detection limits of mc3 and mc6 and samples can be 
further concentrated by evaporation of organic carrier solvent thus allowing for 
enhanced sensitivity when mycolic acid concentrations are low.  
  
 We have therefore isolated and produced the first full length IgG anti-mycolic 
acid antibodies with preferential specificity for the methoxy subclass present in only a 




subset of slow-growing mycobacteria. Crucially, these antibodies also do not cross-
react with cholesterol, a previously reported observation with anti-mycolic acid 
antibodies. We also show that one antibody mc3 can distinguish mycolic acids from 
related actinomycete genera. Its detection limit for methoxy mycolic acid is around 
80ng/ml, a concentration that is below the average in TB patient sputum. It therefore 
has high potential for TB diagnosis but needs verification on patient samples. More 
generally, we have shown that the combination of anti-lipid antibodies obtained via 
phage display and a rapid and simple lipid extraction method can enable the rapid 
and cost effective detection of a set of novel lipid biomarkers in a point-of-care 
setting, which were previously accessible only via expensive and sophisticated 
















Chapter 7: Validation of antibodies on clinical samples 
  






Having optimized our my2F12 antibody and sample processing procedure for 
use on tuberculosis clinical samples, we then proceeded to test our antibody on 
three different types of clinical samples: sputum, urine and serum. All three types of 
clinical samples have been evaluated previously for use in LAM detection assays 
with urine been the focus of multiple studies. The primary assay used has been the 
Clearview sandwich ELISA kit, which was reported to have poor sensitivity in the HIV 
negative cohort when tested on urine samples, ranging from 6% to 21%, although 
specificity was acceptable, ranging from 83% to 100% (151-154,195). It was found to 
have better sensitivity (67%) in HIV patients with CD4 T cell counts less than 50 per 
ml and it was suggested that it could be used as a rule-in assay to provide rapid 
results during severe TB infection for quick initiation of treatment (157,218).  
 
We and others have shown that polyclonal anti-LAM antibodies, such as 
those used in the Clearview ELISA, cross-reacts with multiple non-tuberculous 
mycobacterial species as well as other related non-mycobacterial species (85). This 
has resulted in extremely high cross-reactivity and poor specificity when sputum 
samples were used (154). We therefore sought to ascertain if our monoclonal 
ManLAM antibody can provide improved specificity for this sample group. We also 
tested our antibody on matched urine and serum samples. These are likely to have a 
lower bacterial burden and hence reduced potential for cross-reactivity, which is a 
concern as our antibody is not absolutely specific for Mtb, but also binds other slow 
growing mycobacteria and a related actinomycete species.  
 




Adult volunteers were recruited from patients admitted to the National Centre 
for Tuberculosis and Lung Disease in Tbilisi, Republic of Georgia with suspicion of 
tuberculosis infection. As urinary LAM levels have been reported to be higher in HIV 
positive individuals, we excluded these from our study to ensure that our assay will 
be functional in HIV negative individuals, which comprise the majority of TB patients. 
Recruited patients were classed into four groups: firstly, TB-negative, which were 
confirmed microbiologically negative by sputum smear microscopy and culture and 
without any clinical suspicion of TB; and three TB-positive groups: smear-negative, 
which were not detected by acid-fast staining but positive by culture; patients with 
grade 1+ smears (>10 acid-fast bacilli/100 microscopy fields) and patients with grade 
2+ smears and above (>100 acid-fast bacilli/100 microscopy fields). Patients 
diagnosed only on the basis of clinical presentation without any microbiological 
confirmation of TB were excluded from this study. Fifteen individuals were recruited 
into each group. The purpose of segregating the TB positive patients into three 
groups was firstly for comparison with sputum culture, currently the gold standard 
assay in resource-limited countries (31). Detection of smear-negative, culture-
positive individuals by our assay would suggest that it is a potential substitute for 
culture, which cannot deliver a diagnosis on the same day. The grade 1+ group 
enables comparison with sputum smear microscopy, the current rapid test in 
resource-limited countries (31).  Finally, given the low levels of LAM in urine and 
serum, we may not be able to detect LAM in individuals with low grade infection 
(209,219). Therefore, the grade 2+ group, which are likely to have to most severe 
infections, can serve as a positive control to confirm that the antibody is functional in 
actual clinical samples. Clinical sensitivity could subsequently be improved by using 
diagnostic technologies that can provide a lower limit of detection. 




We also evaluated the potential of the anti-mycolic acid antibody mc3 on lipid 
extracts of sputum using the same chimeric antibody constructs developed for 
my2F12. For initial validation, we chose to focus on sputum as its presence in this 
sample type is known and method for extraction well characterized, although this 
does not preclude the possibility that other sample types may also contain mycolic 
acid (12). Out of the four monoclonals initially characterized, we decided to focus on 
the antibody mc3 due to its high avidity and reduced cross-reactivity to non-
mycobacterial mycolic acids in contrast to mc6. Although we are testing lipid extract 
which should contain minimal amounts of protein, we also sought to produce a 
chimeric variant of mc3 for diagnostic use and thus expressed mc3 using the various 
chimeric constructs developed earlier for my2F12 and tested them for avidity and 
specificity compared to the original antibody.  
 
7.2 Optimization of assay antibody concentration 
 
 Due to the reported low levels of LAM in urine and serum, we first sought to 
further optimize the assay by determining the appropriate concentrations of capture 
(HuG1full) and detector (hG3mG2a) antibodies for maximal signal at such 
concentrations. We coated ELISA plates at 2, 5 and 10µg/ml of HuGfull1 and 
detected ManLAM in spiked serum with 1, 2.5 or 5µg/ml of hG3mG2a, while the 
secondary antibody concentration was kept the same. All possible combinations of 
the above antibody concentrations were tested and the signal-to-noise ratios (SNR) 
and specific absorbance determined (Fig. 7-1A). The pattern for both SNR and 
specific absorbance was the same with an increase from 1 to 5µg/ml of detector 
antibody, which was statistically significant. SNR and specific absorbance also 




increased with higher antibody concentration, although this was not statistically 
significant. We tested the best combination (10µg/ml capture with 5µg/ml detector) 
on ManLAM serially diluted into 1xPBS to obtain a general sensitivity estimate and 
the limit of detection with SNR of 2 was 0.5ng/ml, an improvement from 2ng/ml in the 
previous chapter using 5µg/ml capture with 1µg/ml detector (Fig. 7-1B). This 
concentration was used in all subsequent clinical assays 
 
Figure 7-1: Optimization of capture and detector antibody concentration  
(A) Significant enhancement of signal-to-noise ratio (left panel) and specific 
absorbance above background (right panel) at different antibody concentrations 
in sandwich ELISA, using spiked serum with a low concentration of ManLAM 
(2ngml) (B) Limit of detection of 0.5ng/ml (at signal-to-noise ratio of 2) at 
optimal antibody concentrations of 10µg/ml capture and 5µg/ml detector 
antibody with a 100µl sample of ManLAM spiked into PBS. All results are the 
average of three independent experiments and the error bars show standard 
error of mean. *: p<0.05, **: p<0.01, ***: p<0.001 
 
7.3 Testing of clinical samples for ManLAM 
 
 Using the optimized antibody concentrations, we then proceeded to test 
processed clinical samples for the presence of ManLAM. The strength of the 
sandwich ELISA signal (absorbance) can be influenced by the amount of sample 




used and the length of time of TMB substrate incubation for colour development, 
which can potentially give in improved sensitivity but also higher background and 
reduced specificity i.e. higher false positive rates. We therefore tested sample 
volumes of 100µl and 300µl with incubation times of 15min and 30min in different 
combinations. Initial results were assessed by comparison of the TB negative set 
with the three groups of TB positive individuals combined as a single set.  
 
 Receiver-operating characteristic (ROC) analysis was carried out on these 
two groups to determine the optimal absorbance cut-off value to demarcate positive 
from negative test results due to overlap in the test absorbance values of each 
populations. ROC analysis plots sensitivity against false positive rates as the 
absorbance cut-off value is varied. Sensitivity is defined as the number of true 
positive samples (positives that test positive) divided by the total number of positive 
samples. Specificity is defined as the number of true negative (negatives that test 
negative) divided by the total number of negative samples (false positive rate = 1- 
specificity). Decreasing the cut-off reduces both false positive rates and sensitivity 
but at different rates. The plot enables identification of the cut-off value which 
minimises false positive rates without incurring too great a loss of sensitivity. For 
diagnosing TB, priority is set on keeping false positive rates low to minimise 
unnecessary treatment of non-infected individuals. Therefore we have placed 
emphasis during ROC analysis on minimising false positive rates even though the 
trade-off is reduced sensitivity. Sensitivity and false positive percentages were then 
tested for significant differences using Z-test for proportion at the 95% confidence 
level.  
 




 Sputum samples were tested at 100µl sample volume for 15min and 30min 
incubation and 300µl at 30min. Samples were liquified prior to testing to ensure 
unimpeded capture of target antigen in the assay. Both results obtained at 30min 
incubation gave high background with the mean absorbance of the TB-negative 
group being higher than that of the TB-positive group (Fig. 7-2B & C). As a result, no 
ROC analysis could be done and suitable cut off value determined. This indicated 
that enhancing the signal through increased sample volume or longer incubation 
time was not necessary. When 100µl sample was incubated for 15min, a high 
specificity of 93.3% but low sensitivity of 22.2% was obtained (Fig. 7-2A). However, 
this sensitivity was not significantly different from the false positive rate.  
 
Figure 7-2: Detection of ManLAM in TB patient sputum samples 
Absorbance values from the optimized my2F12 indirect sandwich ELISA on TB 
patients (TB +ve, n=45) and healthy controls (TB –ve, n=15) using (A) 100µl 
sample with 15min TMB incubation (B) 100µl sample with 30min TMB 
incubation (C) 300µl sample with 30min TMB incubation. Specificity and 
sensitivity (L/R) percentages indicated above (A) based on optimal cut-off (red 
line) as determined by ROC analysis. ROC analysis was not carried out for (B) 
and (C) as the mean value for the TB +ve cohort was below that of the TB-ve. 
Error bars show standard deviation of the sample. 
 




 Serum samples, which were anticipated to have very low LAM levels, were 
tested at both sample volumes for 30min and the mean absorbance of the TB-
positive group was higher than the TB-negative under both conditions. ROC analysis 
provided an absorbance cut-off with 93.3% specificity for both groups but only 26.7% 
and 35.6% sensitivity for sample volume of 100 µl and 300µl respectively (Fig. 7-3). 
Both sensitivity percentages were significantly different from the false positive rate. 
In contrast with the sputum sample results, increased sample volume improved 
sensitivity without degrading specificity.  
Figure 7-3: Detection of ManLAM in TB patient serum samples 
Absorbance values from the optimized my2F12 indirect sandwich ELISA on TB 
patients (TB +ve, n=45) and healthy controls (TB –ve, n=15) using (A) 100µl 
sample with 30min TMB incubation (B) 300µl sample with 30min TMB 
incubation (one outlier at OD1.162 not shown). Specificity and sensitivity (L/R) 
percentages are indicated above each chart based on optimal cut-off (red line) 
as determined by ROC analysis. Red highlight indicates test sensitivity rate has 
significant difference from false positive rate in TB –ve group at 95% confidence 
level. Error bars show standard deviation of the sample. 
 
 Urine samples were tested in all four possible sample volume and incubation 
time combinations and the mean absorbance for the TB-positive group was higher in 
all cases. ROC analysis gave a specificity of 92.3% for all four testing conditions but 




the best sensitivity (37.8%) was obtained by using 100µl sample with 15min 
incubation time (Fig. 7-4). Only this level of sensitivity was significantly different from 
the false positive rate. Similar to the sputum results, enhancing signal did not 
improve sensitivity as the increased signals from the TB-negative cohort required 
raising the cut-off value to maintain suitable specificity and hence reduced sensitivity 
instead. 
Figure 7-4: Detection of ManLAM in TB patient urine samples 
Absorbance values from the optimized my2F12 indirect sandwich ELISA on TB 
patients (TB +ve, n=45) and healthy controls (TB –ve, n=13) using (A) 100µl 
sample with 15min TMB incubation (B) 300µl sample with 15min TMB 
incubation (one outlier at OD0.826 not shown) (C) 100µl sample with 30min 
TMB incubation (D) 300µl sample with 30min TMB incubation. Specificity and 
sensitivity (L/R) percentages are indicated above each chart based on optimal 
cut-off (red line) as determined by ROC analysis. Red highlight indicates test 
sensitivity rate has significant difference from false positive rate in TB –ve group 
at 95% confidence level. Error bars show standard deviation of the sample. 




7.4 Analysis of results by individual patient groups 
 
 The data obtained from the most suitable experimental conditions i.e. gave 
best overall specificity and sensitivity rates for each sample type, was then analysed 
according to the individual patient groups. Based on the previously determined cut-
off values, sensitivities for each of the three TB-positive groups were determined, 
along with the false positive rate for the TB-negative group. The ROC curve used to 
determine the cut-off value is also shown (Fig. 7-5). The sensitivities obtained for 
each group were also tested for significant difference using the Z-test for multiple 
independent proportions.  
 
 While sputum and serum had the highest sensitivities in the smear 2+ and 
above group, this rate was not statistically different from the false positive rate for 
sputum (Fig 7-5A). Serum had very high sensitivity in this group (53%) and this rate 
was significantly different from both the false positive rate as well as the sensitivity 
rate of the smear 1+ group (Fig 7-5B). Urine had high sensitivity (40-47%) in both the 
smear 1+ and 2+ or greater groups although the difference between the two was not 
statistically significant (Fig 7-5C). Both rates were significantly different from the false 
positive rate.  
   




Figure 7-5: Sensitivity of optimized my2F12 sandwich assay for individual 
patient groups  
Left panel: Absorbance values of (A) 100µl sputum at 15min TMB incubation, 
(B) 300µl serum at 30min incubation and (C) 100µl urine at 15min TMB 
incubation by individual patient groups (TB –ve: healthy patients, Sm –ve: 
smear-negative, culture positive, 1+: Smear-positive grade 1+, <2+: Smear-
positive grade 2+ and above) Percentage positive values are indicated based 
on the optimal cut-off values (red line), red highlight indicates significant 
difference from TB –ve group at 95% confidence level). Right panel: ROC 
chart indicating variation of false positive rate with sensitivity at increasing 
absorbance cut-off values. Red circle indicates optimal point for greatest 
sensitivity with minimum false positive rates to obtain maximum accuracy. Error 
bars show standard deviation of the sample. 




7.5 Analysis of combined data 
 
 As tests on different sample types were most sensitive for different patients 
groups, we looked to determine if combinations of test results or combination of 
absorbance values of different tests could give better test sensitivity and specificity. 
For combination of test results, a positive test result (as defined by the cut-offs 
established earlier) in any sample type was considered positive while a negative 
result required tests on all three samples to be negative. The combined results these 







Sm -ve 1+ >2+ Overall 
Serum OR Urine OR Sputum 76.92 60.00 53.33 73.33 62.22 
Serum OR Urine 84.62 53.33 53.33 60.00 55.56 
Urine OR Sputum 84.62 40.00 46.67 53.33 46.67 
Serum OR Sputum 84.62 53.33 53.33 60.00 55.56 
 
Table 7-1: Specificity and sensitivity from combination of assay results on 
different clinical sample types.  
Samples were considered positive if they were positive for any one of the 
sample types based on the cut-off values defined earlier. Number of test 
positives/negatives was then used to calculate specificity and sensitivity values. 
N=15 for each TB positive group and N=13 for the TB-negative group. TB –ve: 
healthy patients, Sm –ve: smear-negative, culture positive, 1+: Smear-positive 
grade 1+, <2+: Smear-positive grade 2+ and above. Test sensitivity 
percentages in bold indicates significant difference from the false positive rate in 
the TB-negative group (at 95% confidence level) 
 
 




 Combinations of any two tests showed improved sensitivity up to 55.56% but 
concurrently drop in specificity to 84.6%. A combination of all three tests gave further 
reduced specificity but a higher sensitivity of 62.2% (Table 7-1). This is better than 
that given by the individual tests at that level of specificity; which is 46.62%, 31.1% 
and 48.9% sensitivity for the optimized urine, sputum and serum individual assays 
respectively based on the ROC plots. The overall sensitivity rates for all test 
combinations were significantly different from the false positive rate.  
 
 Individual group sensitivity was the highest in the smear 2+ cohort for all 
combinations and was significantly different from the false positive rate. However, in 
the combination of all three tests, the sensitivity rate for the smear 1+ was not 
significantly different from the false positive rate. In contrast, using the serum test 
results in combination with either urine or sputum gave sensitivity rates for all three 
groups that were significantly different from the false positive rate. The worse result 
was given by the combination of urine and sputum tests which had the lowest rates 
that mostly did not reach statistical significance (2 out of 3) 
 
 Alternatively, absorbance values from individual tests can be summed, a new 
ROC analysis conducted and cut-off values determined. Absorbance summations 
from all three tests or a combination of any two tests were analysed and new 
sensitivity and specificity rates determined for each. While specificity remained high 
at 92.4%, the best sensitivity, given by an absorbance combination of the urine and 
serum tests, was no better than that given by the individual urine test at 37.8% (Fig. 
7-6). Only this sensitivity rate was significantly different from the false positive rate.  
  





Figure 7-6: Sensitivity and specificity rates obtained using combination of 
absorbance values (OD) from different clinical sample types 
ROC analysis was carried out on different combinations of absorbance values 
(All 3: serum + urine + sputum, Ur+Se: urine + serum, Ur+Sp: urine + sputum, 
Se+Sp: serum + sputum) to determine if any combination offered improvement 
in specificity and/or sensitivity. Specificity and sensitivity rates (L/R) based on 
individually calculated cut-off values for each combination are shown above. 
Red highlight indicates test sensitivity has significant difference from false 
positive rate of that particular combination at 95% confidence level. Error bars 
show standard deviation of the sample. 
 
 Based on the above results, using a combination of optimal test results 
appeared to at best improve sensitivity at the cost of specificity. An alternative 
however is to combine absorbance values from non-optimal tests that individually 
had poorer sensitivity rates. One suitable set of results is the absorbance values of 
serum tested using 100µl sample volumes, which had only slightly lower sensitivity 
compared to the optimal serum test which used 300µl sample volumes. A 
combination of absorbance values from this test and the optimal urine test gave an 
overall sensitivity of 60.0% (which was statistically significant) while maintaining high 
specificity (Fig. 7-7). Sensitivity was also maintained or improved for each TB 




positive patient group up to 46.7% for smear-negative patients and 66.7% for smear-
positive patients. All sensitivity rates were significantly different from the false 
positive rate but were not significantly different from each other.  
 
Figure 7-7: Sensitivity and specificity rates obtained from combination of 
absorbance from urine (100µl sample at 15min TMB) and serum (100µl sample 
at 30min TMB)  
Combined absorbance values according to: (A) individual patient groups (TB –ve: 
healthy patients, Sm –ve: smear-negative, culture positive, 1+: Smear-positive grade 
1+, <2+: Smear-positive grade 2+ and above) (B) With all three positive groups 
combined (TB +ve). Overall specificity and sensitivity rates (L/R) are indicated 
above. Percentage positive values are indicated based on the optimal cut-off values 
(red line). Red highlight indicates significant difference from false positive rate in TB 
–ve group at 95% confidence level (C) ROC chart indicating variation of false 
positive rate with sensitivity at increasing absorbance cut-off values. Red circle 
indicates optimal point for greatest sensitivity with minimum false positive rates to 










7.6 Conversion of mc3 to chimeric antibody for diagnostic use 
 
 To avoid potential cross-reactivity to endogenous human antibodies in clinical 
samples, the same constructs developed for my2F12 were used to produce chimeric 
variants of mc3. The antibodies expressed were properly assembled as indicated in 
the reducing and non-reducing Coomassie gels, with a balanced level of heavy and 
light chain on the reducing gel and the majority of the antibody running as fully 
assembled IgG (greater than 150kDa) on the non-reducing gel (Fig. 7-7B & C). 
Western blot probed with anti-human Fc also confirmed the species identity of the 
fully human and chimeric antibodies by highlighting only huG1full and huG3full heavy 
chains (Fig. 7-7D)  
 
  The antibodies were tested for their binding avidity using serially diluted 
antibody against Mtb mycolic acid extract and a pattern similar to that observed for 
the my2F12 antibody variants was observed (Fig. 7-8A). HuG1full and huG3full had 
the highest binding avidity although huG3full binding curve was only marginally 
higher than that of huG1full. hG3mG2a had lower binding avidity than HuG1 full 
while hG1mG2a, moG2a and moG2afull had virtually identical binding curves with 
the lowest binding affinity. hG3mG2, as the chimeric with the highest binding avidity 
and suitable for use as a diagnostic antibody for reduced cross-reactivity, was 
subsequently compared against the original huG1 for specificity with a subset of 
lipids tested earlier, including all the mycolic acid subtypes. 5µg/ml of each antibody 
was used as the earlier binding curves had indicated that maximal absorbance was 
obtained for both antibodies at that concentration. Specificity was identical although 




the absorbance signal is weaker which is probably due to the different secondary 
antibodies used (Fig. 7-8B). 
 
 
Figure 7-8: Design and expression of mc3 chimeric variants 
(A) Structural diagram of the six mc3 antibody variants including the original 
huG1 mc3 showing the human/mouse origins and isotypes of the various 
constant domains. (B) Reducing and (C) Non-reducing Coomassie of the six 
variants. 2µg of each antibody was run on 10% SDS-PAGE gel showing 
individual heavy and light chains (HC/LC) or fully assembled antibody (2H2L) 
(D) Western blot of the six variants with 1:5000 anti-Human Fc-HRP on 0.5µg of 
each antibody run on a reducing SDS-PAGE and transblotted to a nitrocellulose 











Figure 7-9: Avidity and specificity of engineered chimeric mc3 
 
(A) Serial dilution of IgG against mycolic acid on indirect monoclonal ELISA showing 
relative affinities of different chimeric constructs. Red lines indicate parental antibody 
(huG1full) and engineered diagnostic (hG3mG2a). (B) Indirect monoclonal ELISA 
showing specificity of huG1full and the chimeric variant hG3mG2a for mycolic acid 
extract and methoxy mycolic acid in contrast to cholesterol, membrane lipids, β-
hydroxyl lipids and mycobacterial lipids. All antibodies were at 5µg/ml concentration 










7.7 Testing of clinical patient samples for mycolic acid 
  
 We then proceeded to test sputum lipid extracts in hexane using the 
hG3mG2a antibody at the optimized concentration of 5µg/ml to give maximal signal. 
100µl and 300µl of lipid extracts were evaporated onto the ELISA in the same 
manner as that used for testing the purified lipids and bacterial lipid extracts. 
Although high signals were observed for some of the TB positive samples, these 
were also obtained for the TB negative samples, despite the use of a short TMB 
incubation time of 5min (Fig. 7-10). Due to the high background, to obtain high 
specificity, the resultant cut-off had virtually zero sensitivity of 2.2% based on ROC 
analysis for the 100µl sample with no significant difference from the false positive 
rate. No ROC analysis could be carried out for the 300µl sample as the mean of the 
TB negative was higher than that of the TB positive population.  
 
Figure 7-10: Detection of mycolic acid in TB patient sputum 
Absorbance values from the optimized mc3 indirect ELISA on TB patients (TB 
+ve, n=45) and healthy controls (TB –ve, n=15) using (A) 100µl sample with 
5min TMB incubation (B) 300µl sample with 5min TMB incubation. Specificity 
and sensitivity (L/R) percentages are indicated for chart (A) based on optimal 
cut-off (red line) as determined by ROC analysis (C). Red circle indicates 
optimal point for greatest sensitivity with minimum false positive rates to obtain 
maximum accuracy. Error bars show standard deviation of the sample. 




7.8 Discussion  
  
 Despite multiple studies, the utility of LAM in urine as a tuberculosis biomarker 
remains unproven especially in HIV negative cohorts. Limited studies have been 
carried out on both serum and sputum, but the data available suggest that the 
challenges are low sensitivity in the former and low specificity in the latter (154,209). 
Our results on sputum samples also indicate that high background is a potential 
problem, with significant signals observed in the TB negative cohort when too much 
sample was used or when the TMB was incubated for too long. This signal was high 
enough to render the TB negative cohort indistinguishable from the TB positive 
cohort. However, if a lesser amount of sample was used (100µl) and incubated for 
only 15min, the strong signal from the TB positive samples was maintained while 
that from the TB negative cohort was reduced with maximal absorbance values of 
around 1.35 (Fig. 7-2). This could be due to the specificity of the my2F12 for 
ManLAM. In contrast, the polyclonal anti-LAM antibodies used in the Clearview test 
have been shown to generate high absorbance values in TB negative samples 
greater than 2.0 due to high cross-reactivity for other actinomycetes such as 
Nocardia spp. (154). Thus, our results suggest that my2F12 outperforms the 
antibody used in that commercial assay.  
 
 Our antibody is not specific only for Mtb-it can bind LAMs produced by other 
mycobacterial and actinomycete species provided they have α1-2 mannose capping 
motifs and this may be the cause of the high absorbance values observed. This 
resulted in a high-cut off and a lowered sensitivity rate, which was unable to reach 
statistical significance when evaluated both as individual patient groups and when 




the TB-positive groups were combined. Thus, in spite of the superior specificity of 
our antibody, sputum may still not be a suitable sample type for LAM biomarker 
detection by ELISA due to the potential for false positives. Further investigation into 
the source of the false positive signals observed in our assay e.g. determining the 
bacterial species responsible or the type of LAM present, would be useful in 
ascertaining whether sputum is a suitable clinical sample for this assay. 
 
 In contrast, in urine and serum, high false positive signals were not observed. 
This was expected based on previous studies and the lower bacterial burden in 
these sample types. Serum is a particularly attractive sample type as the likelihood 
of bacterial contamination is very low and thus has a very low risk of false positives. 
This allowed for a larger sample volume and long incubation time which served to 
enhance overall sensitivity to a maximum of 36% while retaining good specificity at 
93%, which was statistically significant in contrast to sputum (Fig. 7-3). This result is 
inferior to an earlier study that used polyclonal antibodies in a coagluttination 
reaction and a more recent study that used a bispecific detector antibody that bound 
both LAM and HRP, with 57% and 60% sensitivity respectively and 100% specificity 
(209,220). However, both studies did not distinguish patients by HIV status. Meta-
analysis of studies on urinary LAM diagnostics have indicated that there is a positive 
correlation between the sensitivity performance of the assay and the percentage of 
HIV positive individuals in the study cohort, due to the higher levels of LAM secreted 
in these individuals (13). This may also be the case for detection of LAM in serum 
and may account for the poorer performance in our study. 
 




 In urine, our maximal overall sensitivity attained is 38% with a specificity of 
92% which was statistically significant (Fig. 7-4). While this lies within the range of 
overall assay sensitivities reported previously, meta-analysis of the data suggests 
that the overall sensitivity of previous urinary LAM assays in the HIV negative cohort 
is 14% (13). As such, our antibody assay clearly outperforms the commercial 
polyclonal anti-LAM ELISAs thus far used in these studies. To boost the sensitivity of 
these assays, more sensitive detection technologies could be applied which may 
decrease the lower limit of detection for LAM by several orders of magnitude 
compared to the current sandwich ELISAs in use (221,222). However, with 
polyclonal antibodies, their broad specificity for all LAM variants could also result in 
higher false positive rates. This is evidenced by a recent study that sought to 
improve sensitivity in the polyclonal LAM assay by concentrating urine and hence 
boosting LAM levels (219). While sensitivity was indeed improved, significant 
increases in absorbance values in the TB negative cohort was also observed, which 
could be due to the concentration of contaminating environmental LAM. As our 
antibody is ManLAM specific, it is thus likely to prove superior to polyclonal 
antibodies where extremely sensitivity assay technologies are used.  
 
 As our TB positive cohort is not a representative sample of the TB positive 
population but actually a combination of three separate groups, our calculated 
overall sensitivity is not an exact determination of the assay performance in the field.  
Nevertheless, it provides a general estimate of the performance of the assay and 
helped the establishment of optimal assay parameters as one-third smear-negative 
is similar to that of a typical HIV negative population (52). However, a more detailed 
analysis of the individual groups within the TB positive cohort will give a more 




accurate comparison provided that comparison studies are suitably stratified. It also 
allows us to determine if this assay can offer improvement over smear microscopy 
and substitute for culture. While this cannot be carried out for our sputum and serum 
assays as the data was not stratified, three separate studies on urinary LAM have 
shown that sensitivity in the smear-negative HIV negative cohort in non-concentrated 
urine is 0% for all three studies and 8-23.5% in the smear-positive cohort 
(154,195,219). These results were clearly inferior to smear microscopy. With our 
antibody, the best sensitivity obtained from an individual assay for smear-negative 
samples is 33% from testing serum. In a like for like comparison, our urine assay 
offers a sensitivity of 27% (Fig. 7-5). Although our study was insufficiently powered to 
statistically differentiate these results from our observed false positive rate, these are 
significantly different from the 0% rate reported in other studies assuming the same 
TB-negative sample size.  
 
 The advantage of having matched samples is the ability to combine results 
from various sample types. We have evaluated combinations of either raw 
absorbance values, or individual test results and the best performance is provided 
either by combining results from all three sample types or combination of 
absorbance values of the tests using 100µl serum at 30min incubation and 100µl 
urine sample at 15min incubation. For comparison of individual TB positive patient 
groups, the sensitivity in the smear-negative group is 60% or 47% for combination of 
test results or absorbance values respectively (Table 7-1 and Fig. 7-7). Performance 
in the smear-positive group is higher at 66-63%. These values are statistically 
significant and clearly superior to that of the previously published polyclonal ELISA 
assays on urinary LAM. Higher sensitivity rates in the smear-positive group were 




also observed in individual assays, although the difference was not statistically 
significant for all evaluated results with the exception of the smear 2+ cohort in the 
serum individual assay which was extremely high at 53.3%. However, this result is 
expected as smear-positive patients, especially grade 2+ and above, have higher 
mycobacterial load and as such is likely to carry more LAM in their clinical samples.  
 
 The objectives of this study were to determine the utility of my212 sandwich 
ELISA assay on three different sample types in comparison to previous LAM assays 
and current TB diagnostics. While it appears to reduce false positive signals in 
sputum compared to polyclonal LAM antibodies, high background was still observed 
and further investigation into the cause is required to determine whether this sample 
type has any diagnostic utility. In serum, our assay appears to be less sensitivity 
than others previously reported, but the small sample size in earlier studies and the 
lack of stratification by smear and HIV status prevented an exact comparison. 
However, as an individual assay, it offers better sensitivity in the smear-negative 
cohort as compared to previous polyclonal ELISAs targeting urinary LAM. This is 
also the case if we use a combination of tests including urine. While no combination 
of test offers us 100% sensitivity in the smear-positive group, we surpass the 
previously reported sensitivity of polyclonal LAM ELISAs for both smear-negative 
and positive groups in the HIV negative cohort. As a significant proportion of smear-
positive cases remain undetected, our assay in its current format is unsuitable as a 
direct replacement for smear microscopy. However, it can detect a significant 
proportion of smear-negative cases, which previous LAM assays could not, and as 
such could be useful in combination with smear microscopy as a rapid test in place 
of culture.  





 In contrast to my2F12, sputum tested with the anti-mycolic acid antibody mc3 
showed no difference  between TB-positive and TB-negative samples due to the 
high background/noise of the assay. This is despite the use of a chimeric antibody 
and an anti-mouse secondary antibody to avoid cross-reactivity with any 
endogenous antibodies. Although our extraction method was optimized and is similar 
to that used in previous studies, this was carried out only on bacterial culture and not 
sputum. Further optimization on sputum will be required in order to produce a 
cleaner lipid extract that could be used in this assay.  
  















Chapter 8: Discussion & Conclusion 
  





 The aim of this thesis was to identify and characterize novel anti-Mtb lipid 
antibodies that could provide superior point-of-care detection of TB infection in 
resource-limited settings as compared to other methods currently in use or in testing 
such as smear microscopy or polyclonal anti-LAM ELISA respectively. In comparison 
to proteins, lipids have not been as extensively explored for their potential as disease 
biomarkers. On the other hand, multiple studies on a number of TB protein targets 
have failed to conclusively demonstrate their efficacy in TB diagnosis (8). The 
rationales behind targeting Mtb lipids, in this case LAM and mycolic acid, are their 
stability to heat and other denaturing agents, as well as their presence in multiple 
clinical sample types or high abundance in clinical samples respectively. We also 
aimed to develop a straightforward means of optimizing antibody expression in 
bacteria to enable low-cost production.  
 
 Targeting these lipids using traditional animal immunization methodologies 
has generally not been successful. In the case of LAM, such methods have not been 
able to isolate an antibody that is capable of distinguishing ManLAM, the form of 
LAM produced by Mtb and other slow-growing mycobacteria, from LAM produced by 
other mycobacteria and actinomycetes. This is primarily due to the conservation of 
the vast majority of the LAM molecule structure between the different variants and all 
currently described polyclonal and monoclonal anti-LAM molecules appear to bind 
this conserved structure (83-85,199). This cross-reactivity is the probable cause of 
the significant false positive rate observed when sample types with high bacterial 
load e.g. sputum or concentrated samples were used (154,219). We therefore 
sought to determine if recombinant antibody technology based on antibody phage 




display libraries could be used to select ManLAM specific antibodies by driving 
selection in vitro towards the unique α1-2 mannose caps on this molecule.  
 
 In contrast to LAM, mycolic acid is highly insoluble and hard to immunize with 
in vivo. Thus far only a limited number of anti-mycolic acid antibodies have been 
generated, all using recombinant antibody technology (182). These antibodies are 
cross-reactive to cholesterol and are of the semi-synthetic scFv format, which may 
be difficult to express as more stable full length IgG antibodies (184). We had 
previously optimized a methodology for the isolation of antibodies against insoluble 
lipids from a Fab phage display library and therefore we aimed to repeat this 
selection on mycolic acid to identify specific antibodies and test them as full length 
IgG (10). Our choice of recombinant antibody technology was therefore dictated by 
the constraints imposed by the nature of the target but also relies on the advantages 
of phage display selection, which are the independence from the requirement for a 
strong in vivo immune response and the freedom to apply in vitro selection 
techniques not possible in animals.  
 
 In order to obtain a ManLAM specific antibody, we modified the basic phage 
library panning technique to incorporate a negative selection step by first binding to 
PILAM. This depletes antibody phage that binds the conserved LAM structure but 
retains those against the α1-2 mannose structure, which are then positively selected 
on ManLAM. We showed that this resulted in enrichment of only ManLAM-specific 
phage and isolated the antibody my2F12 from an enriched pan, it being the only 
specific sequence present. The rarity of ManLAM specific antibodies in the library 
suggests that the negative selection was critical to discovery of this antibody and that 




in the absence of this step cross-reactive antibodies would have predominated 
selection. It would be interesting to evaluate whether this method can be replicated 
for other targets to focus specificity on a small region where there are many other 
competing epitopes.  
 
 Based on the ManLAM cap structure, we expected that α1-2 mannose would 
be the principle determinant of the my2F12 epitope. We confirmed this with synthetic 
carbohydrate arrays, where binding was observed only to oligosaccharides with 
terminal α1-2 mannose. We also demonstrated that this specificity is retained on 
conversion to chimeric antibody via sandwich ELISA and immunofluorescence 
microscopy. However, this binding specificity does not restrict recognition to only Mtb 
but to the slow-growing group of mycobacteria and also a unique actinomycete 
species T. paurometabolum. Consequently, our antibody is potentially less specific 
than antibodies and assays that target Mtb unique proteins such as ESAT-6, CFP-10 
and MPT-64 (44,90). However, it is still more specific than currently described anti-
LAM antibodies. Our next step was therefore to determine this antibody would have 
lower false positive absorbance values in clinical sputum samples.  
 
 Despite improved specificity, high signals were still observed in the sputum 
samples of the TB-negative cohort despite assay optimization to improve signal-to-
noise ratio by adjusting assay concentrations, removing cross-reactivity to 
endogenous antibodies through use of chimeric antibodies and minimising 
background by optimizing sample volumes and incubation times. This resulted in 
reduced sensitivity due to elevated absorbance cut offs. Although these absorbance 
values were lower than that reported using polyclonal anti-LAM antibodies, it is 




unclear whether this can be attributed to the better specificity of this antibody or due 
to differences in assay protocol. Follow up comparisons with the Clearview kit and 
determination of the source of the high signal (by identification of the bacterial 
species or LAM variant) in our TB-negative samples will be required to determine if 
the improved specificity of our antibody confers any diagnostic advantage. 
 
 Both the my2F12 human and chimeric variants have very high avidity and can 
detect LAM down to 0.5ng/ml in PBS or serum in a sandwich ELISA assay, which is 
comparable to other diagnostic assays for LAM that lack the fine specificity for 
pathogenic mycobacteria (85,87,209). This superior specificity might be useful for 
testing urine and sputum, which have low levels of LAM and where extremely low 
background would be advantageous (209,219). These sample types also have 
reduced bacterial contamination as compared to sputum and are hence likely to not 
suffer from high false positive values. In serum, sensitivity was speculated to be 
affected by endogenous anti-LAM antibodies that inhibit binding of the assay 
antibodies. A previous study has shown that detection is better in denatured serum 
but did not prove that anti-LAM antibodies were directly involved (209). In this study, 
we have shown that the level of anti-LAM antibodies correlates with reduced 
sensitivity of the assay and that denaturation of anti-LAM antibodies and loss of 
binding was associated with restored sensitivity.  
 
 In urine and denatured serum, high specificity was achieved but sensitivity 
was limited at up to 38% for the overall TB positive cohort. Significantly however, 
there was detection of a significant proportion of the smear-negative culture-positive 
cases (20-33%) and combination of all three assay types or the absorbance values 




of serum and urine gave further improvement in sensitivity in this group to 60% or 
47% respectively. This indicates that our antibody could complement smear 
microscopy and potentially substitute for culture by enabling detection of some 
smear-negative cases, although with the limited sensitivity in the smear-positive 
cohort it cannot replace microscopy in its current assay format. Although not as 
sensitive as culture (which is the gold standard to identify smear-negative cases), it 
can detect a significant proportion of these cases using just serum and urine 
samples, for which processing and testing is fairly straightforward and can be 
completed within one day in contrast to culture which requires a minimum of two 
weeks and can take up to one and a half months (31). This would enable initiation of 
treatment within one visit and accelerate provision of medical care especially in 
resource-limited countries where access to even basic facilities is limited.  
 
 It might be possible to improve sensitivity further through engineering of 
higher affinity mutants of my2F12 with the same specificity to enhance signal thus 
allowing for better discrimination of positive samples and also permit less sample to 
be used thus reducing non-specific background. Affinity enhancement has been 
carried out for other diagnostic antibodies against both protein (tumour necrosis 
factor, Fusarium graminearum cell wall protein) and lipid targets (estradiol). This is 
typically achieved by use of error prone PCR or degenerate primers to introduce 
random mutations into the antibody variable gene sequence to produce a library of 
mutated constructs which can then be screened for higher affinity mutants (224-226).  
Mtb is also unique in that it reportedly carried an additional molecule, 5-
methylthiopentose at the tip of its ManLAM caps (196). This offers the opportunity to 
create a Mtb specific antibody by targeting the complete ManLAM-pentose motif, 




using the same negative depletion technique described earlier but using ManLAM 
sourced from another slow-growing mycobacterial species, which lacks this 
molecule, as the depleting antigen. This could be carried out if further testing on 
clinical samples indicates that cross-reactivity to other slow-growing mycobacterial 
species, resulting in high false positive rates, is a significant issue. 
  
 Previous studies on clinical urine samples with the polyclonal anti-LAM 
indicated that they were unable to detect any smear-negative cases type in the HIV 
negative cohort and had inferior sensitivity in the smear-positive cohort 
(154,195,219). As such, our anti-LAM antibody appears to have superior 
performance as compared to current urinary LAM assays. It remains unclear as to 
whether this can be attributed solely to high avidity or whether ManLAM specificity 
had a role to play by giving very low background values. Again, comparison with the 
Clearview diagnostic kit would be useful in determining this. As LAM excretion in 
urine appears to be elevated in the HIV positive cohort, a trial of our assay might 
demonstrate even superior sensitivity to the current tests available. While HIV 
patients do not comprise the majority of TB patients, they are a significant minority at 
13% globally and would benefit greatly from improved diagnostics (1).  
 
 We have also isolated four mycolic acid-specific antibodies using a panning 
strategy for isolation of antibodies against insoluble lipids. These antibodies all 
preferentially detect methoxy mycolic acid and one (mc3) was found to be specific 
for mycobacterial mycolic acid with no binding to T. paurometabolum and N. 
cyriacigeorgica mycolic extract in contrast to my2F12. Given the earlier high 
background observed with my2F12, this specificity might be critical in ensuring 




accurate diagnosis with sputum samples. Its preferential avidity for methoxy mycolic 
acid is also likely to give it better specificity in comparison to my2F12 which detects 
all slow-growing mycobacteria, as only a limited number of slow-growing 
mycobacterial species, including Mtb, express this mycolic acid subtype (48). In 
contrast to its high specificity when tested on bacterial lipid extracts, extremely high 
absorbance signal was observed in the TB-negative cohort. This was despite use of 
the chimeric variant of mc3 to eliminate the risk of background from endogenous 
antibodies. This could due to the presence of mycolic acid from a non-tuberculous 
source, especially alpha mycolic acid which is ubiquitous among mycobacteria, but is 
unlikely given that the sputum samples were all mycobacterial culture and smear 
negative, which have limits of detection of 10 and 5000 bacilli/ml respectively. 
Alternatively, there could be cross-reactivity to another antigen present in the sample 
that was not tested for in the earlier characterization. Mass spectrometry might be 
able to identify what these are and help determine a strategy for separation of these 
from the mycolic acid biomarker. If there is indeed alpha mycolic acid or another lipid 
present that causes cross-reactivity, re-panning of the library could be carried out to 
produce an antibody with no cross-reactivity to these above lipids. This could be 
accomplished either using negative depletion as described for the anti-ManLAM 
antibody selection and/or selection using synthetic methoxy mycolic acid alone 
instead of purified Mtb mycolic acid.  
  
 In the course of optimizing our antibody, we have developed various chimeric 
constructs to switch the Fc constant region from human to mouse. Comparison of 
the binding avidity of the various constructs for both my2F12 and mc3 have indicated 
a pattern of higher affinity when the human G1 hinge was replaced with the G3 hinge 




and a reduction in affinity when the human constant regions were replaced with 
murine constant regions. Importantly, no change in specificity was observed for 
either antibody in the course of conversion, as previous studies had indicated that 
alterations of the constant region can influence specificity (212). It would therefore be 
interesting to evaluate if an avidity increase without a change in specificity could be 
obtained by using our hG3mG2a construct on a variety of antigens such as proteins 
along with lipids. This is deserving of further investigation as recombinant antibody 
technology is likely to make the isolation of human antibodies increasingly common; 
conversion of these antibodies to a chimeric format would be required for diagnostic 
use and ideally with minimal loss of specificity and avidity. Thus far, conversion of 
murine antibodies to chimeric antibodies with different human isotypes indicated that 
the substitution with the G1 isotype gave higher affinity as compared to the G3 
isotype (207). However, this result may not be comparable as it involved the 
substitution of murine constant regions with human ones, while in this study the 
opposite was carried out. Interestingly, we also showed that G3 was less efficient as 
compared to G1 at capturing antigen. This effect has been observed previously with 
a human anti-HIV gp120 and could be another general characteristic of this isotype 
(223).  
 
 We have also identified various straightforward solutions for improving 
antibody expression yields in E. coli, namely through reducing translational levels via 
reducing inducer concentrations and delayed induction. We have characterized the 
effects of these modifications and our findings suggest that the improvement in 
overall yield is due to two separate mechanisms, increase in wet cell mass and unit 
yield. Despite these improvements, antibody yields especially with our target 




antibody my2F12 were too low for the method to be practicable. As such, we had to 
rely on mammalian cell culture to produce the required antibodies. However, based 
on optimized assay concentrations, we will not require more than 0.5µg/well of 
detector antibody and 1µg/well of capture antibody if 100µl sample volumes are 
used, therefore 1mg of antibody can be used for 1000 tests and should not be 
prohibitively costly even if produced by mammalian cell culture.   
 
 In summary, during the course of this study, we have generated and 
characterized two highly-specific, high avidity recombinant antibodies against LAM 
and mycolic acid, my2F12 and mc3 respectively. Isolation of these antibodies 
required the use of techniques only possible in vitro and it is highly likely that such 
antibodies would be difficult to obtain using traditional immunization techniques. 
While promising, mc3 gave extremely high background on TB-negative sputum 
samples and further optimization of the assay will be required. Crucially, my2F12 is 
able to identify TB patients in the HIV negative, smear-negative cohort. These could 
previously only be identified through NAATs or culture, both of which have significant 
drawbacks in resource-limited settings. To confirm its suitability for TB diagnosis and 
further delineate its sensitivity rates in various patient groups, a follow up clinical trial 
should be carried out with a larger patient cohort and with side-by-side comparison 
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